C LI NI C A L S T U D Y P R O T O C O L 
Pr ot oc ol Title: A P hase 3, Ra n d o mize d, O pe n- La bel St u d y E val uati n g t he Efficac y of 
A xica bta ge ne Cil ole ucel vers us Sta n dar d of Care T hera p y i n S u bjects wit h 
Rela pse d/ Refract or y Diff use Lar ge B Cell L y m p h o ma ( Z U M A- 7) 
Pr ot oc ol N u m ber: K T E- C 1 9- 1 0 7 ( Z U M A- 7) 
U S A N/I N N: A xica bta ge ne cil ole ucel 
C o m pa n y C o de: K T E- C 1 9 
I N D N u m ber: 0 1 6 2 7 8 
E u dra C T N u m ber: 2 0 1 7- 0 0 2 2 6 1- 2 2 
S p o ns or Na me a n d A d dress: Kite P har ma, I nc. 
[ADDRESS_1175110] I nf or mati o n: T he me dical m o nit or na me a n d c o ntact i nf or mati o n is pr o vi de d o n t he Ke y St u d y 
Tea m C o ntact List 
Pr ot oc ol Versi o n/ Date: Ori gi nal: [ADDRESS_1175111] or y: A me n d me nt 1: Versi o n 2 2 7 Se pte m ber 2 0 1 7 
A me n d me nt 2: 2 1 N o ve m ber 2 0 1 7 
A me n d me nt 3: 1 6 Ja n uar y 2 0 1 9 
A me n d me nt 4: 1 9 Marc h 2 0 1 9 
A me n d me nt 5:  2 5 J u ne 2 0 2 0 
A me n d me nt 5. 1: 1 6 Se pte m ber 2 0 2 0 – U S A o nl y 
A me n d me nt 6: 1 4 A pril 2 0 2 3 
C o u ntr y-s pecific Re q uire me nts: C o u ntr y-s pecific re q uire me nts are liste d i n A p pe n di x D 
T his st u d y will be c o n d ucte d i n c o m plia nce wit h t his pr ot oc ol a n d i n acc or da nce wit h t he et hical 
pri nci ples t hat ha ve t heir ori gi n i n t he Declarati o n of Helsi n ki, a n d t hat are c o nsiste nt wit h 
I nter nati o nal C o u ncil f or Har m o nisati o n (I C H) G o o d Cli nical Practice ( G C P) a n d a p plica ble 
re g ulat or y a n d l ocal re q uire me nts. 
C O N FI D E N TI A LI T Y S T A T E M E N T 
T his d oc u me nt c o ntai ns c o nfi de ntial i nf or mati o n of Kite P har ma, I nc., a w h oll y o w ne d s u bsi diar y of 
Gilea d Scie nces I nc. T his d oc u me nt m ust n ot be discl ose d t o a n y o ne ot her t ha n t he st u d y site researc h 
staff, c olla b orat ors, a n d me m bers of t he I nstit uti o nal Re vie w B oar d/I n de pe n de nt Et hics C o m mittee, a 
scie ntific re vie w b oar d, or a n e q ui vale nt. T he i nf or mati o n i n t his d oc u me nt ca n n ot be use d f or a n y 
p ur p ose ot her t ha n t he c o n d uct of t he cli nical i n vesti gati o n wit h o ut t he pri or writte n c o nse nt of 
Kite P har ma, I nc.  
   
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 2 1 4 A pril 2 0 2 3 P R O T O C O L S Y N O P SI S 
Title: A P hase 3, Ra n d o mize d, O pe n- La bel St u d y E val uati n g t he Efficac y of 
A xica bta ge ne Cil ole ucel vers us Sta n dar d of Care T hera p y i n S u bjects wit h 
Rela pse d/ Refract or y Diff use Lar ge B Cell L y m p h o ma ( Z U M A- 7) 
I n dic ati o n: A d ult s u bjects wit h rela pse d/refract or y diff use lar ge B-cell l y m p h o ma (r/r 
D L B C L). 
St u d y Desi g n: T his is a P hase [ADDRESS_1175112] u d y e val uati n g t he 
efficac y of a xica bta ge ne cil ole ucel vers us sta n dar d of care t hera p y ( S O C) 
i n s u bjects wit h r/r D L B C L.  A d ult s u bjects wit h r/r D L B C L after first-li ne 
rit u xi ma b a n d a nt hrac ycli ne- base d c he m ot hera p y will be ra n d o mize d i n a 
1: [ADDRESS_1175113]-li ne t hera p y ( pri mar y refract or y, vs rela pse 
≤ [ADDRESS_1175114]-li ne t hera p y vs rela pse > 6 a n d ≤ [ADDRESS_1175115]-li ne 
t hera p y) a n d sec o n d-li ne a ge-a dj uste d I nter nati o nal Pr o g n ostic I n de x (I PI) 
( 0 t o 1 vs 2 t o 3) as assesse d at t he ti me of scree ni n g. 
F or s u bjects ra n d o mize d t o t he c o ntr ol ar m of t he st u d y, S O C will c o nsist 
of a pr ot oc ol- defi ne d, plati n u m- base d sal va ge c o m bi nati o n c he m ot hera p y 
re gi me n.  S u bjects w h o res p o n d t o sec o n d-li ne c he m ot hera p y ( partial 
res p o nse [ P R] or c o m plete res p o nse [ C R]) s h o ul d pr ocee d t o hi g h- d ose 
t hera p y ( H D T) a n d a ut ol o g o us ste m cell tra ns pla nt ( A S C T). 
A n i n de pe n de nt Data Safet y M o nit ori n g B oar d ( D S M B) will meet e ver y 
[ADDRESS_1175116] u d y ar m, please refer t o t he 
sc he d ule of assess me nts ( S O A) a n d Secti o n [ADDRESS_1175117] u d y sc he ma is dra w n o ut a n d descri be d at t he e n d of t he pr ot oc ol 
s y n o psis secti o n. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 3 1 4 A pril 2 0 2 3 Pri mar y O bjecti ve 
•T o deter mi ne if a xica bta ge ne cil ole ucel is s u peri or t o S O C as meas ure d 
b y e ve nt-free s ur vi val ( E F S), as deter mi ne d b y bli n de d ce ntral re vie w 
Sec o n dar y O bjecti ves 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel c o m pare d t o S O C o n 
o bjecti ve res p o nse rate ( O R R), as deter mi ne d b y bli n de d ce ntral re vie w 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel c o m pare d t o S O C o n 
o verall s ur vi val ( O S) 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel c o m pare d t o S O C o n 
pr o gressi o n-free s ur vi val ( P F S) 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel c o m pare d t o S O C o n 
d urati o n of res p o nse ( D O R) a n d d urati o n of c o m plete res p o nse a m o n g 
res p o n di n g s u bjects, as deter mi ne d b y bli n de d ce ntral re vie w 
•T o e val uate t he safet y of a xica bta ge ne cil ole ucel c o m pare d t o S O C 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel o n patie nt re p orte d 
o utc o mes ( P R Os) a n d q ualit y of life ( Q o L) c o m pare d t o S O C St u d y 
O bjecti ves: 
E x pl orat or y O bjecti ves 
•E x pl ore mec ha nis ms of resista nce t o treat me nt wit h a xica bta ge ne 
cil ole ucel 
•E val uate mec ha nistic as pects a n d re versi bilit y of t o xicities wit h 
a xica bta ge ne cil ole ucel 
•E x pl ore m olec ular a n d hist ol o gic c haracteristics of t he t u m or 
micr oe n vir o n me nt 
•E val uate i m pact of disease a n d treat me nt o n w or k pr o d ucti vit y a n d 
acti vit y 
•Esti mate ti me t o ne xt t hera p y 
H y p ot hesis: A xica bta ge ne cil ole ucel will pr ol o n g E F S c o m pare d t o S O C t hera p y i n 
a d ult s u bjects wit h rela pse d/refract or y D L B C L.  T he h y p ot hesize d 
treat me nt effect c orres p o n ds t o a 5 0 % i m pr o ve me nt i n E F S. 
Pri m ar y 
E n d p oi nt: E ve nt-free S ur vi val ( E F S):  E F S is defi ne d as t he ti me fr o m ra n d o mizati o n 
t o t he earliest date of disease pr o gressi o n per t he L u ga n o Classificati o n 
{C hes o n 2 0 1 4 }, c o m me nce me nt of ne w l y m p h o ma t hera p y, or deat h fr o m 
a n y ca use.  S u bje cts n ot meeti n g t he criteria f or t hese e ve nts b y t he a nal ysis 
data c ut off date will be ce ns ore d.  F or t he pri mar y a nal ysis of E F S, disease 
pr o gressi o n e ve nts a n d ce ns ori n g ti mes will be deter mi ne d b y bli n de d 
ce ntral re vie w.  E ve nts of ne w t hera p y a n d deat h will be base d o n t he 
cli nical trial data base.  
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 4 1 4 A pril 2 0 2 3 Sec o n d ar y 
E n d p oi nt(s): Ke y sec o n dar y e n d p oi nts (i n or der of hierarc hical testi n g) 
•O bjecti ve res p o nse rate 
•O verall s ur vi val 
Sec o n dar y e n d p oi nts 
•E F S base d o n i n vesti gat or disease assess me nts 
•M o difie d E F S base d o n bli n de d ce ntral re vie w a n d o n i n vesti gat or 
disease assess me nts 
•Pr o gressi o n-free s ur vi val 
•D urati o n of res p o nse a n d c o m plete res p o nse 
•I nci de nce of a d verse e ve nts a n d cli nicall y si g nifica nt c ha n ges i n safet y 
la b val ues, i ncl u di n g a nti b o dies t o a xica bta ge ne cil ole ucel 
•C ha n ges fr o m scree ni n g t o p ost baseli ne i n t he gl o bal healt h stat us Q o L 
scale a n d t he p h ysical f u ncti o ni n g d o mai n of t he E ur o pea n 
Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y of Life 
Q uesti o n naire Ca ncer- 3 0 ( E O R T C Q L Q- C 3 0) 
•C ha n ges fr o m scree ni n g t o p ost baseli ne i n t he E ur o- Q O L, Fi ve 
Di me nsi o ns, Fi ve Le vels ( E Q- 5 D- 5 L) i n de x a n d vis ual a nal o g scale 
( V A S) sc ores 
E x pl or at or y 
E n d p oi nt(s): F or a xica bta ge ne cil ole ucel treat me nt ar m o nl y: 
•Le vels of a nti- C D 1 9 c hi meric a nti ge n rece pt or ( C A R) T cells i n bl o o d 
•Le vels of c yt o ki nes i n ser u m 
F or b ot h treat me nt ar ms: 
•T u m or m olec ular a n d hist ol o gical c haracteristics b y le vels of P D- L 1 
a n d m olec ular a n d c yt o ge netic s u bclassificati o ns 
•C ha n ges i n t he w or k pr o d ucti vit y a n d acti vit y i m pair me nt ( W P AI) fr o m 
scree ni n g t o p ost baseli ne 
•Ti me t o ne xt t hera p y 
S a m ple Size: A p pr o xi matel y [ADDRESS_1175118] u d y 
Eli gi bilit y: Please refer t o Secti o n [ADDRESS_1175119] of i ncl usi o n a n d 
e xcl usi o n criteria. 
Tre at me nt: A xica bta ge ne cil ole ucel ar m 
S u bjects ra n d o mize d t o t he a xica bta ge ne cil ole ucel ar m of t he st u d y will 
recei ve a 3- da y c o n diti o ni n g c he m ot hera p y re gi me n c o nsisti n g of 
fl u dara bi ne 3 0 m g/ m 2/ da y a n d c ycl o p h os p ha mi de 5 0 0 m g/ m 2/ da y o n da y - [ADDRESS_1175120] da ys ( da y - 2 a n d da y - 1). 
A si n gle i nf usi o n of a xica bta ge ne cil ole ucel a d mi nistere d i ntra ve n o usl y at a 
tar get d ose of 2 x 1 0 6 a nti- C D 1 9 C A R T cells/ k g o n da y 0. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 5 1 4 A pril 2 0 2 3 Tre at me nt: Sta n dar d of Care ar m 
•S u bject will recei ve a sec o n d-li ne c o m bi nati o n c he m ot hera p y re gi me n 
( R-I C E, R- D H A P, R- E S H A P, or R- G D P) as selecte d b y t he treati n g 
i n vesti gat or. 
•S u bjects res p o n di n g t o sec o n d-li ne c o m bi nati o n c he m ot hera p y after 2 
or 3 c ycles ( P R or C R) s h o ul d pr ocee d t o hi g h- d ose t hera p y ( H D T) a n d 
a ut ol o g o us ste m cell tra ns pla nt ( A S C T). 
•Peri p heral ste m cell c ollecti o n, H D T, a n d A S C T i nf usi o n will be per 
i nstit uti o nal or re gi o nal g ui deli nes. 
Pr oce d ures: As o utli ne d i n t he S O As, s u bjects will u n der g o t he f oll o wi n g pr oce d ures:  
c ollecti o n of i nf or me d c o nse nt; me dical hist or y; p h ysical e xa m; b o ne 
marr o w bi o ps y; disease sta gi n g, i ncl u di n g a baseli ne P E T- C T sca n; a n d 
bl o o d dra ws f or lactate de h y dr o ge nase le vels, c o m plete bl o o d c o u nt ( C B C), 
a n d bl o o d c he mistries.  S u bjects will als o u n der g o baseli ne ec h ocar di o gra m 
( E C H O) a n d electr ocar di o gra m ( E C G) assess me nts a n d Easter n 
C o o perati ve O nc ol o g y Gr o u p ( E C O G) perf or ma nce stat us. W o me n of 
c hil d beari n g p ote ntial will u n der g o a uri ne or ser u m pre g na nc y test. 
S u bjects ra n d o mize d t o t he a xica bta ge ne cil ole ucel ar m will u n der g o 
le u ka p heresis f or t he c ollecti o n of peri p heral bl o o d m o n o n uclear cells 
necessar y f or a xica bta ge ne cil ole ucel ma n ufact uri n g.  C o n diti o ni n g 
c he m ot hera p y will be f oll o we d b y [ADDRESS_1175121] 7 da ys after a xica bta ge ne cil ole ucel i nf usi o n t o m o nit or f or a n d 
ma na ge a n y a d verse e ve nts, u nless ot her wise re q uire d b y c o u ntr y 
re g ulat or y a ge ncies (refer t o A p pe n di x D ).  Bl o o d dra ws f or t he a nal ysis of 
a nti- C D 1 9 C A R T-cell le vels will be perf or me d.  A d diti o nal bl o o d dra ws 
f or c yt o ki nes, a nti-a xica bta ge ne cil ole ucel a nti b o dies, a n d 
re plicati o n-c o m pete nt retr o vir us ( R C R) ma y be perf or me d as cli nicall y 
i n dicate d.  Treat me nt wit h a xica bta ge ne cil ole ucel is i nte n de d t o be 
defi niti ve t hera p y a n d n ot a bri d ge t o A S C T. 
S u bjects ra n d o mize d t o t he S O C ar m will recei ve i n vesti gat or’s c h oice of 
sec o n d-li ne c o m bi nati o n c he m ot hera p y fr o m t he pr ot oc ol- defi ne d o pti o ns. 
U p t o 3 c ycles ( 6 t o 9 wee ks) of c o m bi nati o n c he m ot hera p y will be 
a d mi nistere d e ver y 2 t o 3 wee ks.  S u bjects wit h a P R or C R t o sec o n d-li ne 
t hera p y s h o ul d pr ocee d t o H D T- A S C T.  Peri p heral ste m cell m o bilizati o n 
a n d le u ka p heresis will be perf or me d acc or di n g t o i nstit uti o nal g ui deli nes 
after t he sec o n d or t hir d c ycle of sec o n d-li ne t hera p y t o o btai n a mi ni m u m 
tar get of 2 x 1 0 6 C D 3 4 + he mat o p oietic ste m cells per kil o gra m.  
H D T- A S C T will be perf or me d per i nstit uti o nal g ui deli nes. 
R o uti nel y t hr o u g h o ut t he c o n d uct of t he st u d y, all s u bjects will be as ke d t o 
re p ort c o nc o mita nt me dicati o ns a n d a d verse e ve nts, re p ort s u bse q ue nt 
l y m p h o ma t hera p y, a ns wer patie nt re p orte d o utc o mes ( P R Os), a n d will 
ha ve r o uti ne disease assess me nts as o utli ne d i n t he S O As. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175122]’s scree ni n g re q uire me nts, res p o nse t o treat me nt, p ote ntial f or 
re-treat me nt, s ur vi val, a n d ti mi n g of t he tra nsiti o n t o a se parate Kite 
L o n g-ter m F oll o w- u p ( L T F U) st u d y. 
F or a s u bject w h o c o m pletes t he e ntire pr ot oc ol fr o m t he date of i nf or me d 
c o nse nt t hr o u g h t he c o m pleti o n of t he l o n g-ter m f oll o w- u p peri o d, t he 
st u d y will ta ke a p pr o xi matel y 5 years t o c o m plete f or t h ose ra n d o mize d t o 
t he S O C ar m a n d a p pr o xi matel y 1 5 years t o c o m plete f or t h ose ra n d o mize d 
t o t he a xica bta ge ne cil ole ucel ar m. 
D at a S afet y 
M o nit ori n g 
B o ar d 
( D S M B): A n i n de pe n de nt D S M B will meet e ver y [ADDRESS_1175123] atistic al 
C o nsi der ati o ns: T he pri mar y g oal of t he statistical a nal ysis is t o deter mi ne if t here is a 
statisticall y si g nifica nt i m pr o ve me nt i n e ve nt-free s ur vi val ( E F S) bet wee n 
t he treat me nt gr o u ps.  A p pr o xi matel y 3 5 0 s u bjects ( 1 7 5 per ar m) will be 
ra n d o mize d t o attai n [ADDRESS_1175124] u d y will ha ve a n o verall al p ha of 2. 5 % wit h 1-si de d 
testi n g.  T o preser ve t he o verall si g nifica nce le vel, statistical testi n g of t he 
pri mar y a n d ke y sec o n dar y efficac y e n d p oi nts will f oll o w a hierarc hical 
sc he me.  E F S will be teste d first at t he pri mar y E F S a nal ysis.  C o n diti o nal 
o n a statisticall y si g nifica nt i m pr o ve me nt i n E F S, O R R will be teste d at t he 
2. 5 % le vel at t he ti me of t he pri mar y E F S a nal ysis.  C o n diti o nal o n a 
statisticall y si g nifica nt i m pr o ve me nt i n E F S a n d O R R, O S will be teste d u p 
t o 3 ti mes at a n o verall al p ha le vel of 2. 5 %.  T he pri mar y a nal ysis of O S 
will occ ur w he n a p pr o xi matel y [ADDRESS_1175125] is ra n d o mize d.  A s pe n di n g f u ncti o n of 
t he R h o fa mil y will be use d t o all ocate t he al p ha bet wee n t he 2 i nteri m 
a nal yses of O S a n d t he pri mar y a nal ysis of O S.  A d diti o nall y, o ne i nteri m 
f utilit y a nal ysis of E F S will be c o n d ucte d after 1 3 5 E F S e ve nts ha ve bee n 
o bser ve d.  Stratifie d (ra n d o mizati o n fact ors) l o g-ra n k tests will be use d t o 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175126] t he n ull h y p ot hesis of n o differe nce i n E F S a n d O S usi n g a n o verall 
1-si de d al p ha le vel of 2. 5 %.  A stratifie d (ra n d o mizati o n fact ors) 
C oc hra n- Ma ntel- Hae nszel test will be use d t o test O R R at a n o verall 
1-si de d al p ha le vel of 2. 5 %. 
F or a f ull descri pti o n of statistical a nal ysis met h o ds, refer t o Secti o n 1 0 .
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 8 1 4 A pril 2 0 2 3 S T U D Y  S C H E M A 
Scree ni n g Ra n d o mizati o n Da y 5 0 (fr o m ra n d o mizati o n) Disease Assess me nt b Da y 1 5 0 (fr o m ra n d o mizati o n) Disease Assess me nt b Tre at me nt Pe ri o d: St a n d ar d of C are T her a p y Tre at me nt Ar m 
S u bjects ra n d o m ize d t o t he S O C ar m will recei ve a sec o n d-li ne 
c o m bi nati o n c he m ot hera p y re gi me n ( R-I C E, R- D H A P, R- E S H A P, 
or R- G D P) as selecte d b y t he treati n g i n vesti gat or. 
S u bjects will recei ve 2 or 3 c ycles of c he m ot hera p y a d mi nistere d 
e ver y 2- 3 wee ks. 
S u bjects res p o n di n g t o sec o n d-li ne c o m bi nati o n c he m ot hera p y after 
2 or 3 c ycles s h o ul d pr ocee d wit h H D T a n d A S C T. S u bjects w h o d o 
n ot res p o n d t o sec o n d-li ne c he m ot hera p y ca n recei ve a d diti o nal 
treat me nt off pr ot oc ol. Tre at me nt Pe ri o d: A xic a bt a ge ne Cil ole ucel  Tre at me nt Ar m a
S u bjects ra n d o m ize d t o treat me nt wit h a xica bta ge ne cil ole ucel will 
recei ve a 3 da y c o n diti o ni n g c he m ot hera p y re gi me n c o nsisti n g of 
fl u dara bi ne 3 0 m g/ m 2/ da y a n d c ycl o p h os p ha mi de 5 0 0 m g/ m 2/ da y 
( da y - 5 t o da y - 3) f oll o we d b y [ADDRESS_1175127] da ys ( da y - 2 & da y - 1). 
S u bjects will recei ve a si n gle i nf usi o n of a xica bta ge ne cil ole ucel 
a d mi nistere d i ntra ve n o usl y at a tar get d ose of 2 x 1 0 6 a nti- C D 1 9 
C A R T cells/ k g o n treat me nt da y 0. 
S u bjects will recei ve a xica bta ge ne cil ole ucel i n a healt h care facilit y 
f oll o we d b y a mi ni m u m 7 da y o bser vati o n peri o d. L o n g Ter m F oll o w- u p Peri o d , b,c  
Da y 1 0 0 (fr o m ra n d o mizati o n) Disease Assess me nt b 
aBri d gi n g t her a p y:  At t he discreti o n of t he i n vesti gat or, c ortic oster oi d bri d gi n g t hera p y ma y be c o nsi dere d f or s u bjects wit h hi g h disease 
b ur de n at scree ni n g. Refer t o Secti o n 6. 2. 4. 2  f or details. 
bDise ase Assess me nts:  Calc ulate d fr o m t he da y of  ra n d o mizati o n a n d n ot t he date of d osi n g wit h a xica bta ge ne cil ole ucel or S O C t hera p y.  
I n de pe n de nt of t he ra n d o mize d treat me nt ar m, st u d y pr oce d ures a n d disease assess me nts will occ ur at t he sa me pr ot oc ol defi ne d ti me p oi nts.  
c  After c o m pleti n g at least [ADDRESS_1175128] u d y after pr o vi di n g i nf or me d 
c o nse nt. Refer t o Secti o n 3. 5  
 Mi ni m u m o bser v ati o n peri o d: 7 d a ys u nless  ot her wise re q uire d b y c o u ntr y re g ul at or y a ge ncies (refer t o A p pe n di x D ).  
 
 
  
  
 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175129] ( A xica bta ge ne Cil ole ucel)................................................. [ADDRESS_1175130] u d y Desi g ns a n d Res ults....................................................................... 2 0 
2. 5. 1. Z U M A- 1................................................................................................................................ 2 0 
2. 5. 2. C A R T-cell Rece pt or I m m u n ot hera p y f or Patie nts wit h B-cell L y m p h o ma 
( Pr ot oc ol 0 9- C- 0 0 8 2, N C T 0 0 9 2 4 3 2 6) .................................................................................. [ADDRESS_1175131] u d y Desi g n: Z U M A- 7............................................................................................................. [ADDRESS_1175132] u d y Treat me nt Sc he d ule 
a n d A d mi nistrati o n................................................................................................................ 3 4 
6. 2. 5. E xcl u de d Me dicati o ns ( A xica bta ge ne Cil ole ucel Ar m)........................................................ 4 2 
6. 2. 6. S u bse q ue nt T hera p y ( A xica bta ge ne Cil ole ucel Ar m)........................................................... 4 2 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 1 4 A pril 2 0 2 3 6. 2. 7. T o xicit y Ma na ge me nt ( A xica bta ge ne Cil ole ucel Ar m)........................................................ 4 2 
6. 3. Sta n dar d of Care T hera p y Ar m ............................................................................................................... 4 3 
6. 3. 1. Sta n dar d of Care C he m ot hera p y D osi n g a n d A d mi nistrati o n............................................... 4 3 
6. 3. 2. C o nc o mita nt T hera p y ( Sta n dar d of Care Ar m)..................................................................... 4 4 
6. 3. 3. E xcl u de d Me dicati o ns ( Sta n dar d of Care Ar m).................................................................... 4 5 
6. 3. 4. S u bse q ue nt T hera p y ( Sta n dar d of Care Ar m)....................................................................... 4 5 
6. 3. 5. T o xicit y Ma na ge me nt ( Sta n dar d of Care Ar m)..................................................................... [ADDRESS_1175133] or y............................................................................................................... 4 7 
7. 6. P h ysical E xa m, Vital Si g ns, a n d Perf or ma nce Stat us ............................................................................. 4 8 
7. 7.  Ne ur ol o gical E xa mi nati o n....................................................................................................................... 4 8 
7. 8. Car diac F u ncti o n ..................................................................................................................................... 4 8 
7. 9. T o xicit y E val uati o n................................................................................................................................. 4 9 
7. 1 0.  Disease Res p o nse Assess me nt ................................................................................................................ 4 9 
7. 1 0. 1. I ma gi n g.................................................................................................................................. 4 9 
7. 1 0. 2. B o ne Marr o w Bi o ps y a n d As pi[INVESTIGATOR_337]....................................................................................... 5 0 
7. 1 1. La b orat or y ............................................................................................................................................... 5 0 
7. 1 1. 1. L ocal La b A nal ysis................................................................................................................ 5 0 
7. 1 1. 2. Ce ntral La b A nal ysis............................................................................................................. 5 1 
7. 1 2. Patie nt Re p orte d O utc o mes..................................................................................................................... 5 2 
7. 1 2. 1. E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer ( E O R T C) 
Q L Q- C 3 0 Versi o n 3. 0........................................................................................................... 5 2 
7. 1 2. 2. E ur o Q ol Fi ve Di me nsi o ns Q uesti o n naire ( E Q- 5 D- 5 L)......................................................... 5 3 
7. 1 2. 3.  W or k Pr o d ucti vit y a n d Acti vit y I m pair me nt Q uesti o n naire ( W P AI) ................................... [ADDRESS_1175134]-treat me nt F oll o w- u p........................................................................................................................ 5 5 
7. 1 5. L o n g-ter m F oll o w- u p ( A xica bta ge ne Cil ole ucel a n d Sta n dar d of Care Ar ms) ...................................... [ADDRESS_1175135] u d y E n d p oi nts....................................................................................................................................... 7 4 
1 0. 2. 1. Pri mar y.................................................................................................................................. 7 4 
1 0. 2. 2.  Ke y Sec o n dar y....................................................................................................................... 7 5 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175136] ol o gical 
C haracteristics....................................................................................................................... 8 3 
1 0. 6. 1 0. L o n g-ter m Data A nal ysis ...................................................................................................... 8 4 
1 1. R E G U L A T O R Y O B LI G A TI O N S....................................................................................................................... 8 5 
1 1. 1. I n de pe n de nt Re vie w B oar d/I n de pe n de nt Et hics C o m mittee................................................................... [ADDRESS_1175137] u d y Testi n g Sc he me............................................................................................................. 7 9 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175138] or c o ntai ni n g a nti- C D 1 9 
C D 2 8/ C D 3ζ c hi meric a nti ge n rece pt or 
C A R C hi meric a nti ge n rece pt or 
C B C C o m plete bl o o d c o u nt 
C L L C hr o nic l y m p h oc ytic le u ke mia 
C M R C o m plete meta b olic res p o nse 
C N S Ce ntral ner v o us s yste m 
C R C o m plete res p o nse 
C R F Case Re p ort F or m 
C R P C-reacti ve pr otei n 
C R O C o ntract Researc h Or ga nizati o n 
C R R C o m plete ra di ol o gic res p o nse 
C R S C yt o ki ne release s y n dr o me 
C S F Cere br os pi [INVESTIGATOR_55498] d 
C S R Cli nical St u d y Re p ort 
C T C o m p ute d t o m o gra p h y 
C T C A E C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nts 
D L B C L Diff use lar ge B-cell l y m p h o ma 
D O R D urati o n of res p o nse 
D S M B Data Safet y M o nit ori n g B oar d 
e C R F Electr o nic Case Re p ort F or m 
E C G Electr ocar di o gra m 
E C H O Ec h ocar di o gra m 
E C O G Easter n C o o perati ve O nc ol o g y Gr o u p 
E E G Electr oe nce p hal o gra m 
E F S E ve nt-free s ur vi val 
E n d of st u d y ( pri mar y 
c o m pleti o n) Defi ne d as w he n t he last s u bject has u n der g o ne a n assess me nt f or t he p ur p ose of t he 
e ve nt dri ve n pri mar y a nal ysis 
E O R T C Q L Q- C 3 0 E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y of Life 
Q uesti o n naire Ca ncer- 3 0 ( Q L Q- C 3 0) 
E Q- 5 D- 5 L E ur o- Q O L, Fi ve Di me nsi o ns, Fi ve Le vels 
F A S F ull a nal ysis set 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 3 1 4 A pril 2 0 2 3 A b bre viati o n Defi niti o n 
F L F ollic ular l y m p h o ma 
G C P G o o d Cli nical Practice 
G P Ge neral practiti o ner 
H C P Healt hcare pr o vi der 
H D T Hi g h- d ose t hera p y 
H E E N T Hea d, ears, e yes, n ose, t hr oat 
HI V H u ma n i m m u n o deficie nc y vir us 
H L H He m o p ha g oc ytic l y m p h o histi oc yt osis 
H R Q o L Healt h-relate d q ualit y of life 
I B I n vesti gat or’s Br oc h ure 
I C F I nf or me d C o nse nt F or m 
I C H I nter nati o nal C o nfere nce o n Har m o nisati o n 
I D I de ntificati o n 
I H C I m m u n o hist oc he mistr y 
I L I nterle u ki n 
I P I n vesti gati o nal pr o d uct 
I PI I nter nati o nal Pr o g n ostic I n de x  
I P M I n vesti gati o nal Pr o d uct Ma n ual 
I R B/I E C I nstit uti o nal Re vie w B oar d/I n de pe n de nt Et hics C o m mittee 
I V I ntra ve n o us 
I X R S I nteracti ve V oice/ We b ( X) Res p o nse S yste m 
L D H Lactate de h y dr o ge nase 
L T F U L o n g-ter m f oll o w u p 
L V E F Left ve ntric ular ejecti o n fracti o n 
M C L Ma ntle cell l y m p h o ma 
Me d D R A Me dical Dicti o nar y f or Re g ulat or y Acti vities 
m E F S M o difie d E F S; defi ne d t he sa me wa y as E F S, e xce pt t hat fail ure t o attai n C R or P R 
b y Da y [ADDRESS_1175139] or 
N CI Nati o nal Ca ncer I nstit ute 
N E Ne ur ol o gic e ve nt 
N H L N o n- H o d g ki n l y m p h o ma 
N M R N o meta b olic res p o nse 
N P T Nas o p har y n geal-t hr oat 
O R R O bjecti ve res p o nse rate 
O S O verall s ur vi val 
P B M C Peri p heral bl o o d m o n o n uclear cell 
P C R P ol y merase c hai n reacti o n 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 4 1 4 A pril 2 0 2 3 A b bre viati o n Defi niti o n 
P D Pr o gressi ve disease 
P E T- C T P ositr o n e missi o n t o m o gra p h y-c o m p ute d t o m o gra p h y 
P F S Pr o gressi o n-free s ur vi val 
P K P har mac o ki netic 
P M B C L Pri mar y me diasti nal B-cell l y m p h o ma 
P M D Pr o gressi ve meta b olic disease 
P M R Partial meta b olic res p o nse 
P R Partial res p o nse 
P R D Pr o gressi ve ra di ol o gic disease 
P R O Patie nt re p orte d o utc o me 
P R R Partial ra di ol o gic res p o nse 
Q o L Q ualit y of life 
q P C R Q ua ntitati ve p ol y merase c hai n reacti o n 
R C R Re plicati o n-c o m pete nt retr o vir us 
r/r Rela pse d/refract or y 
S A E Seri o us a d verse e ve nt 
sc F v Si n gle-c hai n varia ble fra g me nt 
S C T Ste m cell tra ns pla nt 
S D Sta ble disease 
S O A Sc he d ule of assess me nt 
S O C Sta n dar d of care 
S R D Sta ble ra di ol o gic disease 
St u d y Da y [ADDRESS_1175140] da y t hat a xica bta ge ne cil ole ucel or C D 3 4 + ste m cells f or A S C T 
are a d mi nistere d t o t he s u bject 
U L N U p per li mit of n or mal 
U TI Uri nar y tract i nfecti o n 
V A S Vis ual a nal o g scale 
W B C W hite bl o o d cell 
W P AI: G H W or k pr o d ucti vit y a n d acti vit y i m pair me nt q uesti o n naire: ge neral healt h 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 5 1 4 A pril 2 0 2 3 1.  O B J E C TI V E S 
1. 1. Pri m ar y O bjecti ve 
•T o deter mi ne if a xica bta ge ne cil ole ucel is s u peri or t o sta n dar d of care ( S O C) as meas ure d b y 
e ve nt-free s ur vi val ( E F S), as deter mi ne d b y bli n de d ce ntral re vie w 
1. 2. Sec o n d ar y O bjecti ves 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel c o m pare d t o S O C o n o bjecti ve res p o nse rate 
( O R R), as deter mi ne d b y bli n de d ce ntral re vie w 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel c o m pare d t o S O C o n o verall s ur vi val ( O S) 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel c o m pare d t o S O C o n pr o gressi o n-free 
s ur vi val ( P F S) 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel c o m pare d t o S O C o n d urati o n of res p o nse 
( D O R) a n d d urati o n of c o m plete res p o nse a m o n g res p o n di n g s u bjects, as deter mi ne d b y 
bli n de d ce ntral re vie w 
•T o e val uate t he safet y of a xica bta ge ne cil ole ucel c o m pare d t o S O C 
•T o e val uate t he effect of a xica bta ge ne cil ole ucel o n patie nt re p orte d o utc o mes ( P R Os) a n d 
q ualit y of life ( Q o L) c o m pare d t o S O C 
1. 3. E x pl or at or y O bjecti ves 
•E x pl ore mec ha nis ms of resista nce t o treat me nt wit h a xica bta ge ne cil ole ucel 
•E val uate mec ha nistic as pects a n d re versi bilit y of t o xicities wit h a xica bta ge ne cil ole ucel 
•E x pl ore m olec ular a n d hist ol o gic c haracteristics of t he t u m or micr oe n vir o n me nt 
•E val uate i m pact of disease a n d treat me nt o n w or k pr o d ucti vit y a n d acti vit y 
•Esti mate ti me t o ne xt t hera p y 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 6 1 4 A pril 2 0 2 3 2.  DI S E A S E B A C K G R O U N D A N D R A TI O N A L E 
N o n- H o d g ki n l y m p h o ma ( N H L) c o m prises a heter o ge ne o us gr o u p of ca ncers ori gi nati n g 
pri maril y i n B l y m p h oc ytes a n d, t o a lesser e xte nt, i n T l y m p h oc ytes a n d nat ural killer cells.  
N H L is t he m ost pre vale nt he mat ol o gical mali g na nc y a n d is t he se ve nt h m ost c o m m o n ne w 
ca ncer a m o n g me n a n d w o me n, acc o u nti n g f or 4 % of all ne w ca ncer cases a n d 3 % of ca ncer- 
relate d deat hs { H o wla der 2 0 1 5 }. 
Diff use lar ge B-cell l y m p h o ma ( D L B C L) is t he m ost c o m m o n s u bt y pe of N H L, acc o u nti n g f or 
a p pr o xi matel y 3 0 % t o 4 0 % of all cases { C ha ga nti 2 0 1 6 , M ort o n 2 0 0 6 , Se h n 2 0 1 5 }.  D L B C L 
c o m prises a gr o u p of l y m p h oi d mali g na ncies c o m p ose d of lar ge cells wit h vesic ular n uclei, 
pr o mi ne nt n ucle oli, bas o p hilic c yt o plas m, a n d a hi g h pr oliferati o n rate { Martelli 2 0 1 3 }.  Patie nts 
ofte n prese nt wit h si n gle or m ulti ple ra pi [INVESTIGATOR_2478] y e nlar gi n g s y m pt o matic masses, wit h u p t o 4 0 % 
occ urri n g at e xtra n o dal sites, partic ularl y t he gastr oi ntesti nal tract (st o mac h a n d ile ocecal 
re gi o n).  Ce ntr o blast- a n d i m m u n o blast-li ke cells are t he pre d o mi na nt m or p h ol o g y, a n d t hese 
cells t y pi[INVESTIGATOR_1306] y e x press t he B-cell mar kers C D [ADDRESS_1175141]-li ne T her a p y 
Si nce t he 1 9 7 0s, t he C H O P c he m ot hera p y re gi me n (c ycl o p h os p ha mi de, d o x or u bici n, vi ncristi ne, 
a n d pre d nis o ne) ha d bee n sta n dar d of care first-li ne t hera p y.  M ore i nte nsi ve c o m bi nati o ns faile d 
t o s h o w a d diti o nal s ur vi val be nefit.  T he c urre nt sta n dar d of care f or first-li ne treat me nt is C H O P 
i n c o m bi nati o n wit h a n a nti- C D 2 0 m o n ocl o nal a nti b o d y rit u xi ma b ( R- C H O P, rit u xi ma b- base d 
c he m oi m m u n ot hera p y) { Fl o wers 2 0 1 0 }.  I n t he se mi nal st u d y b y t he Gr o u pe d’ Et u de des 
L y m p h o mes de l’ A d ulte, first-li ne R- C H O P was s u peri or t o C H O P { Fe u gier 2 0 0 5 }, wit h 
1 0- year O S a n d P F S of 4 3. 5 % vers us  2 7. 6 % a n d 3 6. 5 % vers us 2 0 %, res pecti vel y { Fe u gier 
2 0 0 5 }.  T h us, w hile m ore effecti ve t ha n c he m ot hera p y al o ne, first-li ne R- C H O P still o nl y res ults 
i n l o n g-ter m disease re missi o n i n < 4 0 % of s u bjects.  Rece ntl y a P hase [ADDRESS_1175142]-li ne 
R- C H O P vers us d ose-a dj uste d R- E P O C H de m o nstrate d n o differe nce i n E F S or O S bet wee n t he 
re gi me ns { Wils o n 2 0 1 6 }. 
T he I nter nati o nal Pr o g n ostic I n de x (I PI), w hic h i ncl u des a ge, perf or ma nce stat us, lactate 
de h y dr o ge nase ( L D H) le vel, sta ge, a n d e xtra n o dal i n v ol ve me nt, c orrelates wit h o utc o mes t o 
sta n dar d first-li ne t hera p y.  M ore rece ntl y, pr o g n ostic m olec ular feat ures ha ve bee n i de ntifie d.  
Ge ne e x pressi o n pr ofili n g has bee n use d t o cate g orize D L B C L i nt o t he ger mi nal ce nter B-cell 
t y pe, a n d acti vate d B-cell t y pe is ass ociate d wit h w orse o utc o mes.  A d diti o nall y, d o u ble- a n d 
tri ple- hit l y m p h o mas wit h tra nsl ocati o ns of M Y C a n d eit her B C L 2 a n d/ or B C L 6 ha ve bee n 
s h o w n t o ha ve a p o or pr o g n osis wit h R- C H O P c he m ot hera p y { Gree n 2 0 1 2 }. 
2. 2. St a n d ar d Sec o n d-li ne T her a p y 
Patie nts wit h D L B C L w h o rela pse after or are refract or y t o first-li ne t hera p y (rela pse d/refract or y 
[r/r] D L B C L) ha ve p o or pr o g n osis.  I n t he L N H- 9 8. 5 trial, a p pr o xi matel y 4 0 % of patie nts 
rela pse after R- C H O P, a n d 7 0 % of t hese patie nts die wit hi n t he first 2 years after pr o gressi o n 
des pi[INVESTIGATOR_845631] t hera p y, wit h a me dia n O S of 0. 7 years after pr o gressi o n { C oiffier 2 0 1 0 }. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 7 1 4 A pril 2 0 2 3 Patie nts wit h r/r D L B C L ha ve heter o ge ne o us o utc o mes t o sec o n d-li ne t hera p y.  T he g oal of 
sal va ge c he m ot hera p y is t o deter mi ne c he m o-se nsiti vit y pri or t o pr ocee di n g t o hi g h- d ose 
t hera p y-a ut ol o g o us ste m cell tra ns pla nt ( H D T- A S C T).  T he sec o n d-li ne a ge-a dj uste d I PI 
(s A AI PI: L D H, sta ge, a n d perf or ma nce stat us) ca n f urt her pre dict o utc o me f or r/r D L B C L f or 
b ot h c he m ot hera p y-se nsiti ve a n d all patie nts { Ha mli n 2 0 0 3 }. 
Res ults of t he P A R M A trial { P hili p 1 9 9 5 } de m o nstrate d s u peri or o utc o me f or sal va ge t hera p y 
pl us A S C T c o m pare d wit h sal va ge t hera p y al o ne f or patie nts wit h r/r D L B C L ( 5- year E F S of 
4 6 % vs 1 2 %, a n d O S of 5 3 % a n d 3 2 %, res pecti vel y), lea di n g t o t he a d o pti o n of sec o n d-li ne 
c he m ot hera p y pl us A S C T as t he sta n dar d of care.  Patie nts w h o are u na ble t o u n der g o A S C T d ue 
t o c o m or bi dities or c he m ot hera p y i nse nsiti ve disease ha ve p o or l o n g-ter m o utc o mes. 
Sec o n d-li ne c he m ot hera p y re gi me ns ge nerall y c o nsist of n o n-cr oss-resista nt dr u gs t o first-li ne 
R- C H O P.  C o m m o n re gi me ns i ncl u de R- G D P, R- D H A P, R-I C E, a n d R- E S H A P.  I nstit uti o nal 
prefere nce a n d a d verse e ve nt ( A E) pr ofile ofte n dictate w hic h treat me nt re gi me n is use d.  N o 
re gi me n has de m o nstrate d s u peri orit y i n a ra n d o mize d trial.  T he P hase 3 L Y 1 2 trial c o m pare d 
G D P t o D H A P f oll o we d b y H D T a n d A S C T i n patie nts wit h r/r D L B C L.  O R Rs ( 4 5 % vs 4 4 %), 
E F S ( H R = 0. 9 9), a n d O S ( H R = 1. 0 3) were si milar bet wee n ar ms alt h o u g h he mat ol o gic t o xicit y 
was m ore se vere i n t he D H A P ar m { Cr u m p 2 0 1 4 }.  I n t he P hase 3 C O R A L trial, patie nts wit h r/r 
D L B C L were ra n d o mize d t o R-I C E vers us R- D H A P f oll o we d b y H D T a n d A S C T, f oll o we d b y a 
sec o n d ra n d o mizati o n t o rit u xi ma b mai nte na nce or n o mai nte na nce.  O R Rs ( 6 4 % vs 6 3 %) a n d 
3 year O S ( 4 7 % vs 5 1 %) were si milar bet wee n t he t w o re gi me ns; h o we ver, m ore he mat ol o gic 
t o xicit y was ass ociate d wit h R- D H A P.  Mai nte na nce wit h rit u xi ma b was n ot s h o w n t o be 
be neficial after A S C T. 
T h ose wit h c he m o-se nsiti ve disease t hat res p o n ds t o sec o n d-li ne c he m ot hera p y pr ocee d t o H D T 
a n d A S C T.  H D T- A S C T i n v ol ves peri p heral ste m cell c ollecti o n, m yel oa blati ve hi g h- d ose 
c he m ot hera p y wit h or wit h o ut t otal b o d y irra diati o n ( T BI), a n d ste m cell resc ue.  Alt h o u g h 
treat me nt pr oce d ures ma y var y bet wee n differe nt re gi o ns a n d i nstit uti o ns, t he ge neral pr ocess 
re mai ns c o nsiste nt.  Ste m cells are m o bilize d fr o m t he b o ne marr o w t o t he peri p her y wit h G- C S F 
a n d t he n c ollecte d b y le u ka p heresis.  H D T utilizes a m yel oa blati ve c o n diti o ni n g re gi me n 
c o nsisti n g of c o m bi nati o n c he m ot hera p y wit h or wit h o ut T BI.  T he c h oice of re gi me ns varies 
beca use n o si n gle re gi me n has de m o nstrate d s u peri orit y i n a ra n d o mize d trial; h o we ver, 
c he m ot hera p y- o nl y re gi me ns ma y ha ve l o wer rates of sec o n dar y m yel o d ys plastic s y n dr o me a n d 
ac ute m yel oi d le u ke mia { Barri n gt o n [ADDRESS_1175143] o ne 1 9 9 4 }.  A c o m m o n re gi me n 
is car m usti ne ( B C N U), et o p osi de, ara- C, a n d mel p hala n ( B E A M), w hic h t y pi[INVESTIGATOR_1306] y is i nitiate d a 
wee k pri or t o ste m cell i nf usi o n.  G- C S F is a d mi nistere d t he da y f oll o wi n g ste m cell i nf usi o n t o 
s u p p ort e n graft me nt a n d rec o nstit uti o n of t he b o ne marr o w, effecti vel y resc ui n g he mat o p oiesis 
a n d re d uci n g t he peri o d of pr of o u n d ne utr o pe nia d uri n g w hic h life-t hreate ni n g i nfecti o ns ca n 
occ ur.  T he r o uti ne use of G- C S F has le d t o re d ucti o n of earl y tra ns pla nt-relate d m ortalit y, b ut it 
re mai ns as hi g h as 5 % e ve n i n e x perie nce d i nstit uti o ns. 
I n t he C O R A L trial, patie nts treate d wit h rit u xi ma b- base d first-li ne t hera p y w h o rela pse wit hi n 
1 year of dia g n osis ha ve p o or o utc o mes.  T he 1- year E F S i n t his gr o u p (a p pr o xi matel y 6 0 % of 
t he patie nts) was bel o w 2 0 % i n t h ose w h o rela pse bef ore 1 year c o m pare d t o 5 0 % i n t h ose wit h 
rela pse after 1 year { Gissel brec ht 2 0 1 0 }.  Als o, half of t he patie nts di d n ot reac h A S C T, 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 8 1 4 A pril 2 0 2 3 pre d o mi na ntl y d ue t o i na de q uate res p o nse t o sec o n d-li ne c he m ot hera p y; a p pr o xi matel y 8 4 % d ue 
t o treat me nt fail ure a n d 9. 4 % d ue t o t o xicit y.  I na de q uate res p o nse t o sec o n d-li ne c he m ot hera p y 
i m plies c he m o-resista nce, a n d A S C T w o ul d n ot be i n dicate d beca use of pr o ba ble i na de q uate 
res p o nse t o hi g h- d ose c he m ot hera p y.  T heir pr o g n osis is p o or, wit h a me dia n O S of a b o ut 
4. 4 m o nt hs { Va n De n Neste 2 0 1 6 }. 
T he P hase [ADDRESS_1175144] u d y i n D L B C L wit h p ositr o n e missi o n 
t o m o gra p h y ( P E T)- base d assess me nts, de m o nstrate d t hat patie nts wit h pri mar y refract or y or 
earl y-rela pse d disease ha ve p o or o utc o mes { va n I m h off 2 0 1 7 }.  Patie nts were treate d wit h 
rit u xi ma b- or ofat u m u ma b- base d sal va ge D H A P t hera p y f oll o we d b y H D T- A S C T i n res p o n ders 
base d o n P E T- C T assess me nt.  T h ose wit h pri mar y refract or y disease or w h o rela pse 
≤ [ADDRESS_1175145]-li ne treat me nt, re prese nti n g 7 0 % of patie nts i n t he trial, 
ha ve l o wer P F S a n d O S c o m pare d t o t h ose w h o rela pse > 1 2 m o nt hs, wit h a hi g hl y si g nifica nt 
hazar d rati o of 0. 3 2 ( 9 5 % c o nfi de nce i nter val [ CI] 0. 2 4 t o 0. 4 4) a n d 0. 4 ( 9 5 % CI 0. 2 9 t o 0. 5 5), 
res pecti vel y.  T his, al o n g wit h res ults fr o m ot her A S C T st u dies { G u gliel mi 1 9 9 8 } { Velle n ga 
2 0 0 8 }, hi g hli g hts t hat pri mar y refract or y or earl y rela pse d disease, re gar dless as defi ne d as 
≤ [ADDRESS_1175146] ors. 
T h us, treat me nt of patie nts wit h r/r D L B C L re mai ns c halle n gi n g.  T here is a si g nifica nt u n met 
nee d f or better t hera pi[INVESTIGATOR_014] i n t hese patie nts. 
2. 3. St u d y R ati o n ale 
Patie nts wit h r/r D L B C L es peciall y pri mar y refract or y a n d earl y rela pse wit hi n [ADDRESS_1175147] ors t o be effecti ve.  
C hi meric a nti ge n rece pt or ( C A R) e n gi neere d T cells ma y a d dress t hese iss ues a n d are a 
pr o misi n g a p pr oac h f or ca ncer t hera p y. 
A xica bta ge ne cil ole ucel is a n e n gi neere d a ut ol o g o us T-cell i m m u n ot hera p y b y w hic h a patie nt’s 
o w n T cells are c ollecte d a n d s u bse q ue ntl y ge neticall y altere d t o rec o g nize C D [ADDRESS_1175148] or y a g gressi ve N H L, a xica bta ge ne 
cil ole ucel si g nifica ntl y i m pr o ve d O R R ( P < 0. 0 0 0 1).  T he O R R was 8 2 % wit h a c o m plete 
res p o nse ( C R) rate of 5 4 %.  At t he pri mar y a nal ysis, 4 4 % of s u bjects ha d o n g oi n g res p o nses 
( 3 9 % i n C R) (s h o w n i n Ta ble 1 ).  A xica bta ge ne cil ole ucel ma y ha ve a n i m pr o ve d efficac y a n d 
t olera bilit y i n patie nts wit h less c he m o-refract or y disease a n d l o wer disease b ur de n.  T heref ore, 
a xica bta ge ne cil ole ucel will be c o m pare d t o S O C i n patie nts wit h r/r D L B C L. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175149] plas ma cells.  T he patter n of C D 1 9 
e x pressi o n is mai ntai ne d i n B-cell mali g na ncies, i ncl u di n g s u bt y pes of B-cell N H L, D L B C L, 
pri mar y me diasti nal B-cell l y m p h o ma ( P M B C L), tra nsf or me d f ollic ular l y m p h o ma ( T F L), 
ma ntle cell l y m p h o ma ( M C L), ac ute l y m p h oc ytic le u ke mia ( A L L), c hr o nic l y m p h oc ytic 
le u ke mia ( C L L), a n d n o n T-cell ac ute l y m p h o blastic le u ke mia { Bla nc 2 0 1 1 } wit h t he e xce pti o n 
of m ulti ple m yel o ma. 
2. 4. 2.  A nti- C D [ADDRESS_1175150] ( A xic a bt a ge ne Cil ole ucel) 
A nti- C D 1 9 C A R T cells are a ut ol o g o us h u ma n T cells t hat ha ve bee n e n gi neere d t o e x press a n 
e xtracell ular si n gle-c hai n varia ble fra g me nt (sc F v) wit h s pecificit y f or C D [ADDRESS_1175151] has bee n desi g ne d, o pti mize d, a n d i nitiall y teste d at t he 
S ur ger y Bra nc h of t he Nati o nal Ca ncer I nstit ute ( N CI) (refer t o Fi g ure 1 ); { K oc he n derfer 2 0 0 9 , 
K oc he n derfer 2 0 1 0 }.  T he sc F v is deri ve d fr o m t he varia ble re gi o n of t he a nti- C D 1 9 m o n ocl o nal 
a nti b o d y F M C 6 3 { Nic h ols o n 1 9 9 7 }.  A p orti o n of t he C D [ADDRESS_1175152] a n d e x pa nsi o n of a nti ‑C D 1 9 
C A R T cells { K o w oli k 2 0 0 6 }.  T he si g nali n g d o mai n of t he C D 3ζ c hai n is esse ntial f or T-cell 
acti vati o n.  T hese fra g me nts were cl o ne d i nt o t he m uri ne ste m cell vir us- base d vect or  ( M S G V 1), 
utilize d t o ge neticall y e n gi neer t he a ut ol o g o us T cells.  T he safet y a n d efficac y of a nti- C D 1 9 
C A R T cells has bee n e val uate d i n s u bjects wit h C D 1 9 + B-cell mali g na ncies at t he N CI 
{K oc he n derfer 2 0 1 2 , K oc he n derfer 2 0 1 5 , K oc he n derfer 2 0 1 7 }.  T he sa me a nti ‑C D [ADDRESS_1175153] is i nserte d i nt o t he T cells’ ge n o me b y retr o viral vect or tra ns d ucti o n.  
Briefl y, peri p heral bl o o d m o n o n uclear cells ( P B M Cs) are o btai ne d b y le u ka p heresis a n d Fic oll 
se parati o n.  P B M Cs are acti vate d b y c ult uri n g wit h a n a nti- C D 3 a nti b o d y i n t he prese nce of 
rec o m bi na nt h u ma n i nterle u ki n- 2 (I L- 2).  Sti m ulate d cells are tra ns d uce d wit h a retr o viral vect or 
c o ntai ni n g a n a nti- C D 1 9 C A R ge ne a n d pr o pa gate d i n c ult ure t o ge nerate s ufficie nt e n gi neere d 
T cells f or a d mi nistrati o n. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175154] a n d Mec h a nis m of Acti o n 
A b bre viati o ns:  C D, cl uster of differe ntiati o n; L T R, l o n g ter mi nal re peat; sc F v, si n gle-c hai n varia ble fra g me nt; C A R, c hi meric 
a nti ge n rece pt or. 
2. 5. Pri or A nti- C D [ADDRESS_1175155] u d y Desi g ns a n d Res ults 
2. 5. 1. Z U M A- 1 
Kite P har ma, I nc. ( hereafter referre d t o as Kite or Kite P har ma) is de vel o pi n g a xica bta ge ne 
cil ole ucel, w hic h tar gets C D [ADDRESS_1175156] is 
i de ntical t o t he o ne use d i n N CI pr ot oc ols { K oc he n derfer 2 0 1 7 }.  Kite P har ma, i n c o nj u ncti o n 
wit h t he N CI S ur ger y Bra nc h, has de vel o pe d a strea mli ne d pr ocess f or t he ge nerati o n of t he a nti- 
C D [ADDRESS_1175157] u d y, please refer t o t he I n vesti gat or’s Br oc h ure 
(I B). 
2. 5. 1. 1. Z U M A- 1 St u d y Desi g n 
Z U M A- 1 is p hase 1/ [ADDRESS_1175158] or y a g gressi ve N H L.  
    
   
  
   
   
 
  
   
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175159] or y P M B C L a n d T F L. 
S u bjects were treate d wit h c o n diti o ni n g c he m ot hera p y c o nsisti n g of fl u dara bi ne 3 0 m g/ m 2/ da y 
a n d c ycl o p h os p ha mi de 5 0 0 m g/ m 2/ da y, a d mi nistere d f or [ADDRESS_1175160] da ys bef ore 
recei vi n g a xica bta ge ne cil ole ucel.  A xica bta ge ne cil ole ucel was a d mi nistere d as a si n gle i nf usi o n 
of C A R tra ns d uce d a ut ol o g o us T cells a d mi nistere d i ntra ve n o usl y at a tar get d ose of 2 x 1 0 6 
a nti- C D 1 9 C A R T cells/ k g.  After i n vesti gati o nal pr o d uct (I P) was d ose d, s u bjects were assesse d 
f or p ost-treat me nt res p o nse f oll o we d b y a l o n g-ter m f oll o w- u p peri o d f or d urati o n of res p o nse 
a n d o verall s ur vi val. 
2. 5. 1. 2. Z U M A- 1 Pri mar y A nal ysis 
As of 2 7 Ja n 2 0 1 7, t he ti me of t he pri mar y a nal ysis data c ut off, 7 7 s u bjects i n C o h ort 1 a n d 
2 4 s u bjects i n C o h ort 2 were e val ua ble ( Ta ble 1 ).  A xica bta ge ne cil ole ucel was s uccessf ull y 
ma n ufact ure d i n 9 9 % of s u bjects e nr olle d.  A vera ge t ur nar o u n d ti me fr o m a p heresis t o recei pt of 
a xica bta ge ne cil ole ucel at cli nical sites was 1 7 da ys. 
Wit h a n O R R of 8 2 % i n C o h ort 1 + 2, t he st u d y met t he pri mar y e n d p oi nt ( P < 0. 0 0 0 1; e xact 
bi n o mial test c o m pari n g o bser ve d O R R t o hist orical c o ntr ol of 2 0 %), wit h 4 9 % C Rs.  I n all 
1 0 1 s u bjects, O R R was 8 2 %, wit h C R i n 5 4 % a n d a me dia n ti me t o C R of 1 m o nt h ( Ta ble 1 ); 
4 4 % ha d o n g oi n g res p o nses ( C R i n 3 9 %) at t he ti me of t he pri mar y a nal ysis.  O R R was 
c o nsiste nt acr oss a br oa d ra n ge of c o variates, i ncl u di n g refract or y s u b gr o u p, sta ge, I PI, a n d a ge. 
Wit h a me dia n f oll o w- u p ti me of 8. 7 m o nt hs, t he me dia n D O R was 8. 1 m o nt hs.  T he me dia n 
D O R i n s u bjects ac hie vi n g C R was n ot reac he d.  T he me dia n P F S was 5. 9 m o nt hs, a n d t he 
me dia n O S was n ot reac he d.  Ka pla n – Meier esti mates of O S at 6, 9, a n d 1 2 m o nt hs were 7 9. 8 %, 
6 8. 4 % a n d 5 4. 5 %. 
T he m ost c o m m o n Gra de 3 or hi g her treat me nt-e mer ge nt A Es ( T E A Es) are als o s h o w n i n 
Ta ble 1 .  T here were t w o Gra de 5 a xica bta ge ne cil ole ucel relate d e ve nts, i ncl u di n g 
he m o p ha g oc ytic l y m p h o histi oc yt osis ( H L H) a n d car diac arrest i n t he setti n g of c yt o ki ne release 
s y n dr o me ( C R S). 
Pea k C A R T-cell e x pa nsi o n was ass ociate d wit h o n g oi n g res p o nse at 3 m o nt hs ( P = 0. 0 0 4) a n d 
Gra de ≥ 3 ne ur ol o gical e ve nts ( N Es; P = 0. 0 2).  S u bjects wit h Gra de ≥ 3 C R S a n d N Es ha d 
i ncrease d le vels of I L- 1 5 ( P = 0. 0 4 a n d P = 0. 0 0 6, res pecti vel y) a n d I L- 6 ( P = 0. 0 0 1 a n d 
P = 0. 0 0 0 3, res pecti vel y). 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 2 2 1 4 A pril 2 0 2 3 T a ble 1. B aseli ne C h ar acteristics a n d Res ults fr o m Z U M A- 1 Pri m ar y A n al ysis 
C o h ort 1 
D L B C L 
( N = 7 7) C o h ort 2 
P M B C L/ T F L 
( N = 2 4) T ot al 
( N = 1 0 1) 
Baseli ne C haracteristics    
Me dia n A ge (ra n ge), years 5 8 ( 2 5- 7 6) 5 7 ( 2 3- 7 6) 5 8 ( 2 3- 7 6) 
A ge ≥ 6 5 years, n ( %) 1 7 ( 2 2) 7 ( 2 9) 2 4 ( 2 4) 
Male, n ( %) 5 0 ( 6 5) 1 8 ( 7 5) 6 8 ( 6 7) 
E C O G perf or ma nce stat us 1, n ( %) 4 9 ( 6 4) 1 0 ( 4 2) 5 9 ( 5 8) 
Recei ve d ≥ 3 li nes of pri or t hera p y 4 9 ( 6 4) 2 1 ( 8 8) 7 0 ( 7 0) 
Refract or y ≥ 2 li nes of pri or t hera p y 5 9 ( 7 7) 1 9 ( 7 9) 7 8 ( 7 7) 
Rela pse p ost A S C T 1 6 ( 2 1) 5 ( 2 1) 2 1 ( 2 1) 
Res p o nse    
O bjecti ve res p o nse rate, n ( %) 6 3 ( 8 2) 2 0 ( 8 3) 8 3 ( 8 2) 
9 5 % CI 
P- val ue a ( 7 1, 9 0) ( 6 3, 9 5) ( 7 3, 8 9) 
P < 0. [ADDRESS_1175161] res p o nse, n ( %)    
C R 3 8 ( 4 9) 1 7 ( 7 1) 5 5 ( 5 4) 
P R 2 5 ( 3 2) 3 ( 1 3) 2 8 ( 2 8) 
Safet y T otal ( N = 1 0 1) 
C o m m o n Gra de 3 or hi g her A Es, n ( %) b 
Ne utr o pe nia/ ne utr o p hil c o u nt decrease d 6 6 ( 6 6) 
Le u k o pe nia/ W B C c o u nt decrease d 4 4 ( 4 4) 
A ne mia 4 3 ( 4 3) 
Fe brile ne utr o pe nia 3 1 ( 3 1) 
T hr o m b oc yt o pe nia 2 4 ( 2 4) 
E nce p hal o pat h y 2 1 ( 2 1) 
Gra de [ADDRESS_1175162], n ( %)  
C yt o ki ne release s y n dr o me c1 3 ( 1 3) 
Ne ur ol o gical e ve nts c2 8 ( 2 8) 
A b bre viati o ns:  D L B C L, diff use lar ge B-cell l y m p h o ma; P M B C L, pri mar y me diasti nal B-cell l y m p h o ma; T F L, tra nsf or me d 
f ollic ular l y m p h o ma;  E C O G, Easter n C o o perati ve O nc ol o g y Gr o u p; A S C T, a ut ol o g o us ste m cell tra ns pla nt; CI, c o nfi de nce 
i nter val; C R, c o m plete res p o nse; P R, partial res p o nse; A E, a d verse e ve nt; W B C, w hite bl o o d c o u nt. 
N otes:  All A Es are treat me nt e mer ge nt. 
a E xact bi n o mial test c o m pari n g o bser ve d O R R i n D L B C L t o a hist orical c o ntr ol ass u m pti o n of 2 0 %. 
b  Occ urri n g i n > 2 0 % of patie nts. 
c C o m bi ne d ter ms. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 2 3 1 4 A pril 2 0 2 3 2. 5. 2.  C A R T-cell Rece pt or I m m u n ot her a p y f or P atie nts wit h B-cell L y m p h o m a 
( Pr ot oc ol 0 9- C- 0 0 8 2, N C T 0 0 9 2 4 3 2 6) 
T he N CI cli nical st u d y ( Pr ot oc ol 0 9- C- 0 0 8 2) of a nti- C D [ADDRESS_1175163] is i de ntical t o t he o ne use d i n Z U M A- 1.  I n t he N CI c o h ort of 4 3 s u bjects wit h 
rela pse d/refract or y B-cell mali g na ncies, t he O R R was 7 4 %, wit h a C R rate of 5 4 % a n d a partial 
res p o nse ( P R) rate of 2 1 % (as of 1 0 N o v 2 0 1 6, data o n file at Kite P har ma).  T we nt y- o ne of t he 
4 3 s u bjects ( 4 9 %) were still i n res p o nse, wit h a me dia n f oll o w- u p of 3 6 m o nt hs (ra n ge 1 3 t o 
7 8 m o nt hs). Me dia n D O R was 3 5 m o nt hs (ra n ge 2 3 t o 7 7 m o nt hs).  Ni netee n s u bjects ( 4 4 %) ha d 
o n g oi n g res p o nses f or m ore t ha n [ADDRESS_1175164] rece nt re p ort f oc usi n g o n 2 2 s u bjects treate d wit h l o w d ose c o n diti o ni n g 
c he m ot hera p y, 1 9 ha d D L B C L, 2 ha d f ollic ular l y m p h o ma ( F L), a n d o ne ha d M C L 
{K oc he n derfer 2 0 1 7 }.  T he C R rate was 5 5 % a n d P R rate was 1 8 %.  I n partic ular, a m o n g a 
s u bset of 1 9 s u bjects wit h D L B C L , t he O R R was 6 8 % wit h a C R i n 4 7 % a n d a P R i n 2 1 %.  Of 
t he [ADDRESS_1175165] of 2 4 m o nt hs o n g oi n g at t he ti me of a nal ysis.  P F S was 6 3. 6 % at 1 2 m o nt hs.  Re missi o ns 
were ass ociate d wit h hi g h ser u m I L- 1 5 le vels a n d hi g h pea k bl o o d C A R T-cell e x pa nsi o n.  
Re versi ble Gra de 3 or 4 ne ur ol o gic t o xicities were o bser ve d i n 5 5 % of s u bjects, wit h n o Gra de 5 
e ve nts.  C o m plete res ol uti o n was o bser ve d wit hi n t he maj orit y of s u bjects wit h s u p p orti ve 
treat me nt; o nl y [ADDRESS_1175166] recei ve d de xa met has o ne a n d 2 recei ve d t ociliz u ma b.  Ne ur ol o gic 
t o xicit y was ass ociate d wit h hi g h pea k bl o o d C A R T-cell le vels a n d hi g h ser u m gra nz y me B, 
I L- 1 0, a n d I L- 1 5 le vels. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175167] u d y Desi g n: Z U M A- [ADDRESS_1175168] u d y e val uati n g t he efficac y of 
a xica bta ge ne cil ole ucel vers us S O C i n a d ult s u bjects wit h r/r D L B C L.  A d ult s u bjects wit h r/r 
D L B C L after first-li ne rit u xi ma b a n d a nt hrac ycli ne- base d c he m ot hera p y will be ra n d o mize d i n a 
1: [ADDRESS_1175169]-li ne t hera p y ( pri mar y refract or y, vs rela pse ≤ [ADDRESS_1175170]-li ne t hera p y vs 
rela pse > 6 a n d ≤ [ADDRESS_1175171]-li ne t hera p y) a n d sec o n d-li ne a ge-a dj uste d I PI ( 0 t o 1 vs 2 t o 
3) as assesse d at t he ti me of scree ni n g. 
F or s u bjects ra n d o mize d t o t he c o ntr ol ar m of t he st u d y, S O C will c o nsist of a pr ot oc ol- defi ne d, 
plati n u m- base d sal va ge c o m bi nati o n c he m ot hera p y re gi me n.  S u bjects w h o res p o n d t o 
sec o n d-li ne c he m ot hera p y s h o ul d pr ocee d t o H D T a n d A S C T. 
A n i n de pe n de nt Data Safet y M o nit ori n g B oar d ( D S M B) will meet e ver y [ADDRESS_1175172] u d y ar m, please refer t o t he sc he d ule of assess me nts 
( S O As) a n d Secti o n [ADDRESS_1175173] u d y, a d diti o nal sites, re gi o ns, or c o u ntries ma y be a d de d as 
necessar y. 
3. 3.  N u m ber of S u bjects 
Partici pa nts i n t his trial will be referre d t o as “s u bjects.”  It is a ntici pate d t hat a p pr o xi matel y 
[ADDRESS_1175174] d, a n d all s u bjects ra n d o mize d will be i ncl u de d i n t he i nte nt-t o-treat 
a nal ysis. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175175]’s scree ni n g 
re q uire me nts, res p o nse t o treat me nt, p ote ntial f or re-treat me nt, s ur vi val a n d ti mi n g of tra nsiti o n 
t o a se parate Kite L o n g-ter m F oll o w- u p ( L T F U) st u d y ( disc usse d i n Secti o n 3. 5. 3  a n d 
Secti o n 7. 1 5 ). 
T he nee d f or pr ol o n ge d f oll o w- u p is base d o n t he p ote ntial prese nce of re plicati o n-c o m pete nt 
retr o vir us ( R C R) i n treate d s u bjects a n d t he nee d t o u n dersta n d a n d miti gate t he p ote ntial ris ks of 
dela ye d o nset A Es t hat c o ul d be t he p ote ntial c o nse q ue nce of treat me nt wit h t his e mer gi n g 
tec h n ol o g y. 
3. 5. 2. E n d- of-st u d y Defi niti o n 
T he e n d of st u d y is defi ne d as w he n t he last re mai ni n g s u bject c o m pletes t heir last visit o n t his 
st u d y a n d tra nsiti o ns t o a se parate L T F U st u d y ( Secti o n 3. 5. 3 ), or, w he n t he last re mai ni n g 
s u bject, w hile still a partici pa nt i n t his st u d y, is c o nsi dere d l ost t o f oll o w- u p, wit h dra ws f ull 
c o nse nt, or dies. 
3. 5. 3. L o n g-ter m F oll o w- u p 
After c o m pleti n g at least [ADDRESS_1175176] u d y after pr o vi di n g i nf or me d c o nse nt, w here t he y will be m o nit ore d f or t he p ossi ble 
occ urre nce of late- o nset tar gete d A Es/seri o us A Es ( S A Es) i ncl u di n g sec o n dar y mali g na ncies, 
a n d t he prese nce of R C R s us pecte d t o be relate d t o  a xica bta ge ne cil ole ucel  f or u p t o 1 5 years 
(refer als o t o Secti o n 7. 1 5 ). I n t he L T F U st u d y, s u bjects will c o nti n ue assess me nts at ti me p oi nts 
c o nti g u o us wit h t heir ti me p oi nt i n t his st u d y. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175177] si g n a n d date t he I nstit uti o nal Re vie w B oar d/I n de pe n de nt Et hics C o m mittee 
(I R B/I E C) a p pr o ve d c o nse nt f or m bef ore i nitiati n g a n y st u d y-s pecific pr oce d ures or acti vities 
t hat are n ot part of a s u bject’s r o uti ne care.  Refer t o Secti o n [ADDRESS_1175178] i de ntificati o n (I D)  n u m ber bef ore a n y 
st u d y pr oce d ures are perf or me d f or all s u bjects w h o e nter i nt o t he scree ni n g peri o d f or t he st u d y 
(e ntr y is defi ne d as t he p oi nt at w hic h t he s u bject si g ns t he i nf or me d c o nse nt) as descri be d i n t he 
I n vesti gati o nal Pr o d uct Ma n ual (I P M).  T his scree ni n g s u bject i de ntificati o n n u m ber will be use d 
t o i de ntif y t he s u bject t hr o u g h o ut t he st u d y a n d m ust be use d o n all st u d y d oc u me ntati o n relate d 
t o t he s u bject.  F urt her m ore, t he scree ni n g s u bject i de ntificati o n n u m ber will re mai n c o nsta nt 
t hr o u g h o ut t he e ntire cli nical st u d y; it will n ot be c ha n ge d after e nr oll me nt or if t he s u bject is 
rescree ne d or retreate d. 
F oll o wi n g all scree ni n g acti vities, t he s u bject will be re gistere d i n t he I nteracti ve V oice/ We b 
Res p o nse S yste m (I X R S) f or ra n d o mizati o n u p o n t he i n vesti gat or c o nfir mi n g eli gi bilit y of t he 
s u bject.  F or f urt her details o n t he c o nse nt, scree ni n g, a n d e nr oll me nt pr ocess, refer t o Secti o n 7, 
t he I P M, a n d t he I X R S ma n ual. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 2 7 1 4 A pril 2 0 2 3 5. S U B J E C T E LI GI BI LI T Y 
5. 1. I ncl usi o n Criteri a 
1 0 1) Hist ol o gicall y pr o ve n lar ge B-cell l y m p h o ma i ncl u di n g t he f oll o wi n g t y pes defi ne d b y 
W H O 2 0 1 6 { S wer dl o w 2 0 1 6 }: 
D L B C L n ot ot her wise s pecifie d (i ncl u di n g A B C/ G C B) 
H G B L wit h or wit h o ut M Y C a n d B C L 2 a n d/ or B C L 6 rearra n ge me nt 
D L B C L arisi n g fr o m F L 
T-cell/ histi oc yte ric h lar ge B-cell l y m p h o ma 
D L B C L ass ociate d wit h c hr o nic i nfla m mati o n 
Pri mar y c uta ne o us D L B C L, le g t y pe 
E pstei n- Barr vir us ( E B V) + D L B C L 
1 0 2) Rela pse d or refract or y disease after first-li ne c he m oi m m u n ot hera p y 
Refract or y disease defi ne d as n o c o m plete re missi o n t o first-li ne t hera p y; s u bjects w h o 
are i nt olera nt t o first-li ne t hera p y are e xcl u de d 
■Pr o gressi ve disease ( P D) as best res p o nse t o first-li ne t hera p y 
■Sta ble disease ( S D) as best res p o nse after at least [ADDRESS_1175179]-li ne t hera p y (e g, 
4 c ycles of R- C H O P) 
■P R as best res p o nse after at least 6 c ycles a n d bi o ps y- pr o ve n resi d ual disease or 
disease pr o gressi o n ≤ 1 2 m o nt hs of t hera p y 
Rela pse d disease defi ne d as c o m plete re missi o n t o first-li ne t hera p y f oll o we d b y bi o ps y- 
pr o ve n disease rela pse ≤ [ADDRESS_1175180]-li ne t hera p y 
1 0 3) S u bjects m ust ha ve recei ve d a de q uate first-li ne t hera p y i ncl u di n g at a mi ni m u m: 
A nti- C D 2 0 m o n ocl o nal a nti b o d y u nless i n vesti gat or deter mi nes t hat t u m or is C D 2 0 
ne gati ve, a n d 
A n a nt hrac ycli ne c o ntai ni n g c he m ot hera p y re gi me n 
1 0 4) I nte nt t o pr ocee d t o H D T a n d A S C T if res p o nse t o sec o n d-li ne t hera p y 
1 0 5) S u bjects m ust ha ve ra di o gra p hicall y d oc u me nte d disease 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 2 8 1 4 A pril 2 0 2 3 1 0 6) N o k n o w n hist or y or s us pi[INVESTIGATOR_37180] o n of ce ntral ner v o us s yste m ( C N S) i n v ol ve me nt b y 
l y m p h o ma 
1 0 7) At least [ADDRESS_1175181] pr o vi des c o nse nt 
1 0 8) A ge 1 8 years or ol der at t he ti me of i nf or me d c o nse nt 
1 0 9) E C O G perf or ma nce stat us of 0 or 1 
1 1 0) A de q uate b o ne marr o w, re nal, he patic, p ul m o nar y a n d car diac f u ncti o n defi ne d as: 
A bs ol ute ne utr o p hil c o u nt ( A N C) ≥ 1 0 0 0/ µ L 
Platelet c o u nt ≥ 7 5, 0 0 0/ µ L 
A bs ol ute l y m p h oc yte c o u nt ≥ 1 0 0/ µ L 
Creati ni ne cleara nce (as esti mate d b y C oc kcr oft Ga ult) ≥ 6 0 m L/ mi n 
Ser u m ala ni ne a mi n otra nsferase/as partate a mi n otra nsferase ( A L T/ A S T) ≤ 2. 5 u p per li mit 
of n or mal ( U L N) 
T otal bilir u bi n ≤ 1. 5 m g/ dl, e xce pt i n s u bjects wit h Gil bert’s s y n dr o me 
Car diac ejecti o n fracti o n ≥ 5 0 %, n o e vi de nce of pericar dial eff usi o n as deter mi ne d b y a n 
ec h ocar di o gra m ( E C H O), a n d n o cli nicall y si g nifica nt electr ocar di o gra m ( E C G) fi n di n gs 
N o cli nicall y si g nifica nt ple ural eff usi o n 
Baseli ne o x y ge n sat urati o n > 9 2 % o n r o o m air 
1 1 1) Fe males of c hil d beari n g p ote ntial m ust ha ve a ne gati ve ser u m or uri ne pre g na nc y test 
(fe males w h o ha ve u n der g o ne s ur gical sterilizati o n or w h o ha ve bee n p ost me n o pa usal f or 
at least 2 years are n ot c o nsi dere d t o be of c hil d beari n g p ote ntial) 
5. 2. E xcl usi o n Criteri a 
2 0 1) Hist or y of mali g na nc y ot her t ha n n o n mela n o ma s ki n ca ncer or carci n o ma i n sit u (e g, 
cer vi x, bla d der, breast) u nless disease free f or at least 3 years 
2 0 2) Hist or y of Ric hter’s tra nsf or mati o n of C L L or P M B C L 
2 0 3) Hist or y of a ut ol o g o us or all o ge neic ste m cell tra ns pla nt 
2 0 4) Recei ve d m ore t ha n o ne li ne of t hera p y f or D L B C L 
2 0 5) Pri or C D 1 9 tar gete d t hera p y 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 2 9 1 4 A pril 2 0 2 3 2 0 6) Treat me nt wit h s yste mic i m m u n osti m ulat or y a ge nts (i ncl u di n g, b ut n ot li mite d t o, 
i nterfer o n a n d I L- 2) wit hi n [ADDRESS_1175182] d ose of a xica bta ge ne cil ole ucel or S O C 
2 0 7) Pri or c hi meric a nti ge n rece pt or t hera p y or ot her ge neticall y m o difie d T-cell t hera p y or 
pri or ra n d o mizati o n i nt o Z U M A- 7 
2 0 8) Hist or y of se vere, i m me diate h y perse nsiti vit y reacti o n attri b ute d t o a mi n o gl yc osi des 
2 0 9) Prese nce of f u n gal, bacterial, viral, or ot her i nfecti o n t hat is u nc o ntr olle d or re q uiri n g 
i ntra ve n o us (I V) a nti micr o bials f or ma na ge me nt.  Si m ple uri nar y tract i nfecti o n ( U TI) 
a n d u nc o m plicate d bacterial p har y n gitis are per mitte d if res p o n di n g t o acti ve treat me nt. 
2 1 0) K n o w n hist or y of i nfecti o n wit h h u ma n i m m u n o deficie nc y vir us ( HI V) or he patitis B 
( H Bs A g p ositi ve) or he patitis C vir us (a nti- H C V p ositi ve).  If t here is a p ositi ve hist or y 
of treate d he patitis B or he patitis C, t he viral l oa d m ust be u n detecta ble per q ua ntitati ve 
p ol y merase c hai n reacti o n ( P C R) a n d/ or n ucleic aci d testi n g. 
2 1 1) Acti ve t u berc ul osis 
2 1 2) Prese nce of a n y i n d welli n g li ne or drai n (e g, perc uta ne o us ne p hr ost o m y t u be, i n d welli n g 
F ole y cat heter, biliar y drai n, or ple ural/ perit o neal/ pericar dial cat heter). De dicate d ce ntral 
ve n o us access cat heters, s uc h as a P ort-a- Cat h or Hic k ma n cat heter, are per mitte d. 
2 1 3) S u bjects wit h detecta ble cere br os pi [INVESTIGATOR_55498] d mali g na nt cells or k n o w n brai n metastases or 
wit h a hist or y of cere br os pi [INVESTIGATOR_55498] d mali g na nt cells or brai n metastases 
2 1 4) Hist or y or prese nce of n o n- mali g na nt C N S dis or der, s uc h as seiz ure dis or der, 
cere br o vasc ular isc he mia/ he m orr ha ge, de me ntia, cere bellar disease, or a n y a ut oi m m u ne 
disease wit h C N S i n v ol ve me nt 
2 1 5) S u bjects wit h car diac atrial or car diac ve ntric ular l y m p h o ma i n v ol ve me nt 
2 1 6) Hist or y of m y ocar dial i nfarcti o n, car diac a n gi o plast y or ste nti n g, u nsta ble a n gi na, Ne w 
Y or k Heart Ass ociati o n Class II or greater c o n gesti ve heart fail ure, or ot her cli nicall y 
si g nifica nt car diac disease wit hi n 1 2 m o nt hs of e nr oll me nt 
2 1 7) Re q uire me nt f or ur ge nt t hera p y d ue t o t u m or mass effects, s uc h as b o wel o bstr ucti o n or 
bl o o d vessel c o m pressi o n 
2 1 8) Hist or y of a ut oi m m u ne disease re q uiri n g s yste mic i m m u n os u p pressi o n a n d/ or s yste mic 
disease m o dif yi n g a ge nts wit hi n t he last 2 years 
2 1 9) Hist or y of i di o pat hic p ul m o nar y fi br osis, or ga nizi n g p ne u m o nia (e g, br o nc hi olitis 
o blitera ns), dr u g-i n d uce d p ne u m o nitis, i di o pat hic p ne u m o nitis, or e vi de nce of acti ve 
p ne u m o nitis per c hest c o m p ute d t o m o gra p h y ( C T) sca n at scree ni n g.  Hist or y of ra diati o n 
p ne u m o nitis i n t he ra diati o n fiel d (fi br osis) is all o we d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 3 0 1 4 A pril 2 0 2 3 2 2 0) Hist or y of s y m pt o matic dee p vei n t hr o m b osis or p ul m o nar y e m b olis m wit hi n 6 m o nt hs of 
e nr oll me nt 
2 2 1) A n y me dical c o n diti o n li kel y t o i nterfere wit h assess me nt of safet y or efficac y of st u d y 
treat me nt 
2 2 2) Hist or y of se vere i m me diate h y perse nsiti vit y reacti o n t o t ociliz u ma b or a n y of t he a ge nts 
use d i n t his st u d y (f or sites i n S witzerla n d, refer t o t he a d diti o nal c o u ntr y-s pecific 
e xcl usi o n criteri o n i n A p pe n di x D )
2 2 3) Treat me nt wit h a li ve, atte n uate d vacci ne wit hi n [ADDRESS_1175183] u d y 
2 2 4) W o me n of c hil d beari n g p ote ntial w h o are pre g na nt or breastfee di n g beca use of t he 
p ote ntiall y da n ger o us effects of c he m ot hera p y o n t he fet us or i nfa nt.  S u bjects of eit her 
se x w h o are n ot willi n g t o practice birt h c o ntr ol fr o m t he ti me of c o nse nt a n d at least 
[ADDRESS_1175184] d ose of a xica bta ge ne cil ole ucel or S O C c he m ot hera p y 
2 2 5) I n t he i n vesti gat or’s j u d g me nt, t he s u bject is u nli kel y t o c o m plete all pr ot oc ol-re q uire d 
st u d y visits or pr oce d ures, i ncl u di n g f oll o w- u p visits, or c o m pl y wit h t he st u d y 
re q uire me nts f or partici pati o n 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175185] u d y: 
•Bri d gi n g t hera p y refers t o c ortic oster oi ds a d mi nistere d after le u ka p heresis t hr o u g h 5 da ys 
pri or t o a d mi nistrati o n of a xica bta ge ne cil ole ucel. 
•C o n diti o ni n g c he m ot hera p y refers t o fl u dara bi ne a n d c ycl o p h os p ha mi de use d f or 
l y m p h o de pleti o n pri or t o a d mi nistrati o n of a xica bta ge ne cil ole ucel. 
•T he i n vesti gati o nal pr o d uct is na me d a xica bta ge ne cil ole ucel. 
F or s u bjects ra n d o mize d t o t he S O C ar m of t he st u d y: 
•T he sec o n d-li ne c o m bi nati o n c he m ot hera p y re gi me n refers t o t he rit u xi ma b a n d plati n u m- 
base d c he m ot hera p y re gi me n. 
•T he sec o n d-li ne c o m bi nati o n c he m ot hera p y re gi me n will be selecte d b y t he treati n g 
i n vesti gat or.  T he all o we d re gi me ns are R-I C E, R- D H A P, R- E S H A P, or R- G D P. 
•Res p o nse t o sec o n d-li ne c o m bi nati o n c he m ot hera p y refers t o a P R or C R after 2 or 3 c ycles. 
•Ste m cell c ollecti o n refers t o C D 3 4 + he mat o p oietic ste m cells c ollecte d b y le u ka p heresis 
fr o m t he peri p heral bl o o d after G- C S F sti m ulati o n. 
H D T refers t o t he m yel oa blati ve re gi me n a d mi nistere d pri or t o a ut ol o g o us ste m cell i nf usi o n.  
T he H D T re gi me n will be selecte d b y t he treati n g i n vesti gat or. 
F or s u bjects ra n d o mize d t o eit her t he a xica bta ge ne cil ole ucel or t he S O C ar m of t he st u d y: 
•Le u ka p heresis refers t o: 
T he pr oce d ure f or c ollecti o n of peri p heral bl o o d m o n o n uclear cells use d t o ma n ufact ure 
t he s u bject-s pecific a xica bta ge ne cil ole ucel treat me nt (a xica bta ge ne cil ole ucel ar m) or 
T he pr oce d ure f or peri p heral C D 3 4 + he mat o p oietic ste m cell c ollecti o n ( S O C ar m).  
Cells c ollecte d wit h t he i nte nt of A S C T will f oll o w i nstit uti o nal g ui deli nes a n d will n ot 
be s hi p pe d t o Kite P har ma. 
•C o nc o mita nt me dicati o n refers t o treat me nt t hat s u bjects ca n recei ve d uri n g t he c o n d uct of 
t he st u d y. 
•E xcl u de d me dicati o ns refer t o treat me nt t hat is n ot t o be a d mi nistere d, u nless ot her wise 
s pecifie d, d uri n g t he c o n d uct of t he st u d y. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175186]’s disease. 
6. 2.  A xic a bt a ge ne Cil ole ucel St u d y Tre at me nt Ar m 
6. 2. 1. Le u k a p heresis 
S u bjects will u n der g o le u ka p heresis t o o btai n T cells f or t he ma n ufact uri n g of a xica bta ge ne 
cil ole ucel.  Le u ka p herese d cells o btai ne d at partici pati n g ce nters will be s hi p pe d t o t he Kite 
ma n ufact uri n g facilit y as descri be d i n t he I P M. 
6. 2. 2.  C o n diti o ni n g C he m ot her a p y 
C o n diti o ni n g c he m ot hera p y f or l y m p h o de pleti o n will be s u p plie d b y t he i n vesti gati ve site u nless 
ot her wise n ote d.  Treat me nt s h o ul d be a d mi nistere d per i nstit uti o nal g ui deli nes.  Refer t o t he 
c urre nt pr o d uct la bel f or g ui da nce o n pac ka gi n g, st ora ge, pre parati o n, a d mi nistrati o n, a n d 
t o xicit y ma na ge me nt ass ociate d wit h t he a d mi nistrati o n of c he m ot hera p y a ge nts. 
6. 2. 2. 1. Fl u d ar a bi ne 
Fl u dara bi ne p h os p hate is a s y nt hetic p uri ne n ucle osi de t hat differs fr o m p h ysi ol o gic n ucle osi des 
i n t hat t he s u gar m oiet y is ara bi n ose i nstea d of ri b ose or de o x yri b ose.  Fl u dara bi ne is a p uri ne 
a nta g o nist a nti meta b olite. 
6. 2. 2. 2.  C ycl o p h os p h a mi de 
C ycl o p h os p ha mi de is a nitr o ge n m ustar d- deri vati ve al k ylati n g a ge nt.  F oll o wi n g c o n versi o n t o 
acti ve meta b olites i n t he li ver, c ycl o p h os p ha mi de f u ncti o ns as a n al k ylati n g a ge nt; t he dr u g als o 
p ossesses p ote nt i m m u n os u p pressi ve acti vit y.  T he ser u m half-life after I V a d mi nistrati o n ra n ges 
fr o m 3 t o 1 2 h o urs; t he dr u g a n d/ or its meta b olites ca n be detecte d i n t he ser u m f or u p t o 
[ADDRESS_1175187] yl c o m p o u n d desi g nate d as 
s o di u m- 2- merca pt oet ha ne s ulf o nate wit h a m olec ular f or m ula of C 2H5Na O 3S2.
6. 2. 2. 4.  R ati o n ale f or C o n diti o ni n g C he m ot her a p y 
I ncreasi n g le vels of c o n diti o ni n g c he m ot hera p y c orrelates wit h cli nical res p o nses t o a d o pti ve cell 
t hera p y { D u dle y 2 0 0 8 }.  S pecificall y, t here a p pears t o be a li n k bet wee n a de q uate 
l y m p h o de pleti o n a n d a d o pti vel y tra nsferre d T-cell e x pa nsi o n a n d f u ncti o n i n pre-cli nical m o dels.  
T he de pt h a n d d urati o n of t he l y m p h o de pleti o n i n precli nical m o dels c orrelate wit h a nti-t u m or 
acti vit y of t he a d o pti vel y tra nsferre d t u m or-s pecific C D 8 + T cells { Gatti n o ni 2 0 0 5 }.  
L y m p h o de pleti o n ma y f u ncti o n b y era dicati n g c yt o ki ne si n ks f or t he tra nsferre d cells, 
eli mi nati n g T re g ulat or y cells, or e n ha nci n g a nti ge n prese nti n g cell acti vati o n { Kle ba n off 2 0 0 5 }.  
C ycl o p h os p ha mi de a n d fl u dara bi ne c o m bi nati o n is a p ote nt l y m p h o de pleti n g re gi me n.  
C ycl o p h os p ha mi de ( 5 0 0 m g/ m 2/ da y) a n d fl u dara bi ne ( 3 0 m g/ m 2/ da y) b ot h gi ve n f or 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175188] u die d a n d t olerate d i n s u bjects wit h B-cell mali g na ncies { O' Brie n 
2 0 0 1 } a n d was use d i n t he Z U M A- 1 trial { L oc ke 2 0 1 7 }. 
6. 2. 3.  A xic a bt a ge ne Cil ole ucel 
6. 2. 3. 1. I n vesti g ati o n al Pr o d uct Descri pti o n 
A xica bta ge ne cil ole ucel is s u p plie d cr y o preser ve d i n cr y ost ora ge ba gs.  T he pr o d uct i n t he ba g is 
clear t o o pa q ue i n clarit y a n d w hite t o re d i n c ol or wit h n o visi ble f orei g n particles. T he 
cr y ost ora ge ba g c o ntai ni n g a xica bta ge ne cil ole ucel arri ves fr oze n i n a li q ui d nitr o ge n dr y 
s hi p per.  T he ba g m ust be st ore d i n va p or p hase of li q ui d nitr o ge n, a n d t he pr o d uct m ust re mai n 
fr oze n u ntil t he s u bject is rea d y f or treat me nt t o ass ure via ble li ve a ut ol o g o us cells are 
a d mi nistere d.  Se veral i nacti ve i n gre die nts are a d de d t o t he pr o d uct t o ass ure via bilit y a n d 
sta bilit y of t he li ve cells t hr o u g h t he freezi n g, t ha wi n g, a n d i nf usi o n pr ocess. 
A xica bta ge ne cil ole ucel is a s u bject-s pecific pr o d uct, a n d t he i nte n de d s u bject will be i de ntifie d 
b y a u ni q ue s u bject I D n u m ber.  U p o n recei pt, verificati o n t hat t he pr o d uct a n d s u bject-s pecific 
la bels matc h t he s u bject’s i nf or mati o n (e g, s u bject I D n u m ber) is esse ntial.  D o n ot i nf use t he 
pr o d uct if t he i nf or mati o n o n t he s u bject-s pecific la bel d oes n ot matc h t he i nte n de d s u bject.  T he 
v ol u me of a xica bta ge ne cil ole ucel i nf use d, t he t ha w start/st o p ti me, a n d a xica bta ge ne cil ole ucel 
a d mi nistrati o n start/st o p ti me will all be n ote d i n t he s u bject me dical rec or d.  A xica bta ge ne 
cil ole ucel m ust n ot be t ha we d u ntil t he s u bject is rea d y f or t he i nf usi o n. Refer t o t he I P M f or 
details a n d i nstr ucti o n o n st ora ge, t ha wi n g, a n d a d mi nistrati o n of a xica bta ge ne cil ole ucel. 
T here ha ve bee n n o i nsta nces of acci de ntal o ver d ose of s u bjects i n t his pr o gra m t o date.  I n case 
of acci de ntal o ver d ose, treat me nt s h o ul d be s u p p orti ve.  C ortic oster oi d t hera p y ma y be 
c o nsi dere d if a n y d ose is ass ociate d wit h se vere t o xicit y. 
If a n y pr o ble ms relate d t o t he use of a xica bta ge ne cil ole ucel or a n y pr o d ucts t hat s u p p ort t he 
ma na ge me nt of a xica bta ge ne cil ole ucel (e g, cr y ost ora ge ba gs, s u bject i de ntificati o n la bels) are 
i de ntifie d, researc h staff s h o ul d re p ort t he pr o ble m per t he i nstr ucti o ns i n t he I P M. 
6. 2. 3. 2.  R ati o n ale f or A xic a bt a ge ne Cil ole ucel D ose 
T he rati o nale f or t he a xica bta ge ne cil ole ucel d ose i n t his st u d y is base d o n t he a g gre gate safet y 
a n d efficac y data c o m pi[INVESTIGATOR_5829] d fr o m t he Z U M A- 1 st u d y as o utli ne d i n Secti o n 2. 5. 1. 2  a n d t he I B.  
Base d o n t he fa v ora ble be nefit/ris k rati o see n i n Z U M A- 1, a xica bta ge ne cil ole ucel will be 
a d mi nistere d at a tar get d ose of 2 x 1 0 6 a nti- C D 1 9 C A R T cells/ k g, b ut ma y be d ose d at a 
mi ni m u m of 1 x 1 0 6 a nti- C D 1 9 C A R T cells/ k g.  F or s u bjects wei g hi n g > 1 0 0 k g, a ma xi m u m 
flat d ose of a xica bta ge ne cil ole ucel at 2 x 1 0 8 a nti- C D 1 9 C A R T cells will be a d mi nistere d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175189] u d y Tre at me nt Sc he d ule a n d 
A d mi nistr ati o n 
6. 2. 4. 1. Le u k a p heresis ( Wit hi n A p pr o xi m atel y 5 D a ys of R a n d o miz ati o n) 
If a n y scree ni n g assess me nts or pr oce d ures are re peate d bet wee n c o nfir mati o n of eli gi bilit y a n d 
t he start of le u ka p heresis a n d res ults are o utsi de t he eli gi bilit y criteria liste d i n Secti o n 5, c o ntact 
t he s p o ns or’s me dica l m o nit or pri or t o pr ocee di n g wit h le u ka p heresis. 
Bef ore le u ka p heresis c o m me nces, t he bel o w criteria m ust be met: 
•N o e vi de nce or s us pi[INVESTIGATOR_37180] o n of a n i nfecti o n 
•C ortic oster oi d t hera p y at a p har mac ol o gic d ose ( ≥ 5 m g/ da y of pre d nis o ne or e q ui vale nt 
d oses of ot her c ortic oster oi ds) a n d ot her i m m u n os u p pressi ve dr u gs m ust be a v oi de d f or 
[ADDRESS_1175190] be dela ye d u ntil t he e ve nt res ol ves.  If le u ka p heresis is 
dela ye d m ore t ha n 5 da ys after ra n d o mizati o n, baseli ne c o m plete bl o o d c o u nt ( C B C) wit h 
differe ntial a n d c he mistr y pa nel m ust be re peate d.  If res ults are o utsi de t he eli gi bilit y criteria 
liste d i n Secti o n 5, c o ntact t he me dical m o nit or pri or t o pr ocee di n g wit h le u ka p heresis. 
T he le u ka p heresis visit s h o ul d occ ur wit hi n a p pr o xi matel y 5 da ys of ra n d o mizati o n. 
After t he a b o ve criteria are met, m o n o n uclear cells will be o btai ne d b y le u ka p heresis ( 1 2 t o 
1 5 liter a p heresis wit h a g oal t o tar get a p pr o xi matel y 5 t o 1 0 x 1 0 9 m o n o n uclear cells).  T he 
le u ka p herese d cells are t he n pac ka ge d f or e x pe dite d s hi p me nt t o t he ma n ufact uri n g facilit y as 
descri be d i n t he I P M. 
Refer t o t he S O A Ta ble [ADDRESS_1175191] u d y pr oce d ures t o be c o m plete d d uri n g t he 
le u ka p heresis visit. 
6. 2. 4. 2. Bri d gi n g T her a p y ( a d mi nistere d after le u k a p heresis a n d c o m plete d at le ast 
5 d a ys pri or t o i niti ati n g a xic a bt a ge ne cil ole ucel) 
At t he discreti o n of t he i n vesti gat or, bri d gi n g t hera p y ma y be c o nsi dere d f or s u bjects wit h hi g h 
disease b ur de n at scree ni n g. 
Bri d gi n g t hera p y wit h c ortic oster oi ds is all o we d, s uc h as de xa met has o ne at a d ose of 2 0 t o 
4 0 m g or e q ui vale nt, eit her P O or I V dail y f or 1 t o 4 da ys.  C h oice of c ortic oster oi d a n d d osi n g 
ca n be a dj uste d f or a ge/c o m or bi dities or per cli nical j u d ge me nt. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 3 5 1 4 A pril 2 0 2 3 6. 2. 4. 3.  C o n diti o ni n g C he m ot her a p y ( d a y - 5 t hr o u g h d a y - 3 bef ore i nf usi o n of 
a xic a bt a ge ne cil ole ucel) 
A d mi nistrati o n of C A R T cells t o s u bjects wit h o n g oi n g i nfecti o n or i nfla m mati o n, e ve n if s uc h 
pr ocesses are as y m pt o matic, i ncreases t he ris k of hi g h gra de a n d fatal t o xicit y.  All eff orts s h o ul d 
be ma de t o r ule o ut s uc h c o n diti o ns pri or t o cell i nf usi o n. 
Si g ns, s y m pt o ms, or a b n or mal la b orat or y res ults attri b ute d t o t he mali g na nc y (e g “t u m or fe ver,” 
ele vate d C-reacti ve pr otei n [ C R P]) are dia g n oses of e xcl usi o n t hat re q uire a d oc u me nte d w or k- 
u p t o esta blis h. 
C o n diti o ni n g c he m ot hera p y a n d a xica bta ge ne cil ole ucel i nf usi o n s h o ul d be i nitiate d o nl y o nce it 
is reas o na bl y ass ure d t hat cell i nf usi o n ca n safel y pr ocee d. 
Refer t o Secti o n 6. 2. 4. 8  f or Re q uire me nts t o W or k- u p P ote ntial I nfecti o us a n d/ or I nfla m mat or y 
States. 
6. 2. 4. 3. 1. Re q uire me nts f or I niti ati o n of C o n diti o ni n g C he m ot her a p y 
If a n y of t he f oll o wi n g criteria are met pri or t o t he i nitiati o n of c o n diti o ni n g c he m ot hera p y, t he n 
t he w or k- u p liste d i n Secti o n 6. 2. 4. [ADDRESS_1175192] be perf or me d t o deter mi ne t he p ote ntial ca use if t here 
is n o i de ntifie d s o urce of i nfecti o n. 
•Te m perat ure > 3 8° C wit hi n 7 2 h o urs of c o n diti o ni n g c he m ot hera p y 
•C R P > 1 0 0 m g/ L a n yti me bet wee n e nr oll me nt t o start of c o n diti o ni n g c he m ot hera p y 
•W hite bl o o d cell ( W B C) c o u nt or W B C differe ntial c o ncer ni n g f or i nfecti o us pr ocess 
bet wee n e nr oll me nt t o start of c o n diti o ni n g c he m ot hera p y (e g, W B C > 2 0, 0 0 0, ra pi [INVESTIGATOR_2478] y 
i ncreasi n g W B C, or differe ntial wit h hi g h perce nta ge of se gs/ ba n ds) 
A d diti o nall y: 
•If a n y scree ni n g assess me nts or pr oce d ures are re peate d bet wee n c o nfir mati o n of eli gi bilit y 
a n d t he start of c o n diti o ni n g c he m ot hera p y a n d res ults are o utsi de t he eli gi bilit y criteria liste d 
i n Secti o n 5, t he n t he c o n diti o n m ust res ol ve pri or t o pr ocee di n g wit h c o n diti o ni n g 
c he m ot hera p y. 
•C o m plete hist or y a n d p h ysical e xa m, i ncl u di n g hea d, ears, e yes, n ose, t hr oat ( H E E N T); 
car diac, vasc ular, res pi[INVESTIGATOR_1305] y, gastr oi ntesti nal, i nte g u me ntar y, a n d ne ur ol o gical s yste ms m ust 
n ot re veal e vi de nce of i nfecti o n/i nfla m mati o n. 
•T he s u bject m ust n ot ha ve recei ve d s yste mic a nti- micr o bials f or t he treat me nt of a k n o w n or 
s us pecte d i nfecti o n wit hi n 4 8 h o urs bef ore c o n diti o ni n g c he m ot hera p y ( pr o p h ylactic use of 
a nti- micr o bials is all o we d). 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 3 6 1 4 A pril 2 0 2 3 •Treat me nt c o urse of a n y a nti micr o bials gi ve n f or k n o w n or s us pecte d a ntece de nt i nfecti o n 
s h o ul d be c o m plete as per i nfecti o us disease c o ns ult (if a p plica ble) rec o m me n dati o n bef ore 
st o p pi n g or s witc hi n g t o pr o p h ylactic a nti micr o bials. 
•If a s u bject is c o nfir me d t o ha ve a n i nfecti o us pr ocess f or w hic h a nti micr o bials are n ot 
a vaila ble (e g, viral p ne u m o nia), t he i nfecti o n m ust be cli nicall y res ol ve d as deter mi ne d b y 
t he i n vesti gat or i n c o ns ultati o n wit h i nfecti o us disease ser vice (if a p plica ble). 
•M ost rece ntl y c ollecte d bl o o d, uri ne, or ot her b o d y fl ui d c ult ures m ust s h o w n o gr o wt h f or at 
least 4 8 h o urs, a n d a n y ot her i nfecti o us w or k- u p perf or me d (e g, bacterial, viral ser ol o gies, 
P C R, st o ol st u dies, i ma gi n g st u dies) m ust be ne gati ve.  If cli nical s us pi[INVESTIGATOR_37180] o n is f or a n i nfecti o n 
f or w hic h c ult ures are u nli kel y t o be p ositi ve wit hi n 4 8 h o urs (e g, f u n gal i nfecti o n), a de q uate 
ti me m ust be all o we d f or c ult ures t o bec o me p ositi ve. 
•O nce t he a b o ve criteria are met, t he n t he s u bject ca n pr ocee d wit h c o n diti o ni n g 
c he m ot hera p y. 
6. 2. 4. 3. 2.  C o n diti o ni n g C he m ot her a p y A d mi nistr ati o n ( d a y - 5 t hr o u g h d a y - 3 Pri or t o 
A xic a bt a ge ne Cil ole ucel I nf usi o n) 
S u bjects will recei ve a c o n diti o ni n g c he m ot hera p y re gi me n c o nsisti n g of c ycl o p h os p ha mi de a n d 
fl u dara bi ne.  T he first d ose of c o n diti o ni n g c he m ot hera p y will be desi g nate d as da y - 5. S u bjects 
will i nitiate c o n diti o ni n g c he m ot hera p y wit h c ycl o p h os p ha mi de a n d fl u dara bi ne be gi n ni n g o n 
da y - [ADDRESS_1175193] da ys bef ore recei vi n g a xica bta ge ne cil ole ucel.  T he 3- da y 
c o n diti o ni n g c he m ot hera p y re gi me n will be a d mi nistere d i n a n o ut patie nt setti n g. 
T he 3- da y c o n diti o ni n g re gi me n of fl u dara bi ne a n d c ycl o p h os p ha mi de will be a d mi nistere d i n 
acc or da nce wit h t he bel o w dail y d osi n g i nstr ucti o ns. 
•I V h y drati o n wit h a bala nce d cr ystall oi d acc or di n g t o i nstit uti o nal g ui deli nes pri or t o 
a d mi nistrati o n of c ycl o p h os p ha mi de o n t he da y of i nf usi o n 
•C ycl o p h os p ha mi de 5 0 0 m g/ m 2 I V o ver a p pr o xi matel y 6 0 mi n utes 
•Fl u dara bi ne 3 0 m g/ m 2 I V o ver a p pr o xi matel y 3 0 mi n utes 
•A d diti o nal I V h y drati o n wit h a bala nce d cr ystall oi d acc or di n g t o i nstit uti o nal g ui deli nes t o be 
a d mi nistere d u p o n c o m pleti o n of t he c ycl o p h os p ha mi de i nf usi o n 
•Mes na t o be a d mi nistere d per i nstit uti o nal g ui deli nes 
S u bjects s h o ul d be i nstr ucte d t o dri n k ple nt y of li q ui ds d uri n g a n d f or 2 4 h o urs f oll o wi n g t he 
c he m ot hera p y (a p pr o xi matel y 2 liters/ 2 4 h o urs).  I n ge neral, s u bjects s h o ul d be ke pt 
well- h y drate d b ut cl osel y m o nit ore d t o pre ve nt fl ui d o verl oa d. 
Refer t o t he S O A Ta ble [ADDRESS_1175194] u d y pr oce d ures t o be c o m plete d d uri n g t he 
a xica bta ge ne cil ole ucel c o n diti o ni n g c he m ot hera p y peri o d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 3 7 1 4 A pril 2 0 2 3 6. 2. 4. 4.  Re q uire me nts f or I niti ati n g A xic a bt a ge ne Cil ole ucel I nf usi o n ( Tre at me nt 
d a y 0) 
If a n y of t he f oll o wi n g criteria are met pri or t o t he i nitiati o n of a xica bta ge ne cil ole ucel i nf usi o n, 
t he n t he w or k- u p liste d i n Secti o n 6. 2. 4. [ADDRESS_1175195] be perf or me d t o deter mi ne t he p ote ntial ca use if 
t here is n o i de ntifie d s o urce of i nfecti o n. 
•Te m perat ure > 3 8° C wit hi n 7 2 h o urs of a xica bta ge ne cil ole ucel i nf usi o n 
•C R P > 1 0 0 m g/ L a n yti me bet wee n e nr oll me nt t o start of a xica bta ge ne cil ole ucel i nf usi o n 
•W B C c o u nt or W B C differe ntial c o ncer ni n g f or i nfecti o us pr ocess bet wee n e nr oll me nt t o 
start of a xica bta ge ne cil ole ucel i nf usi o n (e g, W B C > 2 0, 0 0 0, ra pi [INVESTIGATOR_2478] y i ncreasi n g W B C, or 
differe ntial wit h hi g h perce nta ge of ne utr o p hils/ ba n ds) 
A d diti o nall y: 
•If a n y scree ni n g assess me nts or pr oce d ures are re peate d bet wee n c o nfir mati o n of eli gi bilit y 
a n d t he start of a xica bta ge ne cil ole ucel i nf usi o n a n d res ults are o utsi de t he eli gi bilit y criteria 
liste d i n Secti o n 5, t he n t he c o n diti o n m ust res ol ve pri or t o pr ocee di n g wit h a xica bta ge ne 
cil ole ucel i nf usi o n (e xce pt f or peri p heral bl o o d cell c o u nts t hat ha ve bee n i m pacte d b y 
c o n diti o ni n g c he m ot hera p y). 
•C o m plete hist or y a n d p h ysical e xa m i ncl u di n g H E E N T; car diac, vasc ular, res pi[INVESTIGATOR_1305] y, 
gastr oi ntesti nal, i nte g u me ntar y, a n d ne ur ol o gical s yste ms m ust n ot re veal e vi de nce of 
i nfecti o n/i nfla m mati o n. 
•T he s u bject m ust n ot ha ve recei ve d s yste mic a nti- micr o bials f or t he treat me nt of a k n o w n or 
s us pecte d i nfecti o n wit hi n 4 8 h o urs bef ore a xica bta ge ne cil ole ucel ( pr o p h ylactic use of 
a nti- micr o bials is all o we d). 
•Treat me nt c o urse of a n y a nti micr o bials gi ve n f or k n o w n or s us pecte d a ntece de nt i nfecti o n 
s h o ul d be c o m plete as per i nfecti o us disease c o ns ult (if a p plica ble) rec o m me n dati o n bef ore 
st o p pi n g or s witc hi n g t o pr o p h ylactic a nti micr o bials. 
•If a s u bject is c o nfir me d t o ha ve a n i nfecti o us pr ocess f or w hic h a nti micr o bials are n ot 
a vaila ble (e g, viral p ne u m o nia), t he i nfecti o n m ust be cli nicall y res ol ve d as deter mi ne d b y 
t he i n vesti gat or i n c o ns ultati o n wit h i nfecti o us disease ser vice (if a p plica ble). 
•M ost rece ntl y c ollecte d bl o o d, uri ne, or ot her b o d y fl ui d c ult ures m ust s h o w n o gr o wt h f or at 
least 4 8 h o urs, a n d a n y ot her i nfecti o us w or k- u p perf or me d (e g, bacterial, viral ser ol o gies, 
P C R, st o ol st u dies, i ma gi n g st u dies) m ust be ne gati ve.  If cli nical s us pi[INVESTIGATOR_37180] o n is f or a n i nfecti o n 
f or w hic h c ult ures are u nli kel y t o be p ositi ve wit hi n 4 8 h o urs (e g, f u n gal i nfecti o n), a de q uate 
ti me m ust be all o we d f or c ult ures t o bec o me p ositi ve. 
O nce t he a b o ve criteria are met, t he n t he s u bject ca n pr ocee d wit h a d mi nistrati o n of a xica bta ge ne 
cil ole ucel. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 3 8 1 4 A pril 2 0 2 3 If t he a xica bta ge ne cil ole ucel i nf usi o n is dela ye d > 2 wee ks, pr ot oc ol g ui deli nes s h o ul d be 
f oll o we d re gar di n g t he nee d f or re peat c o n diti o ni n g c he m ot hera p y. 
6. 2. 4. 5.  A xic a bt a ge ne Cil ole ucel Pre me dic ati o n D osi n g 
T he f oll o wi n g pre a xica bta ge ne cil ole ucel i nf usi o n me dicati o ns s h o ul d be a d mi nistere d 
a p pr o xi matel y 1 h o ur pri or t o i nf usi o n. 
•Aceta mi n o p he n 6 5 0 m g P O or e q ui vale nt 
•Di p he n h y dra mi ne [ADDRESS_1175196] 7 da ys t o m o nit or f or si g ns a n d s y m pt o ms of 
C R S a n d ne ur ol o gic e ve nts, u nless ot her wise re q uire d b y c o u ntr y re g ulat or y a ge ncies (refer t o 
A p pe n di x D ). Alter nati vel y, s u bjects ma y be h os pi[INVESTIGATOR_18552] d t o recei ve t heir a xica bta ge ne cil ole ucel 
i nf usi o n a n d be o bser ve d f or C R S a n d ne ur ol o gic e ve nts i n t he h os pi[INVESTIGATOR_845632] n g, if dee me d 
a p pr o priate b y t he i n vesti gat or. 
If s u bjects are h os pi[INVESTIGATOR_18552] d, s u bjects s h o ul d n ot be disc har ge d fr o m t he h os pi[INVESTIGATOR_307] u ntil all 
a xica bta ge ne cil ole ucel relate d n o n- he mat ol o gical t o xicities res ol ve t o ≤ Gra de 1 or ret ur n t o 
baseli ne. S u bjects ma y be disc har ge d wit h n o n-critical a n d cli nicall y sta ble or i m pr o vi n g 
t o xicities (e g, re nal i ns ufficie nc y) e ve n if > Gra de 1, if dee me d a p pr o priate b y t he 
i n vesti gat or.  S u bjects s h o ul d re mai n i n a h os pi[INVESTIGATOR_307] f or o n g oi n g a xica bta ge ne cil ole ucel relate d 
fe ver, h y p ote nsi o n, h y p o xia, or o n g oi n g ne ur ol o gic e ve nts > Gra de [ADDRESS_1175197] 
4 wee ks f oll o wi n g a xica bta ge ne cil ole ucel i nf usi o n. S u bjects a n d t heir fa mil y 
me m bers/care gi vers s h o ul d be e d ucate d o n p ote ntial C R S a n d ne ur ol o gic s y m pt o ms, s uc h as 
fe ver, d ys p nea, c o nf usi o n, a p hasia, d ys p hasia, s o m n ole nce, e nce p hal o pat h y, ata xia, or tre m or. 
S u bjects or t heir fa mil y me m bers/care gi vers s h o ul d be i nstr ucte d t o i m me diatel y c o ntact t he 
treati n g i n vesti gat or or see k i m me diate me dical atte nti o n if a n y of t hese s y m pt o ms de vel o p. 
Refer t o t he S O A f or a listi n g of st u d y pr oce d ures t o be c o m plete d d uri n g t he a xica bta ge ne 
cil ole ucel treat me nt peri o d. 
Ce ntral ve n o us access, s uc h as a p ort or a peri p herall y i nserte d ce ntral cat heter, is re q uire d f or 
t he a d mi nistrati o n of a xica bta ge ne cil ole ucel.  Cat heter care, per i nstit uti o nal g ui deli nes, s h o ul d 
be f oll o we d.  Materials a n d i nstr ucti o ns f or t he t ha wi n g, ti mi n g, a n d a d mi nistrati o n of 
a xica bta ge ne cil ole ucel are o utli ne d i n t he I P M.  Vital si g ns s h o ul d be meas ure d d uri n g a n d after 
a xica bta ge ne cil ole ucel treat me nt (see Secti o n 7. 6 ). T he I P M m ust be re vie we d pri or t o 
a d mi nistrati o n of a xica bta ge ne cil ole ucel. 
Researc h sites s h o ul d f oll o w i nstit uti o nal g ui deli nes f or t he i nf usi o n of cell pr o d ucts. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175198] be met i n or der t o be c o nsi dere d f or a re peat c o urse of 
t hera p y: 
•S u bject ha d a P R or C R at t he first disease assess me nt at Da y 5 0 b ut s u bse q ue ntl y 
e x perie nce d pr o gressi o n of disease at a later ti me 
•T u m or t hat is n ot k n o w n t o be C D 1 9 ne gati ve 
•S u bject c o nti n ues t o meet t he ori gi nal st u d y eli gi bilit y criteria wit h t he e xce pti o n of pri or 
a xica bta ge ne cil ole ucel use i n t his st u d y; scree ni n g assess me nts a n d pr oce d ures s h o ul d be 
re peate d if cli nicall y i n dicate d (e g, ma g netic res o na nce i ma gi n g [ M RI], E C H O) 
•S u bject has n ot recei ve d s u bse q ue nt t hera p y f or t he treat me nt of l y m p h o ma 
•S u bject di d n ot e x perie nce a life-t hreate ni n g t o xicit y relate d t o a xica bta ge ne cil ole ucel 
d uri n g t he ori gi nal c o urse of treat me nt 
•T o xicities relate d t o c o n diti o ni n g c he m ot hera p y (fl u dara bi ne a n d c ycl o p h os p ha mi de), wit h 
t he e xce pti o n of al o pecia, ha ve res ol ve d t o ≤ Gra de 1 or ret ur ne d t o baseli ne pri or t o 
re-treat me nt 
•S u bject d oes n ot ha ve k n o w n a xica bta ge ne cil ole ucel ne utralizi n g a nti b o dies (e xce pti o n: if a 
n o n- ne utralizi n g a xica bta ge ne cil ole ucel a nti b o d y de vel o ps, s u bjects ma y be retreate d if t he y 
meet t he ori gi nal st u d y eli gi bilit y criteria) 
•Sites are str o n gl y e nc o ura ge d t o c ollect a bi o ps y c o nfir mi n g disease pr o gressi o n a n d C D 1 9 
e x pressi o n a n d t o s u b mit t he bi o psie d tiss ue t o t he ce ntral la b orat or y bef ore i nitiati n g 
re-treat me nt 
•S u bject recei ve d t he i nitial a xica bta ge ne cil ole ucel i nf usi o n ≤ [ADDRESS_1175199] u d y-relate d pr oce d ures or treat me nt, it is necessar y t o 
1) disc uss t he ris ks a n d be nefits of retreat me nt wit h t he s u bject, a n d 2) c o nfir m wit h t he s u bject 
h o w t he sec o n d d ose will be ma n ufact ure d. T he sec o n d d ose c o ul d be ma n ufact ure d at t he sa me 
ti me t hat t he first a xica bta ge ne cil ole ucel is ma de wit h e xisti n g cr y o preser ve d P B M Cs. 
Alter nati vel y, t he s u bject ma y nee d t o u n der g o a sec o n d le u ka p heresis a n d s h o ul d be i nf or me d of 
t his p ossi bilit y.  T hese c o n versati o ns s h o ul d als o be rec or de d i n t he s u bject’s s o urce d oc u me nt. 
A ma xi m u m of [ADDRESS_1175200].  S u bjects w h o are retreate d will 
f oll o w t he sa me treat me nt sc he d ule a n d pr oce d ural re q uire me nts per t he i nitial treat me nt. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 4 0 1 4 A pril 2 0 2 3 All o wa nce f or retreat me nt is base d o n cli nical e x perie nce i n Z U M A- 1, w here a t otal of 
1 0 s u bjects were retreate d wit h a xica bta ge ne cil ole ucel ( [ADDRESS_1175201] i n P hase 1 a n d 9 s u bjects i n 
P hase 2).  O verall, [ADDRESS_1175202] i n 
P hase 1 ac hie ve d a P R at M o nt h 1 after retreat me nt.  A m o n g t he 9 s u bjects retreate d i n P hase 2, 
fi ve s u bjects res p o n de d ( 2 C R a n d 3 P R) at M o nt h 1.  A nal ysis of d urati o n of retreat me nt 
res p o nse ( D O R R) a m o n g t he retreate d s u bjects i n P hase [ADDRESS_1175203] is dee me d eli gi ble f or retreat me nt a n d t he mea ns b y w hic h t he sec o n d d ose of 
a xica bta ge ne cil ole ucel has bee n c o nfir me d ( w hic h will i ncl u de deter mi ni n g w het her a sec o n d 
le u ka p heresis is re q uire d), t he s u bject will f oll o w t he sa me st u d y pr oce d ure re q uire me nts t hat 
were f oll o we d d uri n g his or her i nitial c o urse of treat me nt. 
Refer t o t he S O A Ta ble [ADDRESS_1175204] u d y pr oce d ures t o be c o m plete d d uri n g t he 
a xica bta ge ne cil ole ucel treat me nt peri o d. 
6. 2. 4. 8.  Re q uire me nts t o W or k- u p P ote nti al I nfecti o us a n d/ or I nfl a m m at or y St ates 
I n t he a bse nce of a n i de ntifie d s o urce of i nfecti o n (e g, li ne i nfecti o n, p ne u m o nia o n C X R), t he 
mi ni m u m w or k- u p t o be perf or me d pri or t o a d mi nistrati o n of c o n diti o ni n g c he m ot hera p y a n d/ or 
a xica bta ge ne cil ole ucel c o nsists of: 
•Call Kite me dical m o nit or 
•I nfecti o us disease ser vice c o ns ult (if a p plica ble) 
•C T i ma gi n g of t he c hest, a b d o me n, a n d pel vis wit h I V c o ntrast.  If t here is a me dical 
c o ntrai n dicati o n t o c o ntrast, t he n n o n-c o ntrast C T is all o we d. 
• T he f oll o wi n g m ust be perf or me d ( pri or t o t he i nitiati o n of a nti micr o bials if cli nicall y 
feasi ble): 
Bl o o d c ult ures (aer o bic a n d a naer o bic x 2 b ottles eac h) a n d U A a n d uri ne c ult ure.   
Dee p/i n d uce d s p ut u m c ult ure if cli nicall y i n dicate d. 
All i n d welli n g li nes, s uc h as ce ntral ve n o us cat heters, s h o ul d be e xa mi ne d f or a n y si g ns 
of i nfecti o n, a n d a d diti o nal c ult ures s h o ul d be dra w n fr o m t he li ne. 
Nas o p har y n geal-t hr oat ( N P T) s wa b or e q ui vale nt assa y f or viral i nfecti o n, s uc h as 
i nfl ue nza A/ B (i ncl u di n g H 1 N 1), parai nfl ue nza 1/ 2/ 3, a de n o vir us, res pi[INVESTIGATOR_1305] y s y nc ytial 
vir us, c or o na vir us, meta p ne u m o vir us 
C ollecti o n of f u n gal c ult ures a n d mar kers as a p pr o priate (e g, galact o ma n na n, f u n gitell) 
C ollecti o n of a p pr o priate ser u m viral st u dies (e g, c yt o me gal o vir us [ C M V]) 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 4 1 1 4 A pril 2 0 2 3 •If a ce ntral ner v o us s yste m pr ocess is s us pecte d, a p pr o priate brai n i ma gi n g a n d s u bse q ue nt 
l u m bar p u nct ure wit h c yt ol o g y, c ult ure, Gra m stai n, a n d viral P C R s h o ul d be perf or me d. 
•A n y a d diti o nal si g n or s y m pt o m- directe d i n vesti gati o n s h o ul d be perf or me d as cli nicall y 
i n dicate d. 
Pri or t o pr ocee di n g wit h c o n diti o ni n g c he m ot hera p y a n d/ or a xica bta ge ne cil ole ucel i nf usi o n, t he 
a b o ve w or k- u p m ust n ot s u g gest t he prese nce of a n acti ve i nfecti o n, a n d all re q uire me nts f or 
c o n diti o ni n g c he m ot hera p y a n d/ or a xica bta ge ne cil ole ucel i nf usi o n m ust be satisfie d. 
If t he a xica bta ge ne cil ole ucel i nf usi o n is dela ye d > 2 wee ks f oll o wi n g c o n diti o ni n g 
c he m ot hera p y, pr ot oc ol g ui deli nes s h o ul d be f oll o we d re gar di n g t he nee d f or re peat c o n diti o ni n g 
c he m ot hera p y. 
If t he a b o ve w or k- u p was tri g gere d d ue t o C R P > 1 0 0 m g/ L, C R P s h o ul d be re peate d, a n d if 
C R P c o nti n ues t o i ncrease si g nifica ntl y, e val uati o n s h o ul d be perf or me d f or a n y ot her p ote ntial 
i nfecti o us or i nfla m mat or y c o n diti o n n ot pre vi o usl y e val uate d. 
6. 2. 4. 9.  C o nc o mit a nt T her a p y ( A xic a bt a ge ne Cil ole ucel Ar m) 
I n vesti gat ors ma y prescri be a n y c o nc o mita nt me dicati o ns or treat me nt dee me d necessar y t o 
pr o vi de a de q uate s u p p orti ve care, i ncl u di n g gr o wt h fact or s u p p ort (e g, G- C S F) a n d r o uti ne 
a nti-e metic pr o p h yla xis e xce pt t h ose me dicati o ns liste d i n t he e xcl u de d me dicati o n Secti o n 6. 2. 5 .  
C o nc o mita nt t hera p y d oes n ot i ncl u de t hera p y use d f or t he treat me nt of t he disease. 
F or s u bjects w h o are n ot ra n d o mize d (e g, scree n fail ure), o nl y c o nc urre nt t hera pi[INVESTIGATOR_845633] d t o a n y 
seri o us a d verse e ve nt(s) ( S A Es) will be rec or de d. 
F or s u bjects w h o are ra n d o mize d b ut n ot d ose d wit h a xica bta ge ne cil ole ucel, c o nc o mita nt 
c o nc urre nt t hera pi[INVESTIGATOR_014] a n d s u bse q ue nt a ntica ncer t hera p y will o nl y be rec or de d fr o m t he date of 
t he i nf or me d c o nse nt t hr o u g h [ADDRESS_1175205] u d y-s pecific pr oce d ure (e g, le u ka p heresis, 
c o n diti o ni n g c he m ot hera p y). 
F or s u bjects w h o are ra n d o mize d t o recei ve a xica bta ge ne cil ole ucel a n d recei ve t he d ose of 
a xica bta ge ne cil ole ucel, all c o nc o mita nt t hera pi[INVESTIGATOR_014], i ncl u di n g me dicati o ns, i nt u bati o n, dial ysis, 
o x y ge n, a n d bl o o d pr o d ucts, s h o ul d be rec or de d fr o m t he date of t he i nf or me d c o nse nt t hr o u g h 
t he Da y [ADDRESS_1175206] u gs, a n d vacci nati o ns.   Refer t o Secti o n 6. 2. 6  f or details s urr o u n di n g s u bse q ue nt 
ca ncer t hera p y. 
S pecific c o nc o mita nt me dicati o n c ollecti o n re q uire me nts a n d i nstr ucti o ns are i ncl u de d i n t he 
Case Re p ort F or m ( C R F) c o m pleti o n g ui deli nes. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 4 2 1 4 A pril 2 0 2 3 6. 2. 5. E xcl u de d Me dic ati o ns ( A xic a bt a ge ne Cil ole ucel Ar m) 
C ortic oster oi d t hera p y at a p har mac ol o gic d ose ( ≥ 5 m g/ da y of pre d nis o ne or e q ui vale nt d oses of 
ot her c ortic oster oi ds) a n d ot her i m m u n os u p pressi ve dr u gs m ust be a v oi de d f or [ADDRESS_1175207] are c o ntrai n dicate d (ie, s u bjects wit h c o ntrast aller g y or i m paire d re nal 
cleara nce).  S uc h s u bjects s h o ul d u n der g o M RI wit h c o ntrast a n d  n o n-c o ntrast C T sca ns i nstea d. 
C ortic oster oi ds a n d ot her i m m u n os u p pressi ve dr u gs s h o ul d als o be a v oi de d f or 3 m o nt hs after 
a xica bta ge ne cil ole ucel a d mi nistrati o n u nless use d t o ma na ge a xica bta ge ne cil ole ucel relate d 
t o xicities.  Ot her me dicati o ns t hat mi g ht i nterfere wit h t he e val uati o n of a xica bta ge ne cil ole ucel, 
s uc h as n o n-ster oi dal a nti-i nfla m mat or y a ge nts, s h o ul d als o be a v oi de d f or t he sa me peri o d 
u nless me dicall y necessar y. 
Treat me nt f or l y m p h o ma, s uc h as c he m ot hera p y, i m m u n ot hera p y, tar gete d a ge nts, ra diati o n, a n d 
hi g h- d ose c ortic oster oi d, ot her t ha n defi ne d/all o we d i n t his pr ot oc ol, a n d ot her i n vesti gati o nal 
a ge nts are pr o hi bite d, e xce pt as nee de d f or treat me nt of disease pr o gressi o n after a xica bta ge ne 
cil ole ucel. 
If per missi bilit y of a s pecific me dicati o n/treat me nt is i n q uesti o n, please c o ntact t he Kite P har ma 
me dical m o nit or.  Please refer t o t he I B f or a d diti o nal i nf or mati o n a b o ut e xcl u de d me dicati o ns. 
6. 2. 6. S u bse q ue nt T her a p y ( A xic a bt a ge ne Cil ole ucel Ar m) 
S u bse q ue nt t hera p y a d mi nistere d after a xica bta ge ne cil ole ucel necessar y t o treat a s u bject’s 
disease, s uc h as n o n-st u d y-s pecifie d c he m ot hera p y, i m m u n ot hera p y, tar gete d a ge nts, as well as 
ste m cell tra ns pla nt a n d ra diati o n t hera p y, will be rec or de d f or all s u bjects ra n d o mize d u ntil o ne 
of t he f oll o wi n g ha p pe ns: t he s u bject c o m pletes t he l o n g-ter m f oll o w- u p peri o d, is c o nsi dere d 
l ost t o f oll o w u p, wit h dra ws c o nse nt, or dies.  If a s u bject pr o gresses, sites are str o n gl y 
e nc o ura ge d t o c ollect a bi o ps y c o nfir mi n g disease pr o gressi o n a n d t o s u b mit t he bi o psie d tiss ue 
t o t he ce ntral la b orat or y.  Treat me nt wit h a xica bta ge ne cil ole ucel is i nte n de d t o be defi niti ve 
t hera p y a n d n ot a bri d ge t o A S C T. 
6. 2. 7. T o xicit y M a n a ge me nt ( A xic a bt a ge ne Cil ole ucel Ar m) 
T o date, t he f oll o wi n g i m p orta nt ris ks ha ve bee n i de ntifie d wit h a xica bta ge ne cil ole ucel:  C R S, 
ne ur ol o gic e ve nts, i nfecti o ns, c yt o pe nias, a n d h y p o ga m ma gl o b uli ne mia.  Refer t o Secti o n [ADDRESS_1175208] c urre nt versi o n of t he 
a xica bta ge ne cil ole ucel I B f or g ui da nce re gar di n g ma na gi n g a xica bta ge ne cil ole ucel relate d 
t o xicities. A d diti o nal i nf or mati o n a n d ma na ge me nt rec o m me n dati o ns ca n als o be f o u n d i n t he I B 
re gar di n g i m p orta nt p ote ntial ris ks ass ociate d wit h a xica bta ge ne cil ole ucel as well as p ossi ble 
c o m plicati o ns ass ociate d wit h mali g na nc y a n d ca ncer treat me nt. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175209] ora ge, pre parati o n, a n d a d mi nistrati o n of eac h 
c he m ot hera p y re gi me n a n d i n di vi d ual c o m p o ne nt of t he re gi me n.  G- C S F will be a d mi nistere d 
base d o n re gi o nal/i nstit uti o nal sta n dar ds t o pre ve nt c he m ot hera p y dela ys a n d i nfecti o n a n d f or 
le u ka p heresis. 
A d mi nistrati o n of S O C t hera p y will be perf or me d i n a setti n g wit h e mer ge nc y me dical facilities 
a n d staff w h o are trai ne d t o m o nit or f or a n d res p o n d t o me dical e mer ge ncies.  A n y o ver d ose or 
i nc orrect a d mi nistrati o n of S O C t hera p y s h o ul d be n ote d o n t he St u d y Dr u g A d mi nistrati o n 
electr o nic Case Re p ort F or m (e C R F). 
After S O C t hera p y is a d mi nistere d t o a s u bject, t he s u bject m ust recei ve t he sa me S O C t hera p y 
o pti o n f or s u bse q ue nt c ycles of t hera p y.  I n di vi d ual a ge nts of t he c h oice of treat me nt ma y be 
altere d base d o n s u bject care a n d t o xicit y ma na ge me nt. 
6. 3. 1. St a n d ar d of C are C he m ot her a p y D osi n g a n d A d mi nistr ati o n 
S O C c he m ot hera p y is rec o m me n de d t o start wit hi n a p pr o xi matel y 5 da ys after ra n d o mizati o n. 
Rit u xi ma b + if osfa mi de, car b o plati n, a n d et o p osi de ( R-I C E) s u g geste d d osi n g { Gissel brec ht 
2 0 1 0 }: 
•Rit u xi ma b 3 7 5 m g/ m 2 bef ore c he m ot hera p y 
•If osfa mi de 5 g/ m2 2 4 h- CI o n da y 2 wit h mes na 
•Car b o plati n area u n der t he c ur ve ( A U C) 5 o n da y 2, ma xi m u m d ose 8 0 0 m g 
•Et o p osi de 1 0 0 m g/ m 2/ d o n da ys 1- 3 
Rit u xi ma b + et o p osi de, met h yl pre d nis ol o ne, c yta ra bi ne, cis plati n ( R- E S H A P) s u g geste d d osi n g 
{Marti n 2 0 0 8 }: 
•Rit u xi ma b 3 7 5 m g/ m 2 da y 1 
•Et o p osi de 4 0 m g/ m 2/ d I V o n da ys 1- 4 
•Met h yl pre d nis ol o ne 5 0 0 m g/ d I V o n da ys 1- 4 or 5 
•Cis plati n at 2 5 m g/ m 2/ d CI da ys 1- 4 
•C ytara bi ne 2 g/ m 2 o n da y 5 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 4 4 1 4 A pril 2 0 2 3 Rit u xi ma b + ge mcita bi ne, de xa met has o ne a n d cis plati n/car b o plati n ( R- G D P) s u g geste d d osi n g 
{Cr u m p 2 0 0 4 , G o pal 2 0 1 0 }
•Rit u xi ma b 3 7 5 m g/ m 2 da y 1 ( or da y 8) 
•Ge mcita bi ne 1 g/ m 2 o n da ys 1 a n d 8 
•De xa met has o ne 4 0 m g o n da ys 1- 4 
•Cis plati n 7 5 m g/ m 2 o n da y 1 ( or car b o plati n A U C = 5) { G o pal 2 0 1 0 }
Rit u xi ma b + de xa met has o ne, hi g h- d ose c ytara bi ne a n d cis plati n ( R- D H A P) s u g geste d d osi n g 
{Gissel brec ht 2 0 1 0 }: 
•Rit u xi ma b 3 7 5 m g/ m 2 bef ore c he m ot hera p y 
•De xa met has o ne 4 0 m g/ d o n da ys 1- 4 
•Hi g h- d ose c ytara bi ne 2 g/ m 2 e ver y 1 2 h f or 2 d oses o n da y 2 f oll o wi n g plati n u m 
•Cis plati n 1 0 0 m g/ m 2 2 4 h- CI o n da y 1 ( or o xali plati n 1 0 0 m g/ m 2) { Li g n o n 2 0 1 0 }
6. 3. 1. 1. Rati o nale f or Sta n dar d of Care D ose a n d Sc he d ule 
Sec o n d-li ne c he m ot hera p y re gi me ns ge nerall y c o nsist of n o n-cr oss-resista nt dr u gs t o first-li ne 
R- C H O P a n d i ncl u des plati n u m.  C o m m o n re gi me ns i ncl u de R- G D P, R- D H A P, R-I C E, a n d 
R- E S H A P.  I nstit uti o nal prefere nce a n d t o xicit y pr ofile ofte n dictate w hic h treat me nt re gi me n is 
use d beca use n o si n gle sal va ge re gi me n has de m o nstrate d s u peri orit y i n a ra n d o mize d trial.  If 
a de q uate disease res p o nse ( C R or P R) is de m o nstrate d after 2 or 3 c ycles of c he m ot hera p y, 
H D T- A S C T ma y be i nitiate d. 
Pri or t o hi g h- d ose t hera p y, w hic h is m yel oa blati ve, peri p heral bl o o d pr o ge nit or cells are 
c ollecte d b y le u ka p heresis t o a mi ni m u m tar get of 2 x 1 0 6 C D 3 4 + he mat o p oietic ste m cells per 
k g b o d y wei g ht, w hic h will be rei nf use d after H D T t o resc ue he mat o p oiesis.  T he H D T 
c o n diti o ni n g re gi me n c o nsists of c o m bi nati o n hi g h- d ose c he m ot hera p y wit h or wit h o ut T BI.  
C o m m o nl y use d hi g h- d ose re gi me ns i ncl u de B E A M ( B C N U, et o p osi de, ara- C, a n d mel p hala n) 
or C B V (c ycl o p h os p ha mi de, B C N U, a n d V P- 1 6).  T here is n o sta n dar d hi g h- d ose re gi me n d ue t o 
lac k of ra n d o mize d st u dies; t heref ore, H D T a n d A S C T pr oce d ures are per re gi o nal a n d 
i nstit uti o nal sta n dar ds. 
6. 3. 2.  C o nc o mit a nt T her a p y ( St a n d ar d of C are Ar m) 
I n vesti gat ors ma y prescri be a n y c o nc o mita nt me dicati o ns or treat me nt dee me d necessar y t o 
pr o vi de a de q uate s u p p orti ve care, i ncl u di n g gr o wt h fact or s u p p ort (e g, G- C S F) a n d r o uti ne 
a nti-e metic pr o p h yla xis, e xce pt t h ose me dicati o ns liste d i n t he e xcl u de d me dicati o n 
Secti o n 6. 3. 3 .  C o nc o mit a nt t hera p y d oes n ot i ncl u de t hera p y use d f or t he treat me nt of t he 
disease. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 4 5 1 4 A pril 2 0 2 3 F or s u bjects w h o are n ot ra n d o mize d (e g, scree n fail ure), o nl y c o nc urre nt t hera pi[INVESTIGATOR_845633] d t o a n y 
S A Es will be rec or de d. 
F or s u bjects w h o are ra n d o mize d b ut n ot d ose d wit h S O C, c o nc urre nt t hera pi[INVESTIGATOR_442687] o nl y be 
rec or de d fr o m t he date of t he i nf or me d c o nse nt t hr o u g h [ADDRESS_1175210].  Refer t o Secti o n 6. 3. 4  f or details s urr o u n di n g s u bse q ue nt ca ncer t hera p y. 
S pecific c o nc o mita nt me dicati o n c ollecti o n re q uire me nts a n d i nstr ucti o ns are i ncl u de d i n t he 
C R F c o m pleti o n g ui deli nes. 
6. 3. 3. E xcl u de d Me dic ati o ns ( St a n d ar d of C are Ar m) 
Treat me nt f or l y m p h o ma, s uc h as c he m ot hera p y, i m m u n ot hera p y, tar gete d a ge nts, ra diati o n ( T BI 
f or H D T is all o we d), a n d hi g h- d ose c ortic oster oi d, ot her t ha n defi ne d/all o we d i n t his pr ot oc ol, 
a n d ot her i n vesti gati o nal a ge nts are pr o hi bite d, e xce pt as nee de d f or c ha n ge i n l y m p h o ma 
t hera p y after lac k of res p o nse t o t he pr ot oc ol- defi ne d S O C t hera p y o pti o ns. 
If per missi bilit y of a s pecific me dicati o n/treat me nt is i n q uesti o n, please c o ntact t he Kite P har ma 
me dical m o nit or. 
6. 3. 4. S u bse q ue nt T her a p y ( St a n d ar d of C are Ar m) 
S u bse q ue nt t hera p y a d mi nistere d after S O C c he m ot hera p y necessar y t o treat a s u bject’s disease, 
s uc h as n o n-st u d y s pecifie d c he m ot hera p y, i m m u n ot hera p y, tar gete d a ge nts, as well as ste m cell 
tra ns pla nt a n d ra diati o n t hera p y, will be rec or de d f or all s u bjects ra n d o mize d u ntil t he s u bject 
c o m pletes t he l o n g-ter m f oll o w- u p peri o d, is c o nsi dere d l ost t o f oll o w- u p, wit h dra ws c o nse nt, or 
dies.  If a s u bject pr o gresses, sites are str o n gl y e nc o ura ge d t o c ollect a bi o ps y c o nfir mi n g disease 
pr o gressi o n a n d t o s u b mit t he bi o psie d tiss ue t o t he ce ntral la b orat or y. 
6. 3. 5. T o xicit y M a n a ge me nt ( St a n d ar d of C are Ar m) 
Refer t o t he c urre nt re gi o nal pr o d uct la bel, a n d f oll o w i nstit uti o nal g ui deli nes f or t o xicit y 
ma na ge me nt ass ociate d wit h t he a d mi nistrati o n of eac h c he m ot hera p y a ge nt. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 4 6 1 4 A pril 2 0 2 3 7. S T U D Y P R O C E D U R E S 
Researc h staff s h o ul d refer t o t he S O As f or a n o utli ne of t he pr oce d ures re q uire d. 
T he visit sc he d ule f or disease assess me nts, i ncl u di n g C T sca ns, p ositr o n e missi o n t o m o gra p h y 
( P E T) sca ns, b o ne marr o w bi o ps y, assess me nt of B-s y m pt o ms, p h ysical e xa ms nee de d t o assess 
disease, a n d c ollecti o n of s u bse q ue nt ne w l y m p h o ma t hera p y, is calc ulate d fr o m ra n d o mizati o n. 
A n o ver vie w of st u d y assess me nts/ pr oce d ures is o utli ne d bel o w.  Refer t o t he C R F c o m pleti o n 
g ui deli nes f or data c ollecti o n re q uire me nts a n d d oc u me ntati o n of st u d y pr oce d ures. 
7. 1. I nf or me d C o nse nt 
Bef ore a s u bject’s partici pati o n i n t he cli nical st u d y, t he i n vesti gat or is res p o nsi ble f or o btai ni n g 
writte n i nf or me d c o nse nt fr o m t he s u bject after a de q uate e x pla nati o n of t he st u d y desi g n, 
a ntici pate d be nefits, a n d t he p ote ntial ris ks.  S u bjects s h o ul d si g n t he m ost c urre nt I R B/I E C 
a p pr o ve d I nf or me d C o nse nt F or m (I C F) pri or t o a n y st u d y-s pecific acti vit y or pr oce d ure is 
perf or me d. 
T he c o nse nt pr ocess a n d t he s u bject’s a gree me nt or ref usal t o partici pate i n t he st u d y is t o be 
d oc u me nte d i n t he s u bject’s me dical rec or ds.  If t he s u bject a grees t o partici pate, t he I C F is t o be 
si g ne d a n d pers o nall y date d b y t he s u bject a n d b y t he pers o n w h o c o n d ucte d t he i nf or me d 
c o nse nt disc ussi o n.  T he ori gi nal si g ne d I C F will be retai ne d i n acc or da nce wit h i nstit uti o n 
p olic y a n d I R B/I E C re q uire me nts wit h a c o p y of t he I C F pr o vi de d t o t he s u bject. 
All s u bjects w h o are e nr olle d i nt o t he st u d y s h o ul d be re-c o nse nte d wit h a n y u p date d versi o ns of 
t he I R B/I E C a p pr o ve d I C F if rele va nt t o t heir partici pati o n i n t he st u d y. 
7. 2. Scree ni n g 
I n vesti gati ve sites will mai ntai n a l o g of all scree ne d s u bjects w h o were re vie we d a n d e val uate d 
f or st u d y partici pati o n.  I nf or mati o n c ollecte d o n t he scree ni n g l o g s h o ul d i ncl u de li mite d 
i nf or mati o n, s uc h as t he date of scree ni n g, date t he s u bject was e nr olle d, or t he reas o n f or w h y 
t he s u bject faile d scree ni n g. 
T he scree ni n g peri o d be gi ns o n t he date t he s u bject si g ns t he I R B/I E C a p pr o ve d I C F a n d 
c o nti n ues t hr o u g h c o nfir mati o n of eli gi bilit y a n d ra n d o mizati o n i nt o t he st u d y.  I nf or me d 
c o nse nt m ust be o btai ne d bef ore c o m pleti o n of a n y n o n-sta n dar d of care st u d y-s pecific 
pr oce d ures.  Pr oce d ures t hat are part of sta n dar d of care are n ot c o nsi dere d st u d y-s pecific 
pr oce d ures a n d ma y be perf or me d pri or t o o btai ni n g c o nse nt a n d use d t o c o nfir m eli gi bilit y.  
C o nfir mati o n of t his data m ust occ ur wit hi n t he ti me all o wa nce as o utli ne d bel o w a n d i n t he 
S O A. 
After writte n i nf or me d c o nse nt has bee n o btai ne d, Kite P har ma will assi g n a scree ni n g n u m ber 
t o t he s u bject.  S u bse q ue ntl y, t he s u bject will be re gistere d i nt o t he I X R S as descri be d i n t he 
I X R S user ma n ual.  S u bjects w h o fail t o meet t he eli gi bilit y criteria will be all o we d t o rescree n 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175211] faili n g 
scree ni n g, i ncl u di n g a n y ot her pr oce d ures t hat fell o utsi de of t he desi g nate d scree ni n g wi n d o w 
(ie, la b assess me nts or P E T- C T sca ns). 
O nl y s u bjects w h o meet t he eli gi bilit y criteria liste d i n Secti o n [ADDRESS_1175212] u d y has bee n c o nfir me d, s u bjects will be ra n d o mize d i n a 1: [ADDRESS_1175213]-li ne t hera p y ( pri mar y refract or y, vs rela pse ≤ [ADDRESS_1175214]-li ne 
t hera p y vs rela pse > 6 a n d ≤ [ADDRESS_1175215]-li ne t hera p y) a n d sec o n d-li ne a ge-a dj uste d I PI 
( 0 t o 1 vs 2 t o 3) as assesse d at t he ti me of scree ni n g. 
After data ha ve bee n e ntere d i nt o t he I X R S, a c o nfir mati o n fa x or e mail will be se nt t o t he site t o 
verif y t hat t he c orrect i nf or mati o n has bee n e ntere d.  T he site re prese ntati ve will recei ve a si n gle, 
u ni q ue ra n d o mizati o n n u m ber f or eac h s u bject a n d t he ra n d o mizati o n treat me nt assi g ne d.  A 
s u bject will be c o nsi dere d e nr olle d/ra n d o mize d i nt o t he st u d y w he n a ra n d o mizati o n n u m ber is 
assi g ne d. 
T he ra n d o mizati o n date is t o be d oc u me nte d i n t he s u bject’s me dical rec or d a n d o n t he 
e nr oll me nt C R F. 
De pe n di n g o n w hic h ar m of t he st u d y s u bjects are ra n d o mize d, s u bjects s h o ul d i nitiate 
le u ka p heresis or S O C t hera p y wit hi n a p pr o xi matel y [ADDRESS_1175216]’s c o nc urre nt me dical c o n diti o n t hat w o ul d be 
t y pi[INVESTIGATOR_1306] y s hare d i n a referral letter.  All fi n di n gs will be rec or de d i n t he C R Fs. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175217]’s disease, treat me nt, a n d 
res p o nse t o treat me nt will be c ollecte d a n d m ust date bac k t o t he ori gi nal dia g n osis. 
F or s u bjects w h o are bei n g referre d fr o m a n ot her cli nic or i nstit uti o n t o t he partici pati n g researc h 
ce nter, c o pi[INVESTIGATOR_845634] o m t he s u bject’s c hart s h o ul d be o btai ne d. 
7. 6. P h ysic al E x a m, Vit al Si g ns, a n d Perf or m a nce St at us 
P h ysical e xa ms will be perf or me d d uri n g scree ni n g a n d at ti mes n ote d i n t he S O A.  C ha n ges 
n ote d i n s u bse q ue nt e xa ms w he n c o m pare d t o t he baseli ne e xa m will be re p orte d as a n a d verse 
e ve nt. 
Vital si g ns, i ncl u di n g bl o o d press ure, heart rate, res pi[INVESTIGATOR_1305] y rate, o x y ge n sat urati o n, a n d 
te m perat ure, will be m o nit ore d a n d rec or de d at ti mes o utli ne d i n t he S O A. 
I n a d diti o n t o t he ti me p oi nts o utli ne d i n t he S O A, it is rec o m me n de d t hat vital si g ns be 
m o nit ore d d uri n g a n d after a xica bta ge ne cil ole ucel or S O C t hera p y a n d e ver y [ADDRESS_1175218]’s 
ge neral well- bei n g a n d a bilit y t o perf or m acti vities of dail y life. 
7. 7.  Ne ur ol o gic al E x a mi n ati o n 
A ne ur ol o gical e xa mi nati o n will be perf or me d wit h a n y a b n or malities of t he f oll o wi n g rec or de d:  
le vel of c o nsci o us ness, orie ntati o n, visi o n, cra nial ner ves a n d brai n ste m f u ncti o ns, p yra mi dal 
a n d e xtra p yra mi dal m ot or s yste m, refle xes, m uscle t o ne a n d tr o p hic fi n di n gs, c o or di nati o n, 
se ns or y s yste m, ne ur o ps yc h ol o gical fi n di n gs (e g, s peec h, c o g niti o n a n d e m oti o n). A ne ur ol o gical 
assess me nt ( w hic h ma y i ncl u de t he Mi ni- Me ntal Stat us E xa m [ M M S E]) s h o ul d be d o ne pri or t o 
a xica bta ge ne cil ole ucel i nf usi o n o n treat me nt da y 0, t he n o n treat me nt da y 1, a n d e ver y ot her da y 
d uri n g t he mi ni m u m 7- da y o bser vati o n peri o d (refer t o A p pe n di x D  f or s pecific re q uire me nts of 
c o u ntr y re g ulat or y a ge ncies re gar di n g d urati o n of o bser vati o n peri o d). 
S u bjects will be s pecificall y q uerie d f or ne ur ol o gical s y m pt o ms o bser ve d i n t he i nter val si nce t he 
last baseli ne ne ur ol o gical e xa mi nati o n. 
7. 8.  C ar di ac F u ncti o n 
Eac h s u bject’s car diac f u ncti o n, as meas ure d b y left ve ntric ular ejecti o n fracti o n ( L V E F), will be 
assesse d d uri n g t he scree ni n g peri o d t o c o nfir m st u d y eli gi bilit y.  N o e vi de nce of pericar dial 
eff usi o n as re q uire d b y eli gi bilit y will als o be c o nfir me d.  B ot h L V E F a n d pericar dial eff usi o n 
will be assesse d pri or t o st u d y e ntra nce b y E C H O.  A n E C H O perf or me d f oll o wi n g t he s u bjects 
last c he m ot hera p y treat me nt a n d wit hi n 2 8 da ys pri or t o si g ni n g t he c o nse nt ma y be use d f or 
c o nfir mati o n of eli gi bilit y. 
T o esta blis h a baseli ne, a 1 2-lea d E C G will als o be perf or me d d uri n g t he scree ni n g peri o d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175219] u d y a n d 
recei ve a xica bta ge ne cil ole ucel as part of t heir i nitial treat me nt, or as part of re-treat me nt, 
s us pecte d relate d t o xicities s h o ul d be e val uate d wit h t he f oll o wi n g: 
•F or ne w o nset s y m pt o ms p ote ntiall y relate d t o C R S, a p h ysical e xa m, a n d assess me nts of 
vital si g ns (i ncl u di n g p ulse o xi metr y) a n d car di o p ul m o nar y stat us s h o ul d be perf or me d.  
Refer t o t he S O A Ta ble 2  f or f urt her details, Secti o n 6. 2. 7 , a n d t he I B f or C R S ma na ge me nt. 
•F or ne w o nset ne ur ol o gic s y m pt o ms, ne ur ol o gic assess me nt s h o ul d be perf or me d at least 
dail y u ntil s y m pt o ms res ol ve t o baseli ne.  F or Gra de ≥ 2 ne ur ol o gical s y m pt o ms, a brai n 
M RI, electr oe nce p hal o gra m ( E E G), a n d e xa mi nati o n of C S F s h o ul d be perf or me d i n a d diti o n 
t o fre q ue nt ne ur ol o gic assess me nt.  A d diti o nal e val uati o ns of t he C S F s h o ul d be perf or me d 
per i nstit uti o nal sta n dar d of care.  C S F sa m ples (ie, if c ollecte d at  baseli ne, a n d c ollecte d o n 
st u d y t o assess ne ur ol o gical s y m pt o ms) will be s u b mitte d t o t he ce ntral la b orat or y.  Refer t o 
t he S O A Ta ble 2  f or f urt her details, Secti o n 6. 2. 7 , a n d t he I B f or ma na ge me nt. 
•F or Gra de ≥ 3 C R S, ne ur ol o gic, or H L H s y m pt o ms, C R P a n d ferriti n le vels s h o ul d be 
e val uate d a n d f oll o we d. 
7. 1 0.  Dise ase Res p o nse Assess me nt 
S u bjects will be e val uate d f or disease res p o nse b y t he site i n vesti gat or at ti mes i n dicate d i n t he 
S O A.  Disease assess me nts will be e val uate d per t he L u ga n o Classificati o n { C hes o n 2 0 1 4 }.  
Fl o w c yt o metric, m olec ular, or c yt o ge netic st u dies will n ot be use d t o deter mi ne res p o nse. 
7. 1 0. 1. I m a gi n g 
Scree ni n g fl u or o de o x y gl uc ose ( F D G)- P E T fr o m s k ull base t o mi d-t hi g hs a n d dia g n ostic q ualit y 
c o ntrast-e n ha nce d ( u nless c o ntrai n dicate d) C T fr o m s k ull base t hr o u g h lesser tr oc ha nters 
( P E T- C T), al o n g wit h t he a p pr o priate i ma gi n g of all ot her sites of disease, are re q uire d t o 
c o nfir m eli gi bilit y a n d t o esta blis h a baseli ne, w hic h m ust be perf or me d wit hi n [ADDRESS_1175220]’s ra n d o mizati o n date. 
S u bjects’ disease will f urt her be assesse d a n d at re g ular i nter vals as hi g hli g hte d i n t he S O A 
d uri n g t he p ost treat me nt a n d l o n g-ter m f oll o w- u p p orti o n of t he st u d y.  P E T- C Ts will c o nti n ue 
t hr o u g h M o nt h [ADDRESS_1175221]’s disease has n ot pr o gresse d b y M o nt h 9, disease assess me nts ca n be e val uate d 
per C T sca ns w here a C R is s us pecte d a n d per P E T- C Ts w here a P R is s us pecte d.  S u bjects wit h 
s y m pt o ms s u g gesti ve of disease pr o gressi o n s h o ul d be e val uate d f or pr o gressi o n at t he ti me 
s y m pt o ms occ ur e ve n if it is off sc he d ule as per t he S O A. P E T- C T ca n be perf or me d at a n y ti me 
disease pr o gressi o n is s us pecte d.  F D G- P E T assess me nt ta kes prece de nce o ver C T assess me nt 
f or ti me p oi nts w he n b ot h are a vaila ble.  If o nl y C T is a vaila ble f or a ti me p oi nt, assess me nt 
s h o ul d i ncl u de a n d ma y be affecte d b y t he P E T- C T assess me nt at t he pri or ti me p oi nt.  Please 
refer t o t he i ma gi n g ma n ual f or f urt her details. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 5 0 1 4 A pril 2 0 2 3 I n a d diti o n t o t he i n vesti gat or’s assess me nt, P E T- C T sca ns of all s u bjects e val uate d f or disease 
res p o nse will be s u b mitte d t o a n d re vie we d b y a n i n de pe n de nt ce ntral re vie wer bli n de d t o 
treat me nt ar m.  F or s u bjects w h o disc o nti n ue pr ot oc ol t hera p y d ue t o a n assess me nt of 
pr o gressi ve disease b ut f or w h o m t here was n o c ha n ge i n l y m p h o ma t hera p y, a n y a d diti o nal 
i ma gi n g data, s u bse q ue nt t o t he i ma ge i n q uesti o n, will be s u b mitte d t o t he ce ntral re vie wer t o 
c o nfir m disease res p o nse.  Re q uire me nts f or P E T- C T sca ns a n d s hi p pi n g re q uire me nts will be 
o utli ne d i n t he st u d y i ma gi n g ma n ual. 
If t he s u bject is eli gi ble f or retreat me nt wit h a xica bta ge ne cil ole ucel, t he last sca n pri or t o 
retreat me nt will be c o nsi dere d t he baseli ne f or t he p ur p ose of e val uati n g t he res p o nse t o 
retreat me nt. 
7. [ADDRESS_1175222]’s b o ne marr o w i n v ol ve me nt s h o ul d be c o nfir me d b y P E T- C T or b o ne marr o w bi o ps y 
a n d as pi[INVESTIGATOR_845635] t o ra n d o mizati o n.  C o nfir mati o n of marr o w i n v ol ve me nt ca n be deter mi ne d 
u p o n i nitial dia g n osis of disease or if ne gati ve or u n k n o w n at i nitial dia g n osis, at t he ti me of 
rela pse fr o m first-li ne t hera p y.  If b o ne marr o w i n v ol ve me nt was n ot e val uate d at t he ti me of 
rela pse a n d wit hi n [ADDRESS_1175223] u d y e ntr y, a P E T- C T a n d/ or b o ne marr o w bi o ps y a n d as pi[INVESTIGATOR_845636] d t o esta blis h a baseli ne. 
If t here is e vi de nce of baseli ne b o ne marr o w i n v ol ve me nt, if P E T- C T is n ot a vaila ble or if t here 
are u ne x plai ne d c yt o pe nias or s us pi[INVESTIGATOR_37180] o n of b o ne marr o w i n v ol ve me nt, a b o ne marr o w as pi[INVESTIGATOR_337] 
a n d bi o ps y will be perf or me d i n s u bjects w h o are bei n g assesse d f or C R i n or der t o c o nfir m 
c o m plete res p o nse.  T he b o ne marr o w as pi[INVESTIGATOR_337] a n d bi o ps y m ust s h o w n o e vi de nce of disease b y 
m or p h ol o g y or, if i n deter mi nate b y m or p h ol o g y, it m ust be ne gati ve b y i m m u n o hist oc he mistr y.  
Refer t o A p pe n di x B  f or treat me nt res p o nse assess me nt re q uire me nts per t he L u ga n o 
Classificati o n { C hes o n 2 0 1 4 }. 
7. 1 1. L a b or at or y 
T he bel o w sa m ples will be c ollecte d at t he ti me p oi nts i n dicate d i n t he S O A.  A d diti o nal sa m ples 
(e g, bl o o d, uri ne, C S F, tiss ue) ma y be c ollecte d as nee de d d uri n g t he c o urse of t he st u d y f or 
f urt her safet y testi n g. 
7. 1 1. 1. L oc al L a b A n al ysis 
•S o di u m ( Na), p otassi u m ( K), c hl ori de ( Cl), bicar b o nate ( C O 2), creati ni ne, gl uc ose, al b u mi n, 
calci u m t otal, ma g nesi u m t otal ( M g), al kali ne p h os p hatase, A L T/ S G P T, A S T/ S G O T, t otal 
bilir u bi n, a nal yze d per t he S O A 
•Baseli ne L D H at scree ni n g fr o m a n o n- he m ol yze d sa m ple t o be use d f or t he assess me nt of 
t he s A AI PI 
•C R P at le u ka p heresis, treat me nt da y 0, treat me nt da ys 1- 7, a n d f or Gra de ≥ 3 C R S, 
ne ur ol o gic, H L H e ve nts. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 5 1 1 4 A pril 2 0 2 3 •Ferriti n at le u ka p heresis, treat me nt da y 0, treat me nt da ys 1- 7, a n d f or Gra de ≥ 3 C R S, 
ne ur ol o gic, H L H e ve nts. 
•C B C wit h differe ntial a nal yze d per t he S O A 
•A uri ne or ser u m sa m ple will be c ollecte d a n d assesse d l ocall y f or fe males of c hil d beari n g 
p ote ntial.  If t he scree ni n g pre g na nc y test is p ositi ve, t he s u bjects s h o ul d n ot be e nr olle d.  If a 
sta n dar d of care pre g na nc y test is c ollecte d d uri n g t he c o urse of t he st u d y, a n d t he res ult is 
p ositi ve, t he i n vesti gat or s h o ul d c o ntact t he Kite P har ma me dical m o nit or f or i nstr ucti o ns.  If 
a fe male part ner of a male s u bject bec o mes pre g na nt d uri n g t he c o n d uct of t he st u d y, it m ust 
be re p orte d b y c o ntacti n g Kite P har ma me dical m o nit or f or i nstr ucti o ns. 
•Ser ol o g y Testi n g:  F or E ur o pea n U ni o n ( E U) sites, viral ser ol o gic tests (e g, HI V, He p B, He p 
C) will be carrie d o ut per i nstit uti o n g ui deli nes a n d E U re g ulati o ns. T his ma y be d o ne wit hi n 
t he 3 0 da ys pri or t o le u ka p heresis a n d/ or o n t he da y of le u ka p heresis. 
7. 1 1. 2.  Ce ntr al L a b A n al ysis 
•Bl o o d dra ws f or le vels of a nti- C D 1 9 C A R T cells b y q ua ntitati ve p ol y merase c hai n reacti o n 
( q P C R) a nal ysis a n d m o nit ori n g of l y m p h oc ytes s u bsets, i ncl u di n g ret ur n of n or mal B cells, 
will be perf or me d at i nter vals o utli ne d i n t he S O A. 
•Bl o o d dra ws f or re plicati o n-c o m pete nt retr o vir us ( R C R), treat me nt-relate d a nti b o d y 
de vel o p me nt, a n d c yt o ki nes will be perf or me d at i nter vals o utli ne d i n t he S O A or as 
cli nicall y i n dicate d. 
•Arc hi ve d t u m or sa m ples will be s u b mitte d t o ce ntral la b orat or y f or e val uati o n of C D 1 9 
e x pressi o n a n d pr o g n ostic varia bles.  Eit her f or mali n-fi xe d paraffi n-e m be d de d ( F F P E) t u m or 
bl oc k or [ADDRESS_1175224] u d y.  
Sli des t hat ha ve bee n pre vi o usl y stai ne d wit h a nti b o dies or ot her rea ge nts are n ot acce pta ble. 
•A d diti o nal a nal ysis ma y i ncl u de C D [ADDRESS_1175225] will be retai ne d a n d teste d b y t he s p o ns or or 
s pecialt y la b orat or y f or t he p ur p ose of u n dersta n di n g t he mec ha nis m of acti o n a n d safet y pr ofile 
of a xica bta ge ne cil ole ucel. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175226] or; he nce, t here is a 
t he oretical ris k f or R C R de vel o pi n g i n e x p ose d s u bjects.  A d diti o nal i nf or mati o n is pr o vi de d i n 
t he I n vesti gat or’s Br oc h ure. T he ti mi n g of bl o o d dra ws f or deter mi nati o n of t he prese nce of R C R 
is s pecifie d i n t he S O A or ma y be d o ne or as cli nicall y i n dicate d. 
R C R testi n g will occ ur at baseli ne, st u d y Da y [ADDRESS_1175227] bef ore a n y pr oce d ures are 
perf or me d, e xcl u di n g bl o o d dra ws, a n d at t he ti me p oi nts n ote d i n t he S O A. 
T he s p o ns or will pr o vi de trai ni n g f or rele va nt pers o n nel (e g, ke y i n vesti gat ors) f or t he 
a d mi nistrati o n of t he q uesti o n naires s o t hat s u bjects fill i n t he q uesti o n naires as c o m pletel y a n d 
acc uratel y as p ossi ble.  It is i m p orta nt t hat t he si g nifica nce a n d rele va nce of t he data are 
e x plai ne d caref ull y t o partici pati n g s u bjects s o t hat t he y are m oti vate d t o c o m pl y wit h data 
c ollecti o n { Fall o wfiel d 1 9 8 7 }.  T he meas ures are self-re p orte d, a n d t he s u bject m ust c o m plete 
t he q uesti o n naires i n pri vate a n d s h o ul d n ot be gi ve n hel p fr o m relati ves or cli nic staff; hel p i n 
i nter preti n g t he q uesti o ns is n ot all o we d. 
Bel o w is a descri pti o n of eac h patie nt re p orte d o utc o me, w hic h are e x pecte d fr o m all s u bjects 
w h o re mai n o n-st u d y at t he sc he d ule d assess me nts.  All P R O meas ures will be sc ore d usi n g t heir 
p u blis he d a d mi nistrati o n a n d sc ori n g ma n ual.  F or ite ms wit h missi n g res p o nses, t he res p o nse 
will be ma na ge d as per t he sc ori n g ma n ual. 
7. 1 2. 1. E ur o pe a n Or g a nis ati o n f or Rese arc h a n d Tre at me nt of C a ncer ( E O R T C) 
Q L Q- C 3 0 Versi o n 3. 0. 
T his meas ure pr o vi des a m ulti- di me nsi o nal assess me nt of healt h-relate d q ualit y of life ( H R Q o L).  
T he E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer ( E O R T C) Q ualit y of Life 
Q uesti o n naire Ca ncer ( Q L Q- C 3 0 versi o n 3. 0 i ncl u des t he f oll o wi n g c o nte nt: 
•Fi ve ( 5) m ulti-ite m f u ncti o nal scales ( p h ysical f u ncti o ni n g, r ole f u ncti o ni n g, e m oti o nal 
f u ncti o ni n g, c o g niti ve f u ncti o ni n g, s ocial f u ncti o ni n g) 
•T hree ( 3) m ulti-ite m s y m pt o m scales (fati g ue, na usea a n d v o miti n g, pai n) 
•Si x ( 6) s y m pt o m si n gle-ite m scales ( d ys p nea, i ns o m nia, a p petite l oss, c o nsti pati o n, diarr hea, 
fi na ncial diffic ulties) 
•O ne ( 1) Gl o bal Healt h Stat us scale a n d 
•O ne ( 1) Gl o bal H R Q o L scale 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 5 3 1 4 A pril 2 0 2 3 Eac h scale is meas ure d fr o m 0 t o 1 0 0 after a li near tra nsf or mati o n.  Hi g her sc ores f or f u ncti o ni n g 
scales a n d f or t he Gl o bal Healt h Stat us or Gl o bal H R Q o L scales i n dicate a hi g her le vel of 
f u ncti o ni n g a n d a better H R Q o L res pecti vel y, w hereas hi g her sc ores i n s y m pt o m scales re prese nt 
a hi g her le vel of s y m pt o ms. 
T his i nstr u me nt d oes n ot s u m t o get her all ite ms t hat ca n p ote ntiall y gr o u p differe nces a n d all o ws 
a n assess me nt of c ha n ge acr oss t he 1 5 differe nt d o mai ns.  I n its c urre nt versi o n ( versi o n 3), t he 
q uesti o n naire ta kes a p pr o xi matel y 1 1 mi n utes t o c o m plete. 
7. 1 2. 2. E ur o Q ol Fi ve Di me nsi o ns Q uesti o n n aire ( E Q- 5 D- 5 L) 
T he E ur o- Q O L, Fi ve Di me nsi o ns, Fi ve Le vels ( E Q- 5 D- 5 L) q uesti o n naire is a ge neric meas ure of 
healt h stat us t hat pr o vi des a si m ple descri pti ve pr ofile a n d a si n gle i n de x val ue.  T he E Q- 5 D- 5 L 
c o m prises 2 c o m p o ne nts:  a q uesti o n naire c o veri n g [ADDRESS_1175228] val uati o ns of healt h states usi n g a vis ual a nal o g scale ( V A S). 
T he E Q- 5 D- 5 L V A S is a 2 0-c m V A S f or rec or di n g self-rate d c urre nt H R Q o L state a n d is use d t o 
descri be t he s u bjects’ healt h stat us o n t he da y of t he assess me nt.  T he E Q- [ADDRESS_1175229] f or his or her c urre nt H R Q o L state a n d sc ore d 0 (“t he w orst healt h y o u 
ca n i ma gi ne”) t o 1 0 0 (“t he best healt h y o u ca n i ma gi ne”). 
T his q uesti o n naire ta kes a p pr o xi matel y 5 mi n utes t o c o m plete. 
7. 1 2. 3.  W or k Pr o d ucti vit y a n d Acti vit y I m p air me nt Q uesti o n n aire ( W P AI) 
T he W or k Pr o d ucti vit y a n d Acti vit y I m pair me nt Q uesti o n naire ( Ge neral Healt h V 2. 0 
[ W P AI: G H]; see A p pe n di x C ) meas ures w or k a n d acti vit y i m pair me nt d uri n g t he past 7 da ys.  It 
c o ntai ns 2 d o mai ns:  w or k a n d acti vit y. 
•T he w or k d o mai n i ncl u des [ADDRESS_1175230] w or ke d, a n d h o w healt h pr o ble ms ma y ha ve affecte d pr o d ucti vit y. 
•T he acti vit y d o mai n c o ntai ns a si n gle ite m t hat as ks t he s u bject h o w healt h pr o ble ms affecte d 
his or her a bilit y t o d o re g ular acti vities o utsi de of t heir w or k. 
T he W P AI yiel ds 4 t y pes of sc ores: a bse nteeis m, prese nteeis m, w or k pr o d ucti vit y l oss, a n d 
acti vit y i m pair me nt.  W P AI o utc o mes are e x presse d as i m pair me nt perce nta ges, wit h hi g her 
n u m bers i n dicati n g greater i m pair me nt a n d less pr o d ucti vit y. 
T his q uesti o n naire ta kes a p pr o xi matel y 2 t o 3 mi n utes t o c o m plete. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175231], bl o o d, a n d t u m or sa m ples t o e val uate 
pre dicti ve, p har mac o ki netic ( P K), a n d p har mac o d y na mic mar kers f or a xica bta ge ne cil ole ucel. 
A F F P E t u m or bl oc k or [ADDRESS_1175232] oc he mistr y 
(I H C), ge ne e x pressi o n pr ofili n g f or cell of ori gi n a nal ysis, a n d ce ntral a nal ysis of D N A 
alterati o ns f or s u b-classificati o n of D L B C L d o u ble- a n d tri ple- hit stat us.  Re mai ni n g sa m ples 
ma y be st ore d f or f ut ure e x pl orat or y a nal ysis of t u m or D N A, R N A, or pr otei n mar kers rele va nt 
t o t his li ne of t hera p y. 
A d diti o nal cli nical s peci me ns ma y be o btai ne d as nee de d t o assess safet y i n s u bjects or if n o vel 
fi n di n gs are o bser ve d i n t his st u d y. 
F or s u bjects ra n d o mize d t o t he a xica bta ge ne cil ole ucel ar m: 
•Bl o o d dra ws f or le vels of a nti ‑C D 1 9 C A R T cells i n bl o o d 
•Bl o o d dra ws f or e val uati o n of ser u m c yt o ki nes a n d c he m o ki nes.  T he f oll o wi n g c yt o ki nes 
ma y be i ncl u de d i n t he pa nel:  h o me ostatic, pr o-i nfla m mat or y a n d i m m u ne m o d ulati n g 
c yt o ki nes I L- 2, I L- 6, I L- 1 0, I L- 1 2 p 4 0/ p [ADDRESS_1175233] or ( T N F)- α, 
I F N-γ, G M- C S F, a n d C R P, H L H relate d mar kers ferriti n a n d I L- 2 R α a n d c he m o ki nes 
MI P- 1 α, MI P- 1 β, a n d I L- 8. 
•C S F, a n d a d diti o nal s u bject sa m ples (e g, ple ural fl ui d), will be o btai ne d fr o m s u bjects w h o 
de vel o p Gra de ≥ [ADDRESS_1175234] sa m ples, ma y als o be m o nit ore d f or t he 
p ur p ose of u n dersta n di n g t he safet y pr ofile of a xica bta ge ne cil ole ucel. 
•Bl o o d dra ws f or R C R a nal ysis (see Secti o n 7. 1 1. 2. 2 ). 
•A baseli ne ser u m  sa m ple a n d a d diti o nal ser u m sa m ples o utli ne d i n t he S O A ma y be a nal yze d 
f or de vel o p me nt of a nti b o dies if a treat me nt-relate d h y perse nsiti vit y reacti o n is o bser ve d. 
•Baseli ne le u ka p heresis a n d fi nal a xica bta ge ne cil ole ucel sa m ples will be c ollecte d a n d 
a nal yze d b y i m m u n o p he n ot y pi n g, q P C R, a n d/ or ge ne e x pressi o n pr ofili n g.  Re mai ni n g 
sa m ples ma y be st ore d f or f ut ure e x pl orat or y a nal ysis of i m m u ne-relate d mar kers a n d t o ai d 
i n t he u n dersta n di n g of t he safet y a n d efficac y pr ofile of a xica bta ge ne cil ole ucel. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175235] u d y. 
S u bjects ra n d o mize d t o t he S O C ar m a n d w h o res p o n d t o S O C t hera p y after 2 or 3 c ycles 
( defi ne d as ac hie vi n g a P R or C R) s h o ul d pr ocee d t o H D T a n d A S C T per i nstit uti o nal or nati o nal 
g ui deli nes as o utli ne d i n Secti o n 6. 3. 1. [ADDRESS_1175236]-treat me nt f oll o w- u p peri o d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175237] Tre at me nt visits are c alc ul ate d 
fr o m d ate of  r a n d o miz ati o n 
D a y Wit hi n 1 4 d a ys 
of 
r a n d o miz ati o n R a n d o miz ati o n 
Wit hi n a p pr o x. 
5 d a ys after 
r a n d o miz ati o n d- 5 d- 4 d- 3 d- 2 d- 1 Tre at me nt 
d 0 d 1 – 7 mD a y 5 0 
(- 7 t o + 2 1 d a ys) D a y 1 0 0 
( ± 1 4 d a ys) D a y 1 5 0 
( ± 1 4 d a ys) 
Me dical hist or y X
P h ysical e xa m aX X X X
Ne ur ol o gical assess me nt X XbQ O D bX
Wei g ht ( pl us hei g ht at 
scree ni n g) X X 
Vital si g ns ( B P, H R, R R, O 2 
sat, te m p) X X X X X
E C O G perf or ma nce stat us X
E C G X
E C H O cX
P E T- C T disease assess me nt dP E T- C T dP E T- C T P E T- C T P E T- C T 
Arc hi ve d t u m or sa m ple eXe
Pre g na nc y test (ser u m or 
uri ne) X X
Bl o o d dra w f or c he mistr y 
pa nel X X X X X X X X
Bl o o d dra w f or C B C 
w/ differe ntial X X X X X X X X
Bl o o d dra w f or a nti- 
a xica bta ge ne cil ole ucel 
a nti b o dies fX Xf
Bl o o d dra w f or L D H X
I X R S/ Ra n d o mizati o n call X
L u m bar P u nct ure gXg
Bl o o d dra w f or C R P/ Ferriti n X X X
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175238] Tre at me nt visits are c alc ul ate d 
fr o m d ate of  r a n d o miz ati o n 
D a y Wit hi n 1 4 d a ys 
of 
r a n d o miz ati o n R a n d o miz ati o n 
Wit hi n a p pr o x. 
5 d a ys after 
r a n d o miz ati o n d- 5 d- 4 d- 3 d- 2 d- 1 Tre at me nt 
d 0 d 1 – 7 mD a y 5 0 
(- 7 t o + 2 1 d a ys) D a y 1 0 0 
( ± 1 4 d a ys) D a y 1 5 0 
( ± 1 4 d a ys) 
Bl o o d dra w f or P B M Cs a n d 
a d diti o nal a nal ysis h Xd 1, 3 & 
7h XhXhXh
Bl o o d dra w f or c yt o ki nes hX Xd 1, 3 & 
7h  Xh Xh
Bl o o d dra w f or ser ol o g y ( E U 
sites) l XlXl
E O R T C Q L Q- C 3 0 iX X X X X X
E Q- 5 D- 5 L iX X X X X X
W P AI iX X X X X X
Le u ka p heresis X
Fl u dara bi ne/ C ycl o p h os p ha mi d 
eX X X
A xica bta ge ne cil ole ucel 
i nf usi o n I V X
A d verse e ve nts j/ C o nc o mita nt 
me dicati o n k X X X X X X X X X X X  X 
A b bre viati o ns:  D, da y; I P, i n vesti gati o nal pr o d uct; B P, bl o o d press ure; H R, heart rate; E C O G, Easter n C o o perati ve O nc ol o g y Gr o u p; E C G, electr ocar di o gra m; E C H O, 
ec h ocar di o gra m; P E T- C T, p ositr o n e missi o n t o m o gra p h y c o m p uter t o m o gra p h y; C B C, c o m plete bl o o d c o u nt; L D H, lactate de h y dr o ge nase; I X R S, I nteracti ve V oice/ We b ( X) 
Res p o nse S yste m; C R P, C-reacti ve pr otei n; P B M C, peri p heral bl o o d m o n o n uclear cell; E O R T C Q L Q- C 3 0, E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y 
of Life Q uesti o n naire Ca ncer- 3 0; E Q- 5 D- 5 L, E ur o- Q O L, Fi ve Di me nsi o ns, Fi ve Le vels; W P AI, W or k pr o d ucti vit y a n d acti vit y i m pair me nt q uesti o n naire. 
a P h ysical E xa m: S u bjects wit h ne w- o nset s y m pt o ms relate d t o C R S s h o ul d u n der g o p h ysical e xa mi nati o n at least dail y u ntil s y m pt o ms res ol ve t o baseli ne.  S u bjects wit h 
s y m pt o ms of ce ntral ner v o us s yste m mali g na nc y s uc h as ne w o nset se vere hea dac hes, nec k stiff ness, seiz ures, e nce p hal o pat h y, cra nial ner ve deficits, or a n y f ocal ne ur ol o gic 
fi n di n gs o n p h ysical e xa m will ha ve a brai n M RI a n d l u m bar p u nct ure f or e xa mi nati o n of cere bral s pi [INVESTIGATOR_55498] d. 
b  Ne ur ol o gic assess me nt: A ne ur ol o gical assess me nt s h o ul d be d o ne pri or t o a xica bta ge ne cil ole ucel i nf usi o n o n treat me nt da y 0, t he n o n treat me nt da y [ADDRESS_1175239] dail y u ntil s y m pt o ms res ol ve t o 
baseli ne. 
c Ec h o: Perf or me d f oll o wi n g t he s u bjects last c he m ot hera p y treat me nt a n d wit hi n 2 8 da ys pri or t o si g ni n g t he c o nse nt ma y be use d f or c o nfir mati o n of eli gi bilit y 
d P E T- C T disease assess me nt:  P E T- C T s h o ul d be perf or me d as cl ose t o ra n d o mizati o n as p ossi ble a n d wit hi n [ADDRESS_1175240] u d y e ntr y, a P E T- C T or a b o ne marr o w bi o ps y will be perf or me d t o esta blis h a baseli ne. P E T- C T s hall be 
perf or me d at a n y ti me disease pr o gressi o n is s us pecte d. If t here is e vi de nce of baseli ne b o ne marr o w i n v ol ve me nt, if P E T- C T is n ot a vaila ble or if t here are u ne x plai ne d 
c yt o pe nias or s us pi[INVESTIGATOR_37180] o n of b o ne marr o w i n v ol ve me nt, a b o ne marr o w as pi[INVESTIGATOR_337] a n d bi o ps y will be perf or me d i n s u bjects w h o are bei n g assesse d f or C R i n or der t o c o nfir m 
c o m plete res p o nse. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 5 8 1 4 A pril 2 0 2 3 e  Arc hi ve d t u m or sa m ple:  Arc hi ve d t u m or sa m ples will be s u b mitte d t o ce ntral la b orat or y f or e val uati o n of C D [ADDRESS_1175241] u d y. Sli des t hat ha ve bee n pre vi o usl y stai ne d wit h a nti b o dies or ot her rea ge nts are n ot acce pta ble.  Scree n faile d s u bjects’ arc hi ve d sa m ples s h o ul d n ot be s u b mitte d. 
f Bl o o d dra w f or a nti-a xica bta ge ne cil ole ucel a nti b o dies: Baseli ne a nti b o d y sa m ples t o be c ollecte d pri or t o start of le u ka p heresis.  If p ositi ve at baseli ne or Da y [ADDRESS_1175242] ure:  S u bjects wit h ne w o nset Gra de ≥ [ADDRESS_1175243] ure perf or me d t o assess cere bral 
s pi [INVESTIGATOR_55498] d. 
h Bl o o d dra ws f or P B M Cs, c yt o ki nes, a n d a d diti o nal a nal ysis per Secti o n 7. 1 1. 2 : P B M C bl o o d will be use d f or t he a nal ysis of tests t hat i ncl u de a nti- C D 1 9 C A R T cells, 
l y m p h oc ytes, a n d R C R, a n d will be c ollecte d at baseli ne ( pri or t o i nitiati o n of c o n diti o ni n g c he m ot hera p y), da y 1, 3, [ADDRESS_1175244] u d y Da ys 5 0, 1 0 0, a n d 1 5 0.  Bl o o d dra ws f or 
c yt o ki nes will be c ollecte d at baseli ne ( pri or t o i nitiati o n of c o n diti o ni n g c he m ot hera p y), treat me nt da y 0, 1, 3, 7, a n d st u d y Da ys [ADDRESS_1175245] e x perie nces a Gra de ≥ 3 a xica bta ge ne cil ole ucel-relate d t o xicit y s uc h as Gra de 3 C R S or ne ur ol o gic e ve nt, o ne a d diti o nal bl o o d dra w f or c yt o ki nes 
will be ta ke n at t he ti me of t he Gra de ≥ 3 a xica bta ge ne cil ole ucel-relate d t o xicit y a n d u p o n res ol uti o n of t he e ve nt.  Bl o o d a n d ser u m sa m ples ma y als o be use d f or f urt her 
a nti- C D 1 9 C A R T cell, R C R a n d i m m u n o ge nicit y e val uati o n as cli nicall y i n dicate d. 
i E O R T C Q L Q- C 3 0/ E Q- 5 D- 5 L/ W P AI: T o be c o m plete d b y t he s u bject bef ore a n y pr oce d ures are perf or me d-e xcl u di n g bl o o d dra ws. 
j  A d verse E ve nts: T he i n vesti gat or is res p o nsi ble f or re p orti n g all a d verse e ve nts o bser ve d b y t he i n vesti gat or or re p orte d b y t he s u bject t hat occ ur after ra n d o mizati o n t hr o u g h 
t he Da y [ADDRESS_1175246]. 
l F or E ur o pea n U ni o n ( E U) sites, viral ser ol o gic tests (e g, HI V, He p B, He p C) will be carrie d o ut per i nstit uti o n g ui deli nes a n d E U re g ulati o ns. T his ma y be d o ne wit hi n t he 
3 0 da ys pri or t o le u ka p heresis a n d/ or o n t he da y of le u ka p heresis. 
m S u bjects will be m o nit ore d dail y t hr o u g h da y 7 after treat me nt wit h a xica bta ge ne cil ole ucel u nless ot her wise re q uire d b y c o u ntr y re g ulat or y a ge ncies (refer t o A p pe n di x D ). 
All assess me nts descri be d i n t his ta ble f or da y 1- 7, are a p plica ble bet wee n da ys 7 a n d 1 0 if re q uire d b y c o u ntr y re g ulat or y a ge ncies. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175247] Tre at me nt visits are c alc ul ate d 
fr o m d ate of r a n d o miz ati o n 
Pr oce d ures Scree ni n g Tre at me nt Peri o d 
C ycle 1 a n d C ycle 2 Dise ase Assess me nt 
c alc ul ate d fr o m d ate 
of r a n d o miz ati o n Tre at me nt Peri o d 
H D T- A S C T or 
C ycle 3 – H D T- 
A S C T ( o pti o n al) P ost H D T- A S C T P ost T x F U 
D a y Wit hi n 1 4 
d a ys of 
r a n d o miz ati o n R a n d o miz ati o n 
C ycle 1 
Wit hi n 
a p pr o x. 5 d a ys 
after 
r a n d o miz ati o n C ycle 2 D a y 5 0 
(- 7 t o + 2 1 d a ys) H D T- A S C T or 
C ycle 3- H D T- 
A S C T D 1 0 0 
( ± 1 4 d a ys) D a y 1 5 0 
( ± 1 4 d a ys) 
Me dical hist or y X
P h ysical e xa m aX X X X
Ne ur ol o gical assess me nt X X
Wei g ht ( pl us hei g ht at scree ni n g) X
Vital si g ns ( B P, H R, R R, O 2 sat, 
te m p) X X X X
E C O G perf or ma nce stat us X
E C G X
E C H O bX
P E T- C T disease assess me nt cP E T- C T cP E T- C T P E T- C T P E T- C T 
Arc hi ve d t u m or sa m ple dX
Pre g na nc y test (ser u m or uri ne) X X
Bl o o d dra w f or c he mistr y pa nel X X X X X X X
Bl o o d dra w f or C B C w/ differe ntial X X X X X X X
Bl o o d dra w f or L D H X
Bl o o d dra w f or a d diti o nal a nal ysis jX X X X
I X R S / Ra n d o mizati o n call X
E O R T C Q L Q- C 3 0 eX X X da y of tra ns pla nt X X
E Q- 5 D- 5 L eX X X da y of tra ns pla nt X X
W P AI eX X X da y of tra ns pla nt X X 
S O C c he m ot hera p y fX XX ( C ycle 3 is 
o pti o nal) 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175248] Tre at me nt visits are  c alc ul ate d 
fr o m d ate of r a n d o miz ati o n 
Pr oce d ures Scree ni n g Tre at me nt Pe ri o d 
C ycle 1 a n d C ycle 2 Dise ase Asse ss me nt 
c alc ul ate d fr o m d ate 
of r a n d o miz ati o n Tre at me nt Pe ri o d 
H D T- A S C T or 
C ycle 3 – H D T- 
A S C T ( o pti o n al) P ost H D T- A S C T P ost T x F U 
D a y Wit hi n 1 4 
d a ys of 
r a n d o miz ati o n R a n d o miz ati o n 
C ycle 1 
Wit hi n 
a p pr o x. 5 d a ys 
after 
r a n d o miz ati o n C ycle 2 D a y 5 0 
(- 7 t o + 2 1 d a ys) H D T- A S C T or 
C ycle 3- H D T- 
A S C T D 1 0 0 
( ± 1 4 d a ys) D a y 1 5 0 
( ± 1 4 d a ys) 
Le u ka p heresis gXg
H D T gXg
C D 3 4 + ste m cell i nf usi o n gXg
A d verse e ve nts h/ C o nc o mita nt 
me dicati o n i X X X X X X X
A b bre viati o ns:  H D T, hi g h- d ose t hera p y; A S C T, a ut ol o g o us ste m cell tra ns pla nt; T x, treat me nt; F U, f oll o w- u p; B P, bl o o d press ure; H R, heart rate; E C O G, Easter n C o o perati ve 
O nc ol o g y Gr o u p; E C G, electr ocar di o gra m; E C H O, ec h ocar di o gra m; P E T- C T, p ositr o n e missi o n t o m o gra p h y c o m p uter t o m o gra p h y; C B C, c o m plete bl o o d c o u nt; L D H, lactate 
de h y dr o ge nase; I X R S, I nteracti ve V oice/ We b ( X) Res p o nse S yste m; E O R T C Q L Q- C 3 0, E ur o pea n Or ga nisati o n f or Researc h a n d Treat me nt of Ca ncer Q ualit y of Life 
Q uesti o n naire Ca ncer- 3 0; E Q- 5 D- 5 L, E ur o- Q O L, Fi ve Di me nsi o ns, Fi ve Le vels; W P AI, W or k pr o d ucti vit y a n d acti vit y i m pair me nt q uesti o n naire; S O C, sta n dar d of care. 
a P h ysical E xa m: S u bjects wit h s y m pt o ms of ce ntral ner v o us s yste m mali g na nc y s uc h as ne w o nset se vere hea dac hes, nec k stiff ness, seiz ures, e nce p hal o pat h y, cra nial ner ve 
deficits, or a n y f ocal ne ur ol o gic fi n di n gs o n p h ysical e xa m will ha ve l u m bar p u nct ure f or e xa mi nati o n of cere bral s pi [INVESTIGATOR_55498] d. 
b Ec h o: Perf or me d f oll o wi n g t he s u bjects last c he m ot hera p y treat me nt a n d wit hi n 2 8 da ys pri or t o si g ni n g t he c o nse nt ma y be use d f or c o nfir mati o n of eli gi bilit y. 
c P E T- C T disease assess me nt:  P E T- C T s h o ul d be perf or me d as cl ose t o ra n d o mizati o n as p ossi ble a n d wit hi n [ADDRESS_1175249] u d y e ntr y, a P E T- C T or a b o ne marr o w bi o ps y will be perf or me d t o esta blis h a baseli ne. P E T- C T s h o ul d be 
perf or me d at a n y ti me disease pr o gressi o n is s us pecte d. If t here is e vi de nce of baseli ne b o ne marr o w i n v ol ve me nt, if P E T- C T is n ot a vaila ble or if t here are u ne x plai ne d 
c yt o pe nias or s us pi[INVESTIGATOR_37180] o n of b o ne marr o w i n v ol ve me nt, a b o ne marr o w as pi[INVESTIGATOR_337] a n d bi o ps y will be perf or me d i n s u bjects w h o are bei n g assesse d f or C R i n or der t o c o nfir m 
c o m plete res p o nse. 
d  Arc hi ve d t u m or sa m ple:  Arc hi ve d t u m or sa m ples will be s u b mitte d t o ce ntral la b orat or y f or pr o g n ostic varia bles. Eit her F F P E t u m or bl oc k or [ADDRESS_1175250] u d y e ntra nce. Scree n faile d s u bjects’ arc hi ve d sa m ples s h o ul d 
n ot be s u b mitte d. 
e E O R T C Q L Q- C 3 0/ E Q- 5 D- 5 L/ W P AI: T o be c o m plete d b y t he s u bject bef ore a n y pr oce d ures are perf or me d-e xcl u di n g bl o o d dra ws. 
f S O C D osi n g a n d A d mi nistrati o n Refer t o Secti o n 6. 3. 1  f or i n vesti gat or c h oice of S O C re gi me ns a n d d osi n g details.  If a de q uate disease res p o nse ( C R or P R) is de m o nstrate d 
after t he sec o n d or t hir d c ycle of c he m ot hera p y, H D T- A S C T ma y be i nitiate d. 
g Le u ka p heresis, H D T, a n d C D 3 4 + ste m cell i nf usi o n pr oce d ures perf or me d f or s u bjects u n der g oi n g H D T- A S C T o nl y.  T his occ urs if a de q uate disease res p o nse ( C R or P R) is 
de m o nstrate d after t w o or t hree c ycles of c he m ot hera p y. 
h  A d verse E ve nts: T he i n vesti gat or is res p o nsi ble f or re p orti n g all a d verse e ve nts o bser ve d b y t he i n vesti gat or or re p orte d b y t he s u bject t hat occ ur after ra n d o mizati o n t hr o u g h 
t he Da y [ADDRESS_1175251] u d y s pecific pr oce d ure. 
j Bl o o d dra ws f or a d diti o nal a nal yses per Secti o n 7. 1 1. 2 .
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 6 1 1 4 A pril  2 0 2 3 7. 1 5. L o n g-ter m F oll o w- u p ( A xic a bt a ge ne Cil ole ucel a n d St a n d ar d of C are Ar ms) 
All s u bjects will be f oll o we d i n t he l o n g-ter m f oll o w- u p peri o d f or disease assess me nts a n d 
s ur vi val stat us per t he S O A ( Ta ble 4 ) u ntil t he tra nsiti o n t o t he se parate L T F U st u d y. S u bjects 
will be gi n t he l o n g-ter m f oll o w- u p peri o d be gi n ni n g at t he M o nt h 9 visit a n d will be assesse d as 
f oll o ws: 
•E ver y 3 m o nt hs ( ± 2 8 da ys) t hr o u g h M o nt h 2 4 
•E ver y 6 m o nt hs ( ± 2 8 da ys) bet wee n M o nt h 2 4 a n d M o nt h 6 0 
S O C Ar m O nl y: 
•All s u bjects i n t he S O C ar m will disc o nti n ue partici pati o n i n t he st u d y after c o m pleti o n of 
t he M o nt h 6 0 visit a n d assess me nts. 
A xic a bt a ge ne Cil ole ucel Ar m O nl y: 
•After M o nt h [ADDRESS_1175252] o ne d ose of a xica bta ge ne cil ole ucel as 
pr ot oc ol t hera p y will ret ur n t o t he cli nic o nce a n n uall y f or u p t o 1 5 years .
•All s u bjects w h o recei ve d at least o ne d ose of a xica bta ge ne cil ole ucel  as pr ot oc ol t hera p y 
will be tra nsiti o ne d t o t he se parate L T F U st u d y after pr o vi di n g si g ne d i nf or me d c o nse nt f or 
t he L T F U st u d y a n d after c o m pleti n g at least [ADDRESS_1175253]-treat me nt f oll o w u p 
peri o d as per t he S O A ( Ta ble 4 ). 
•I n t he L T F U st u d y, s u bjects will c o nti n ue assess me nts at ti me p oi nts c o nti g u o us wit h t he 
l o n g-ter m f oll o w u p peri o d ti me p oi nts i n t his st u d y. 
S O C a n d A xic a bt a ge ne Cil ole ucel Ar ms: 
S u bjects w h o di d n ot res p o n d t o treat me nt ma y recei ve off pr ot oc ol t hera p y b ut will c o nti n ue t o 
be f oll o we d f or disease assess me nts (if pr o gressi o n was n ot d oc u me nte d), s u bse q ue nt a ntica ncer 
t hera p y, a n d s ur vi val. 
S u bjects ma y als o be c o ntacte d b y tele p h o ne t o c o nfir m s ur vi val stat us a n d s u bse q ue nt ne w 
l y m p h o ma t hera p y use.  S h o ul d a s u bject re q uire la b c ollecti o n, la bs ma y be c ollecte d at t he 
cli nic or at a n o utsi de facilit y t o re d uce t he s u bject b ur de n. 
If a s u bject fails t o ret ur n t o t he cli nic f or a sc he d ule d pr ot oc ol s pecific visit, sites will nee d t o 
ma ke 2 atte m pts b y a c o m bi nati o n of tele p h o ne a n d mail/e mail t o c o ntact t he s u bject.  Sites m ust 
d oc u me nt b ot h atte m pts t o c o ntact t he s u bject.  If a s u bject d oes n ot res p o n d wit hi n [ADDRESS_1175254] 
will be re q uire d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175255] u d y site ma y ha ve f oll o w u p data f or t his 
peri o d o btai ne d fr o m cli nical, la b orat or y, a n d/ or dia g n ostic assess me nts c o n d ucte d b y t he 
referri n g healt hcare pr o vi der ( H C P) a n d/ or ge neral practiti o ner ( G P). I n a d diti o n, ot her healt h 
stat us i nf or mati o n ma y be o btai ne d fr o m t he s u bject a n d/ or t he s u bject’s referri n g H C P a n d/ or 
G P via tele p h o ne or e mail c o m m u nicati o n. T his i nf or mati o n will be use d t o detect late- o nset 
tar gete d S A Es t hat ma y be relate d t o st u d y t hera p y. 
S u bjects a n d/ or t he s u bject’s referri n g H C Ps a n d/ or G Ps ma y be c o ntacte d directl y b y tele p h o ne 
or e mail t o c o nfir m s ur vi val stat us a n d o btai n i nf or mati o n a b o ut tar gete d c o nc o mita nt me dicati o n 
use, s u bse q ue nt a ntica ncer t hera p y use, a n d late- o nset tar gete d S A Es (if t he S A E d oes n ot 
re q uire a test t o be perf or me d i n t he cli nic). 
Refer t o t he S O A ( Ta ble 4 ) f or a listi n g of st u d y pr oce d ures a n d disease assess me nts t o be 
c o m plete d d uri n g t he l o n g-ter m f oll o w- u p peri o d. 
S u bjects w h o are e nr olle d/ra n d o mize d b ut di d n ot recei ve i n vesti gati o nal pr o d uct, or recei ve d 
t hera p y b ut di d n’t res p o n d t o treat me nt, will be f oll o we d i n t he l o n g-ter m f oll o w- u p peri o d u ntil 
M o nt h 6 0 (refer t o Secti o n 3. 5. 3 ) a n d will u n der g o t he f oll o wi n g assess me nts at t he ti me p oi nts 
o utli ne d i n t he S O A ( Ta ble 4 ): 
•S u bse q ue nt t hera p y f or t he treat me nt of N H L 
•S ur vi val stat us: S u bjects a n d/ or t he s u bject’s referri n g H C Ps a n d/ or G Ps ma y be c o ntacte d 
directl y b y tele p h o ne or e mail t o assess s ur vi val stat us 
•Disease assess me nts per pr ot oc ol 
•A Es/ S A Es per Secti o n 9
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 6 3 1 4 A pril  2 0 2 3 T a ble 4. Sc he d ule of Assess me nts L o n g-ter m F oll o w- u p Peri o d 
L o n g-ter m F oll o w- u p Peri o d 1 
E ac h visit c alc ul ate d fr o m r a n d o miz ati o n 
( all visits h a ve ± 2 8 d a y wi n d o w) L o n g-ter m F oll o w- u p 
Peri o d 2 
E ac h visit c alc ul ate d 
fr o m r a n d o miz ati o n 
( all visits h a ve 
± 3 m o nt h wi n d o w) 
Pr oce d ure A xic a bt a ge ne Cil ole ucel Ar m a n d St a n d ar d of C are Ar m A xic a bt a ge ne 
Cil ole ucel Ar m O nl y 
Visit fre q ue nc y M o nt h 
9M o nt h 
1 2 M o nt h 
1 5 M o nt h 
1 8 M o nt h 
2 1 M o nt h 
2 4 M o nt h 
3 0 M o nt h 
3 6 M o nt h 
4 2 M o nt h 
4 8 M o nt h 
5 4 M o nt h 
6 0 M o nt h 7 2 a n d 
A n n u all y T here after 
t o 1 5 Ye ars * 
P h ysical e xa m aX X X X X X        
P E T- C T sca n/ C T 
Sca n disease 
assess me nt bP E T- 
C T P E T- 
C T/ C T bP E T- 
C T/ C T bP E T- 
C T/ C T bP E T- 
C T/ C T bP E T- 
C T/ C T bP E T- 
C T/ C T bP E T- 
C T/ C T bP E T- 
C T/ C T bP E T- 
C T/ C T bP E T- 
C T/ C T bP E T- 
C T/ C T bXb 
S ur vi val stat us cX X X X X X X X X X X X Xc
C B C 
w/ differe ntial d X X X X X X        
Bl o o d dra w f or 
P B M Cs a n d 
a d diti o nal a nal ysis eX X  X  X  X  X  X X e
Tar gete d S A Es fX X X X X X X X X X X X Xf
S u bse q ue nt 
t hera p y f or N H L g X X X X X X X X X X X XXg
P R Os hX X X X X X        
A b bre viati o ns:  P B M C, peri p heral bl o o d m o n o n uclear cell; P E T- C T, p ositr o n e missi o n t o m o gra p h y c o m p uter t o m o gra p h y; C T, c o m p ute d t o m o gra p h y; C B C, c o m plete bl o o d  
c o u nt; S A E, seri o us a d verse e ve nt; N H L, n o n- H o d g ki n l y m p h o ma; P R O, patie nt re p orte d o utc o me. 
* After c o m pleti n g at least [ADDRESS_1175256]’s disease has n ot pr o gresse d b y M o nt h 9, disease assess me nts will be 
e val uate d per C T sca ns w here a C R is s us pecte d a n d per P E T- C Ts w here a P R is s us pecte d. P E T- C T s h o ul d be perf or me d at a n y ti me disease pr o gressi o n is s us pecte d. If 
s u bject’s disease has n ot pr o gresse d b y M o nt h [ADDRESS_1175257]’s pri mar y mali g na nt disease will be m o nit ore d per l ocal sta n dar d of care. T he s u bject’s disease 
stat us d oes n ot nee d t o be assesse d at t he i n vesti gati ve site. Rec or ds fr o m t he referri n g H C P a n d/ or G P ma y be o btai ne d f or s u bjects w h o are u na ble or u n willi n g t o ret ur n t o 
t he i n vesti gati ve sites. 
c S ur vi val stat us: S u bjects a n d/ or t he s u bject’s referri n g H C Ps a n d/ or G Ps ma y be c o ntacte d directl y b y tele p h o ne or e mail t o assess s ur vi val stat us. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 6 4 1 4 A pril  2 0 2 3 d C B C w/ differe ntial: S u bjects will c o nti n ue t o pr o vi de sa m ples f or C B C w/ diffs a n d l y m p h oc yte s u bsets t hr o u g h M o nt h 2 4. 
e Bl o o d dra ws f or a nal ysis, s uc h as R C R (f or s u bjects ra n d o mize d i nt o t he a xica bta ge ne cil ole ucel ar m), P B M Cs, a n d a d diti o nal a nal ysis per Secti o n 7. [ADDRESS_1175258]. After M o nt h 6 0 tar gete d S A Es will be re p orte d t hr o u g h 
1 5 years or u ntil disease pr o gressi o n a n d/ or start of s u bse q ue nt a ntica ncer t hera p y, w hic he ver occ urs first. T hese e ve nts will be i de ntifie d fr o m r o uti ne safet y assess me nts (ie, 
p h ysical e xa mi nati o n a n d la b orat or y assess me nts) perf or me d as sta n dar d of care ( n ot re q uire d t o be perf or me d at t he st u d y site). 
g S u bse q ue nt t hera p y will be c ollecte d f or all e nr olle d s u bjects u ntil t he e n d of t he s u bject’s partici pati o n i n t his st u d y or, w hile still a partici pa nt i n t his st u d y, t he s u bject is 
c o nsi dere d l ost t o f oll o w- u p, wit h dra ws c o nse nt, or dies. S u bjects a n d/ or t he s u bject’s referri n g H C Ps a n d/ or G Ps ma y be c o ntacte d directl y b y  tele p h o ne or e mail t o c ollect 
i nf or mati o n a b o ut s u bse q ue nt t hera p y. Refer t o Secti o ns 6. 2. 6  a n d 6. 3. 4  f or m ore details. 
h P R Os i ncl u de t he f oll o wi n g assess me nts: E O R T C Q L Q- C 3 0, E Q- 5 D- 5 L, & W P AI 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175259] u d y re q uire d treat me nt a n d/ or ot her pr ot oc ol 
re q uire d pr oce d ures at a n y ti me d uri n g t he st u d y b ut c o nti n ue t o partici pate i n certai n f oll o w- u p 
ele me nts of t he st u d y.  T his is referre d t o as partial wit h dra wal of c o nse nt. 
If partial wit h dra wal of c o nse nt occ urs, t he i n vesti gat or m ust disc uss wit h t he s u bject t he 
a p pr o priate pr ocess f or disc o nti n uati o n fr o m i n vesti gati o nal pr o d uct, st u d y treat me nt, or ot her 
pr ot oc ol-re q uire d t hera pi[INVESTIGATOR_014] a n d m ust disc uss o pti o ns f or c o nti n ue d partici pati o n, c o m pleti o n of 
pr oce d ures, a n d t he ass ociate d data c ollecti o n as o utli ne d i n t he S O A i ncl u di n g t he f oll o wi n g: 
•S ur vi val stat us, i ncl u di n g t he ca use of deat h 
•Safet y re p orti n g, i ncl u di n g ne w mali g na ncies; S A Es relate d t o a xica bta ge ne cil ole ucel a n d 
tar gete d S A Es i ncl u di n g, b ut n ot li mite d t o, ne ur ol o gic e ve nts, i nfecti o ns, bl o o d dis or ders, or 
i m m u ne dis or ders; a n d pre g na ncies 
•Tar gete d c o nc o mita nt me dicati o ns as per t he S O A a n d Secti o n 6. 2. 4. 9 
•S u bse q ue nt t hera pi[INVESTIGATOR_014] 
•Ce ntral la b orat or y sa m ples ( per t he S O A) 
T he le vel of f oll o w- u p a n d met h o d of c o m m u nicati o n s h o ul d als o be disc usse d bet wee n t he 
researc h staff a n d t he s u bject a n d d oc u me nte d i n t he s o urce d oc u me nts. 
Wit h dra wal of f ull c o nse nt fr o m a st u d y mea ns t hat t he s u bject d oes n ot wis h t o recei ve f urt her 
pr ot oc ol re q uire d t hera p y or u n der g o pr oce d ures a n d t he s u bject d oes n ot wis h t o c o nti n ue 
f urt her st u d y f oll o w- u p.  S u bject data c ollecte d u p t o wit h dra wal of c o nse nt will be retai ne d a n d 
i ncl u de d i n t he a nal ysis of t he st u d y, a n d, w here per mitte d b y l ocal re g ulati o ns, p u blicl y 
a vaila ble data ( deat h rec or ds) ca n be i ncl u de d after wit h dra wal of c o nse nt.  T he i n vesti gat or is t o 
disc uss wit h t he s u bject a p pr o priate pr oce d ures f or wit h dra wal fr o m t he st u d y. 
As part of t he st u d y sites ma y be as ke d t o c o n d uct searc hes of p u blic rec or ds, s uc h as t h ose 
esta blis hi n g s ur vi val stat us, if a vaila ble, t o o btai n s ur vi val data f or a n y s u bject f or w h o m t he 
s ur vi val stat us is n ot k n o w n, per t he a p plica ble l ocal la ws.  Sites ma y be als o as ke d t o als o 
retrie ve a ut o ps y re p orts t o c o nfir m t he stat us of disease at t he ti me of deat h, if p ossi ble, per t he 
a p plica ble l ocal la ws. 
T he i n vesti gat or a n d/ or s p o ns or ca n als o deci de t o wit h dra w a s u bject fr o m t he i n vesti gati o nal 
pr o d uct a n d/ or ot her pr ot oc ol-re q uire d t hera pi[INVESTIGATOR_014], pr ot oc ol pr oce d ures, or t he st u d y as a w h ole or 
at a n y ti me pri or t o st u d y c o m pleti o n. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 6 6 1 4 A pril 2 0 2 3  8. 1.  Re as o ns f or Re m o v al fr o m Tre at me nt 
Reas o ns f or re m o val fr o m pr ot oc ol re q uire d i n vesti gati o nal pr o d ucts or pr oce d ures i ncl u de a n y 
of t he f oll o wi n g: 
•A E 
•Disease pr o gressi o n 
•S u bject re q uest/ n o nc o m plia nce 
•Pr o d uct n ot a vaila ble 
•L ost t o f oll o w- u p 
•Deat h 
•Decisi o n b y s p o ns or 
8. 2.  Re as o ns f or Re m o v al fr o m St u d y 
Reas o ns f or re m o val of a s u bject fr o m t he st u d y are as f oll o ws: 
•S u bject wit h dra wal of c o nse nt fr o m f urt her f oll o w- u p 
•I n vesti gat or decisi o n 
•L ost t o f oll o w- u p 
•Deat h 
•Ter mi nati o n of t he st u d y b y t he s p o ns or 
•Ot her (e g, n o nc o m plia nce) 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175260]’s me dical rec or d. 
T he defi niti o n of A Es i ncl u des w orse ni n g of a pre-e xisti n g me dical c o n diti o n.  W orse ni n g 
i n dicates t hat t he pre-e xisti n g me dical c o n diti o n has i ncrease d i n se verit y, fre q ue nc y, a n d/ or 
d urati o n or has a n ass ociati o n wit h a w orse o utc o me.  W he n rec or di n g s uc h e ve nts, pr o vi de 
descri pti o ns t hat t he pre-e xisti n g c o n diti o n has c ha n ge d (e g, m ore fre q ue nt hea dac hes f or a 
s u bject wit h pre-e xisti n g hea dac hes).  A pre-e xisti n g c o n diti o n t hat has n ot w orse ne d d uri n g t he 
st u d y or i n v ol ves a n i nter ve nti o n, s uc h as electi ve c os metic s ur ger y or a me dical pr oce d ure w hile 
o n st u d y, is n ot c o nsi dere d a n A E. 
I nter ve nti o ns f or pretreat me nt c o n diti o ns (s uc h as electi ve c os metic s ur ger y) or me dical 
pr oce d ures t hat were pla n ne d bef ore st u d y partici pati o n are n ot c o nsi dere d a d verse e ve nts.  
H os pi[INVESTIGATOR_1314] o n f or st u d y treat me nt i nf usi o ns or preca uti o nar y meas ures per i nstit uti o nal p olic y 
are n ot c o nsi dere d A Es. 
T he ter m “ disease pr o gressi o n” as assesse d b y meas ure me nt of mali g na nt lesi o ns o n ra di o gra p hs 
or ot her met h o ds s h o ul d n ot be re p orte d as A Es.  Deat h d ue t o disease pr o gressi o n i n t he a bse nce 
of si g ns a n d s y m pt o ms s h o ul d be re p orte d wit h t he preferre d ter m “ B-cell l y m p h o ma”. 
F or sit uati o ns w he n a n A E or S A E is d ue t o t he disease u n der i n vesti gati o n, re p ort t he si g ns a n d 
s y m pt o ms.  W orse ni n g of si g ns a n d s y m pt o ms of t he mali g na nc y u n der st u d y s h o ul d als o be 
re p orte d as A Es i n t he a p pr o priate secti o n of t he C R F. 
T he i n vesti gat or’s cli nical j u d g me nt is use d t o deter mi ne w het her a s u bject is t o be re m o ve d 
fr o m treat me nt d ue t o a n A E.  I n t he e ve nt of a s u bject re q uests t o wit h dra w fr o m pr ot oc ol- 
re q uire d t hera pi[INVESTIGATOR_34405] t he st u d y d ue t o a n A E, t he s u bject s h o ul d u n der g o t he pr oce d ures o utli ne d 
i n t he Da y [ADDRESS_1175261] pr oce d ure 
(e g, le u ka p heresis, c o n diti o ni n g c he m ot hera p y). 
T he i n vesti gat or m ust pr o vi de t he i nf or mati o n liste d bel o w re gar di n g t he A Es bei n g re p orte d: 
•A E dia g n osis or s y n dr o me (if n ot k n o w n, si g ns or s y m pt o ms) 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 6 8 1 4 A pril 2 0 2 3  •Dates of o nset a n d res ol uti o n 
•Se verit y 
•Assess me nt of relate d ness t o i n vesti gati o nal pr o d uct, c o n diti o ni n g c he m ot hera p y, or st u d y 
pr oce d ures 
•Acti o n ta ke n 
A d verse e ve nt gra di n g scale use d will be t he N CI C o m m o n Ter mi n ol o g y Criteria f or A d verse 
E ve nts ( C T C A E) versi o n 4. 0 3.  A c o p y of t he gra di n g scale ca n be d o w nl oa de d fr o m t he C T E P 
h o me pa ge ( htt p://cte p.ca ncer. g o v).  C R S e ve nts will be re p orte d usi n g t he gra di n g scale o utli ne d 
i n t he I n vesti gat or Br oc h ure. 
I n re vie wi n g a d verse e ve nts, i n vesti gat ors m ust assess w het her t he a d verse e ve nt is p ossi bl y 
relate d t o 1) a xica bta ge ne cil ole ucel or S O C c he m ot hera p y, 2) c o n diti o ni n g c he m ot hera p y (f or 
s u bjects e nr olle d i nt o t he a xica bta ge ne cil ole ucel ar m of t he st u d y), 3) a n y pr ot oc ol-re q uire d 
st u d y pr oce d ure or treat me nt (ie, H D T A S C T), 4) disease pr o gressi o n, 5) c o nc urre nt disease, 6) 
c o nc o mita nt me dicati o n, or 7) ot her.  T he relati o ns hi p is i n dicate d b y a yes or n o res p o nse a n d 
e ntere d i nt o t he C R F.  A yes res p o nse s h o ul d i n dicate t hat t here is e vi de nce t o s u g gest a ca usal 
relati o ns hi p bet wee n t he st u d y treat me nt or pr oce d ure a n d t he A E.  A d diti o nal rele va nt data wit h 
res pect t o descri bi n g t he A E will be c ollecte d i n t he C R Fs. 
T he i n vesti gat or is e x pecte d t o f oll o w re p orte d A Es u ntil sta bilizati o n or res ol uti o n.  If a s u bject 
be gi ns a ne w l y m p h o ma t hera p y, t he A E re p orti n g peri o d f or n o n- S A Es e n ds at t he ti me t he ne w 
treat me nt is starte d. 
9. 2. 1.  Re p orti n g A b n or m al L a b or at or y Fi n di n gs 
T he i n vesti gat or is res p o nsi ble f or re vie wi n g la b orat or y test res ults a n d deter mi ni n g w het her a n 
a b n or mal val ue i n a n i n di vi d ual st u d y s u bject re prese nts a cli nicall y si g nifica nt c ha n ge fr o m t he 
s u bject’s baseli ne val ues.  I n ge neral, a b n or mal la b orat or y fi n di n gs wit h o ut cli nical si g nifica nce 
( base d o n t he i n vesti gat or's j u d g me nt) are n ot t o be rec or de d as A Es.  H o we ver, a b n or mal 
la b orat or y fi n di n gs t hat res ult i n ne w or w orse ni n g cli nical se q uelae, re q uire t hera p y, or 
a dj ust me nt i n c urre nt t hera p y are c o nsi dere d A Es.  W here a p plica ble, cli nical se q uelae ( n ot t he 
la b orat or y a b n or malit y) are t o be rec or de d as t he A E. 
A n a b n or mal la b orat or y test res ult m ust be re p orte d as a n a d verse e ve nt if it is a c ha n ge fr o m 
baseli ne a n d meets a n y of t he f oll o wi n g criteria: 
•Ass ociate d wit h cli nical s y m pt o ms 
•Res ults i n a me dical i nter ve nti o n (e g, p otassi u m s u p ple me ntati o n f or h y p o kale mia or ir o n 
re place me nt t hera p y f or a ne mia) or a c ha n ge i n c o nc o mita nt t hera p y 
•Cli nicall y si g nifica nt i n t he i n vesti gat or’s j u d g me nt 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175262] 1 of t he f oll o wi n g seri o us criteria: 
•Fatal 
•Life-t hreate ni n g ( places t he s u bject at i m me diate ris k of deat h) 
•Re q uires i n- patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of e xisti n g h os pi[INVESTIGATOR_1314] o n 
•Res ults i n persiste nt or si g nifica nt disa bilit y/i nca pacit y 
•C o n ge nital a n o mal y/ birt h defect 
•Ot her me dicall y i m p orta nt seri o us e ve nt 
A n A E w o ul d meet t he criteri o n of “re q uires h os pi[INVESTIGATOR_1314] o n” if t he e ve nt necessitate d a n 
a d missi o n t o a healt hcare facilit y (e g, o ver ni g ht sta y). 
E ve nts t hat re q uire a n escalati o n of care w he n t he s u bject is alrea d y h os pi[INVESTIGATOR_18552] d s h o ul d be 
rec or de d as a n S A E.  E xa m ples of s uc h e ve nts i ncl u de m o ve me nt fr o m r o uti ne care i n t he 
h os pi[INVESTIGATOR_307] t o t he I C U or if t hat e ve nt res ulte d i n a pr ol o n gati o n of t he e xisti n g pla n ne d 
h os pi[INVESTIGATOR_1314] o n. 
If a n i n vesti gat or c o nsi ders a n e ve nt t o be cli nicall y i m p orta nt, b ut it d oes n ot meet a n y of t he 
seri o us criteria, t he e ve nt c o ul d be classifie d as a n S A E wit h t he criteri o n of “ ot her me dicall y 
i m p orta nt seri o us e ve nt.” 
T he ter ms “se vere” a n d “seri o us” are n ot s y n o n y m o us. Se verit y refers t o t he i nte nsit y of a n A E 
acc or di n g t o N CI C T C A E criteria; t he e ve nt itself ma y be of relati vel y mi n or me dical 
si g nifica nce a n d, t heref ore, ma y n ot meet t he seri o us ness criteria. Se verit y a n d seri o us ness nee d 
t o be i n de pe n de ntl y assesse d f or eac h A E rec or de d o n t he electr o nic C R F. 
9. 4.  Re p orti n g of Seri o us A d verse E ve nts 
T he i n vesti gat or is res p o nsi ble f or re p orti n g all S A Es o bser ve d b y t he i n vesti gat or or re p orte d b y 
t he s u bject t hat occ ur after si g ni n g of t he i nf or me d c o nse nt t hr o u g h t he Da y [ADDRESS_1175263]. 
Seri o us a d verse e ve nts, w hic h t he i n vesti gat or assesses as relate d t o a xica bta ge ne cil ole ucel, 
s h o ul d be re p orte d re gar dless of t he ti me peri o d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175264] pr oce d ure (e g, scree n pr oce d ure, 
le u ka p heresis, c o n diti o ni n g c he m ot hera p y). 
All S A Es m ust be s u b mitte d via e mail t o Safet y _ F C @ gilea d.c o m wit hi n 2 4 h o urs f oll o wi n g t he 
i n vesti gat or’s k n o wle d ge of t he e ve nt. After t he electr o nic S A E s yste m is a vaila ble, all S A Es 
m ust be s u b mitte d t o Kite via t he e S A E s yste m wit hi n 2 4 h o urs of t he i n vesti gat or’s k n o wle d ge 
of t he e ve nt.  If t he e S A E s yste m is u na vaila ble (e g, s yste m o uta ge), t he n t he S A E m ust be 
s u b mitte d usi n g t he S A E Re p ort F or m a n d e maile d t o t he S A E Re p orti n g 
mail b o x: Safet y _ F C @ gilea d.c o m. 
After c o m pleti o n of t his st u d y a n d data base cl os ure, a n y rele va nt i nf or mati o n o n o n g oi n g S A Es 
m ust be s u b mitte d t o Kite wit hi n 2 4 h o urs after t he i n vesti gat or’s k n o wle d ge of t he e ve nt usi n g 
t he p orta ble d oc u me nt f or mat ( P D F) versi o n of t he pa per S A E Re p ort F or m a n d se nt via e- mail 
t o t he S A E Re p orti n g mail b o x: Safet y _ F C @ gilea d.c o m. 
All S A Es will be re p orte d t o t he healt h a ut h orities per l ocal re p orti n g g ui deli nes. 
Disease pr o gressi o n of t he mali g na nc y is n ot c o nsi dere d a n A E.  H o we ver, si g ns a n d s y m pt o ms 
of disease pr o gressi o n ma y be rec or de d as A Es or S A Es a n d i n dicate d as d ue t o disease 
pr o gressi o n o n t he e C R F.  If t he mali g na nc y has a fatal o utc o me bef ore Da y [ADDRESS_1175265]- 
ra n d o mizati o n visit, t he n t he e ve nt “ B-cell l y m p h o ma” m ust be rec or de d as a n S A E wit h t he 
o utc o me fatal. 
Deat h m ust be re p orte d if it occ urs d uri n g t he S A E re p orti n g peri o d, irres pecti ve of a n y 
i nter ve ni n g treat me nt. 
A n y deat h occ urri n g after ra n d o mizati o n a n d pri or t o Da y [ADDRESS_1175266]-ra n d o mizati o n visit re q uires e x pe dite d re p orti n g wit hi n 
2 4 h o urs o nl y if it is c o nsi dere d relate d t o treat me nt. 
9. 4. 1.  Re p orti n g De at hs 
Deat hs occ urri n g d uri n g t he pr ot oc ol-s pecifie d A E re p orti n g peri o d t hat i n vesti gat ors attri b ute 
s olel y t o pr o gressi o n of u n derl yi n g l y m p h o ma s h o ul d be rec or de d as S A Es a n d o n t he A E 
electr o nic C R F wit h t he preferre d ter m “ B-cell l y m p h o ma” a n d m ust be re p orte d t o t he s p o ns or 
i m me diatel y. Deat h is a n o utc o me a n d n ot a disti nct e ve nt. F or deat hs n ot d ue t o t he u n derl yi n g 
mali g na nc y, t he e ve nt or c o n diti o n t hat ca use d or c o ntri b ute d t o t he fatal o utc o me s h o ul d be 
rec or de d o n t he A E f or m. T he ter m “ u ne x plai ne d deat h” s h o ul d be ca pt ure d if t he ca use of deat h 
is n ot k n o w n. H o we ver, e ver y eff ort s h o ul d be ma de t o ca pt ure t he esta blis he d ca use of deat h, 
w hic h ma y bec o me a vaila ble later (e g, after a ut o ps y). Deat hs occ urri n g d uri n g t he p ost-st u d y 
s ur vi val f oll o w- u p peri o d t hat are d ue t o u n derl yi n g ca ncer s h o ul d be rec or de d o n t he S ur vi val 
Stat us C R F a n d t he Deat h S u m mar y Pa ge. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 7 1 1 4 A pril 2 0 2 3  9. 5.  Di a g n osis Vers us Si g ns a n d S y m pt o ms 
F or A Es, a dia g n osis (if k n o w n) s h o ul d be rec or de d o n t he A E f or m i n lie u of si g ns a n d 
s y m pt o ms. T he e xce pti o n is f or C R S, w here b ot h t he dia g n osis a n d si g ns a n d s y m pt o ms s h o ul d 
be ca pt ure d o n t he A E f or m. Si g ns a n d s y m pt o ms of t he u n derl yi n g ca ncer s h o ul d als o be 
rec or de d. H o we ver, t he i n vesti gat or s h o ul d state t hat t hese si g ns a n d s y m pt o ms are d ue t o t he 
u n derl yi n g disease. 
9. 6. Pre g n a nc y a n d L act ati o n 
T here is n o rele va nt cli nical e x perie nce wit h a xica bta ge ne cil ole ucel i n pre g na nt or lactati n g 
w o me n, a n d a ni mal re pr o d ucti ve st u dies ha ve n ot bee n perf or me d.  W o me n of c hil d beari n g 
p ote ntial m ust ha ve a ne gati ve pre g na nc y test pri or t o e nr oll me nt beca use of t he p ote ntiall y 
da n ger o us effects of t he pre parati ve c he m ot hera p y o n t he fet us.  W o me n of c hil d beari n g 
p ote ntial s h o ul d be m o nit ore d acc or di n g t o l ocal a n d c o u ntr y-s pecific re g ulati o ns. T his 
e x peri me ntal t hera p y s h o ul d n ot be a d mi nistere d t o pre g na nt w o me n or w o me n w h o are 
breastfee di n g. Refer t o A p pe n di x E  f or t he defi niti o n of c hil d beari n g p ote ntial. 
Fe male s u bjects a n d fe male part ners of male s u bjects are rec o m me n de d t o use hi g hl y effecti ve 
c o ntrace pti o n ( met h o d m ust ac hie ve a n a n n ual fail ure rate of < 1 %) f or at least [ADDRESS_1175267] be re p orte d t o Kite Patie nt Safet y a n d P har mac o vi gila nce usi n g t he Pre g na nc y 
Re p ort F or m wit hi n 2 4 h o urs after bec o mi n g a ware of t he pre g na nc y. I nf or mati o n re gar di n g t he 
pre g na nc y a n d/ or t he o utc o me will be re q ueste d b y t he s p o ns or. Pre g na nc y Re p ort F or ms s h o ul d 
be re p orte d t o Kite Patie nt Safet y a n d P har mac o vi gila nce at Safet y _ F C @ gilea d.c o m or 
fa x: + 1 ( 6 5 0) 5 2 2- 5 4 7 7. 
T he pre g na nc y itself is n ot c o nsi dere d a n A E n or is a n i n d uce d electi ve a b orti o n t o ter mi nate a 
pre g na nc y wit h o ut me dical reas o ns. A n y pre mat ure ter mi nati o n of pre g na nc y (e g, a s p o nta ne o us 
a b orti o n, a n i n d uce d t hera pe utic a b orti o n d ue t o c o m plicati o ns or ot her me dical reas o ns) m ust be 
re p orte d wit hi n [ADDRESS_1175268] be re p orte d t o Kite Patie nt Safet y a n d P har mac o vi gila nce. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175269] be re p orte d t o 
Kite Patie nt Safet y a n d P har mac o vi gila nce wit hi n 2 4 h o urs after t he i n vesti gat or’s a ware ness of 
t he e ve nt usi n g t he S pecial Sit uati o ns Re p orti n g F or m. I n a d diti o n t o re p orti n g a lactati o n case 
d uri n g t he st u d y, i n vesti gat ors s h o ul d m o nit or f or pre g na nc y a n d lactati o n cases t hr o u g h o ut t he 
l o n g-ter m f oll o w- u p peri o d. Re p ort t he lactati o n case a n d S pecial Sit uati o ns Re p orti n g F or ms t o 
Kite Patie nt Safet y a n d P har mac o vi gila nce at Safet y _ F C @ gilea d.c o m or fa x: + 1 ( 6 5 0) 5 2 2- 5 4 7 7. 
9. 7.  H os pit aliz ati o n a n d Pr ol o n ge d H os pit aliz ati o n 
A n y A E t hat res ults i n h os pi[INVESTIGATOR_1314] o n or pr ol o n ge d h os pi[INVESTIGATOR_1314] o n s h o ul d be d oc u me nte d a n d 
re p orte d as a n S A E, as descri be d i n Secti o n 9. 4 .
T he f oll o wi n g h os pi[INVESTIGATOR_1314] o n sce nari os are n ot c o nsi dere d t o be S A Es: 
•H os pi[INVESTIGATOR_1314] o n f or palliati ve care or h os pi[INVESTIGATOR_3677] 
•Pla n ne d h os pi[INVESTIGATOR_1314] o n re q uire d b y t he pr ot oc ol (e g, f or m o nit ori n g t he s u bject or t o perf or m 
a n efficac y meas ure me nt f or t he st u d y) 
•Pla n ne d h os pi[INVESTIGATOR_1314] o n f or a pre-e xisti n g c o n diti o n 
•H os pi[INVESTIGATOR_1314] o n d ue t o pr o gressi o n of t he u n derl yi n g ca ncer 
9. 8.  A b n or m al Vit al Si g n V al ues 
N ot all vital si g n a b n or malities q ualif y as a n A E. A vital si g n res ult m ust be re p orte d as a n A E if 
it is a c ha n ge fr o m baseli ne a n d meets a n y of t he f oll o wi n g criteria: 
•Acc o m pa nie d b y cli nical s y m pt o ms 
•Res ults i n a me dical i nter ve nti o n or a c ha n ge i n c o nc o mita nt t hera p y 
•Cli nicall y si g nifica nt i n t he i n vesti gat or’s j u d g me nt 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 7 3 1 4 A pril 2 0 2 3  It is t he i n vesti gat or’s res p o nsi bilit y t o re vie w all vital si g n fi n di n gs. Me dical a n d scie ntific 
j u d g me nt s h o ul d be e xercise d w he n deci di n g w het her a n is olate d vital si g n a b n or malit y s h o ul d 
be classifie d as a n A E. H o we ver, if a cli nicall y si g nifica nt vital si g n a b n or malit y is a si g n of a 
disease or s y n dr o me (e g, hi g h bl o o d press ure), o nl y t he dia g n osis (ie, h y perte nsi o n) s h o ul d be 
rec or de d o n t he C R F. 
9. 9.  D at a S afet y M o nit ori n g B o ar d 
A n i n de pe n de nt D S M B will meet e ver y [ADDRESS_1175270] rec o m me n dati o ns base d o n a n 
a nal ysis of ris k vers us be nefit.  T he D S M B ma y meet m ore ofte n as nee de d. 
T he D S M B will als o re vie w S A E i nf or mati o n a n d s us pecte d u ne x pecte d seri o us a d verse 
reacti o ns ( S U S A Rs) o n a re g ular basis t hr o u g h o ut s u bject treat me nt i n t he st u d y.  T he D S M B 
ma y re q uest a d diti o nal safet y or efficac y data or rec o m me n d m o dif yi n g t he st u d y c o n d uct.  T he 
s p o ns or ma y re q uest a d diti o nal re vie ws b y t he D S M B.  Data s u b mitte d t o t he D S M B ma y be 
m o nit ore d or u n m o nit ore d t o facilitate ti mel y D S M B re vie w. 
At t he ti me of e x pe dite d re p orti n g of S U S A Rs t o F D A, Kite P har ma ( or desi g nee) will 
c o nc urre ntl y s u b mit t hese re p orts t o t he D S M B C hair.  T he D S M B C hair will als o re vie w S A E 
narrati ve re p orts m o nt hl y. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 7 4 1 4 A pril 2 0 2 3  1 0. S T A TI S TI C A L C O N SI D E R A TI O N S 
1 0. 1.  H y p ot hesis 
T he h y p ot hesis is t hat a xica bta ge ne cil ole ucel will pr ol o n g E F S c o m pare d t o S O C t hera p y i n 
a d ult s u bjects wit h rela pse d/refract or y D L B C L.  T he h y p ot hesize d treat me nt effect c orres p o n ds 
t o a 5 0 % i m pr o ve me nt i n t he E F S ti me. 
[ADDRESS_1175271] date of disease pr o gressi o n per 
L u ga n o Classificati o n { C hes o n 2 0 1 4 }, c o m me nce me nt of ne w l y m p h o ma t hera p y, or deat h fr o m 
a n y ca use.  T he f oll o wi n g criteria will be use d t o f urt her defi ne e ve nts a n d e ve nt ti mes: 
•S u bjects wit h esta blis he d P R or C R a n d s u bse q ue ntl y c o m me nce ne w l y m p h o ma t hera p y 
(i ncl u di n g ra di ot hera p y, e xce pt f or T BI as n ote d bel o w) i n t he a bse nce of d oc u me nte d 
disease pr o gressi o n will ha ve E F S ti me defi ne d as t he ti me fr o m ra n d o mizati o n t o t he last 
e val ua ble disease assess me nt pri or t o t he ne w l y m p h o ma t hera p y 
•S u bjects wit h best res p o nse of S D a n d s u bse q ue ntl y c o m me nce ne w l y m p h o ma t hera p y 
(i ncl u di n g ra di ot hera p y, e xce pt f or T BI as n ote d bel o w) i n t he a bse nce of d oc u me nte d 
disease pr o gressi o n will ha ve E F S ti me defi ne d as t he ti me fr o m ra n d o mizati o n t o t he first 
ti me S D was esta blis he d pri or t o t he ne w l y m p h o ma t hera p y 
•S u bjects w h o c o m me nce ne w l y m p h o ma t hera p y (i ncl u di n g ra di ot hera p y, e xce pt f or T BI as 
n ote d bel o w) i n t he a bse nce of a n y e val ua ble disease assess me nt will ha ve t he E F S e ve nt 
date i m p ute d as t he ra n d o mizati o n date 
•S u bjects wit h best res p o nse of S D u p t o a n d i ncl u di n g Da y [ADDRESS_1175272] ti me S D was esta blis he d u p t o a n d 
i ncl u di n g t he Da y 1 5 0 disease assess me nt 
T he f oll o wi n g criteria will be use d t o f urt her defi ne ce ns ori n g ti mes: 
•S u bjects ali ve, i n res p o nse, a n d wit h n o ne w t hera p y will be ce ns ore d at t he last e val ua ble 
disease assess me nt 
•S u bjects wit h n o e val ua ble disease assess me nt b y Da y [ADDRESS_1175273]-ra n d o mizati o n 
will n ot be c o nsi dere d t o ha ve a n E F S e ve nt, a n d t he E F S ti me will be ce ns ore d at t he 
ra n d o mizati o n date 
•T he E F S ti me f or s u bjects i n t he a xica bta ge ne cil ole ucel ar m w h o u n der g o S C T i n t he 
a bse nce of a n y d oc u me nte d pr o gressi o n or ne w t hera p y will be ce ns ore d o n t he da y of S C T 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 7 5 1 4 A pril 2 0 2 3  •F or s u bjects i n t he S O C ar m, T BI, H D T, a n d S C T t hat occ ur w hile t he s u bject is i n res p o nse 
fr o m pr ot oc ol-s pecifie d i n d ucti o n t hera p y will n ot be c o nsi dere d a n E F S e ve nt.  T he E F S 
ti me f or S O C ar m s u bjects ali ve, pr o gressi o n-free, a n d wit h n o ne w l y m p h o ma t hera p y will 
be ce ns ore d at t he last e val ua ble disease assess me nt date 
•At t he ti me of t he i nteri m a nal ysis of E F S, s u bjects w h o ha ve n ot ha d t he o p p ort u nit y t o be 
f oll o we d t o t he Da y [ADDRESS_1175274] e val ua ble disease assess me nt pri or t o Da y 1 5 0. 
1 0. 2. 2.  Ke y Sec o n d ar y 
O R R is defi ne d as t he i nci de nce of eit her a c o m plete res p o nse or a partial res p o nse b y t he 
L u ga n o Classificati o n { C hes o n 2 0 1 4 } as deter mi ne d b y bli n de d ce ntral re vie w.  All s u bjects t hat 
d o n ot meet t he criteria f or a n o bjecti ve res p o nse b y t he a nal ysis c ut off date will be c o nsi dere d 
n o n-res p o n ders.  F or t he deri vati o n of O R R i n b ot h ar ms, disease assess me nts o btai ne d after 
ra n d o mizati o n a n d u p t hr o u g h a n o bser vati o n of pr o gressi o n per L u ga n o Classificati o n will be 
use d.  I n b ot h ar ms, deri vati o n of best res p o nse will i ncl u de all assess me nts u ntil a n E F S e ve nt, 
i ncl u di n g a n y assess me nts o btai ne d after S C T  f or t he S O C ar m. 
O S is defi ne d as t he ti me fr o m ra n d o mizati o n t o deat h fr o m a n y ca use.  S u bjects w h o ha ve n ot 
die d b y t he a nal ysis data c ut off date will ha ve s ur vi val ti me ce ns ore d at t heir last date k n o w n t o 
be ali ve.  F or s u bjects ali ve or dea d after t he data c ut off date, s ur vi val ti me will be ce ns ore d at 
t he data c ut off date. 
1 0. 2. 3. Sec o n d ar y 
E F S base d o n i n vesti gat or disease assess me nts:  E F S base d o n i n vesti gat or disease assess me nts 
will use t he sa me defi niti o n as E F S, e xce pt t hat pr o gressi o n e ve nts a n d ce ns ori n g ti mes will be 
base d o n t he i n vesti gat or disease assess me nts. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 7 6 1 4 A pril 2 0 2 3  M o difie d E F S ( m E F S): m E F S is defi ne d t he sa me wa y as E F S, e xce pt t hat fail ure t o attai n C R or 
P R b y Da y 1 5 0 assess me nt is n ot c o nsi dere d as a n e ve nt.  m E F S will be a nal yze d per bli n de d 
ce ntral re vie w a n d per i n vesti gat or disease assess me nts. 
P F S is defi ne d as t he ti me fr o m ra n d o mizati o n t o disease pr o gressi o n per L u ga n o Classificati o n 
{C hes o n 2 0 1 4 } as deter mi ne d b y i n vesti gat or re vie w or deat h fr o m a n y ca use.  S u bjects ali ve 
a n d n ot me eti n g t he criteria f or pr o gressi o n at t he a nal ysis data c ut off date will ha ve P F S ti me 
ce ns ore d at t he last e val ua ble disease assess me nt.  S u bjects w h o recei ve s u bse q ue nt ne w 
l y m p h o ma t hera p y ( wit h t he e xce pti o n of H D T, T BI f or H D T, a n d S C T w hile i n a pr ot oc ol 
t hera p y i n d uce d res p o nse) i n t he a bse nce of d oc u me nte d disease pr o gressi o n will be ce ns ore d at 
t heir last e val ua ble disease assess me nt date pri or t o t he c o m me nce me nt of t he s u bse q ue nt ne w 
l y m p h o ma t hera p y.  S C T t hat occ urs w hile a s u bject is i n res p o nse fr o m a pr ot oc ol t hera p y will 
n ot be c o nsi dere d a P F S e ve nt, a n d s uc h s u bjects will be ce ns ore d f or P F S at t he of t he last 
e val ua ble disease assess me nt date pri or t o t he S C T f or s u bjects i n t he a xica bta ge ne cil ole ucel 
ar m a n d will be ce ns ore d at t he last e val ua ble disease assess me nt date i ncl u di n g assess me nts 
after S C T f or s u bjects i n t he S O C ar m f or t he pri mar y a nal ysis of P F S. Disease o utc o mes will be 
base d o n i n vesti gat or assess me nt. 
D O R is deri ve d o nl y a m o n g s u bjects w h o e x perie nce a n o bjecti ve res p o nse per L u ga n o 
Classificati o n { C hes o n 2 0 1 4 } as deter mi ne d b y bli n de d ce ntral re vie w a n d is defi ne d as t he ti me 
fr o m first o bje cti ve res p o nse t o disease pr o gressi o n per t he L u ga n o Classificati o n or deat h fr o m 
a n y ca use.  S u bjects n ot meeti n g t he criteria f or pr o gressi o n or deat h b y t he a nal ysis data c ut off 
date will ha ve D O R ce ns ore d at t heir last e val ua ble disease assess me nt date.  S u bjects w h o 
recei ve s u bse q ue nt ne w l y m p h o ma t hera p y ( wit h t he e xce pti o n of H D T, T BI f or H D T, a n d S C T 
w hile i n a pr ot oc ol t hera p y i n d uce d res p o nse) i n t he a bse nce of d oc u me nte d pr o gressi o n will 
ha ve D O R ce ns ore d at t he last e val ua ble disease assess me nt pri or t o t he c o m me nce me nt of t he 
ne w l y m p h o ma t hera p y.  F or t he pri mar y a nal ysis of D O R, D O R will be ce ns ore d at t he last 
e val ua ble disease assess me nt date pri or t o t he S C T f or s u bjects u n der g o S C T w hile i n pr ot oc ol 
t hera p y i n d uce d res p o nse i n t he a xica bta ge ne cil ole ucel ar m, a n d will be ce ns ore d at t he last 
e val ua ble disease assess me nt date i ncl u di n g assess me nts after S C T f or s u bjects i n t he S O C ar m. 
I nci de nce of a d verse e ve nts a n d cli nical si g nifica nt c ha n ges i n safet y la b val ues, i ncl u di n g 
a nti b o dies t o a xica bta ge ne cil ole ucel. 
C ha n ges i n E O R T C Q L Q- C [ADDRESS_1175275] or at or y 
F or a xica bta ge ne cil ole ucel treat me nt ar m o nl y: 
•Le vels of a nti- C D 1 9 C A R T cells i n bl o o d 
•Le vels of h o me ostatic (I L- 2, I L- 1 5), pr o-i nfla m mat or y (I L- 6, I L- 1 7, T N F α, I L 2 R α, I L 1 Ra) 
a n d i m m u ne m o d ulati n g c yt o ki nes (I F N-γ, I L 1 0), a n d c he m o ki nes ( MI P 1 α, MI P 1 β, I L- 8) i n 
ser u m. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 7 7 1 4 A pril 2 0 2 3  F or b ot h treat me nt ar ms: 
•T u m or m olec ular a n d hist ol o gical c haracteristics b y le vel of P D- L 1 a n d m olec ular a n d 
c yt o ge netic s u bclassificati o ns. 
•C ha n ges i n t he W P AI fr o m scree ni n g t o p ost baseli ne. 
•Ti me t o ne xt t hera p y is defi ne d as t he ti me fr o m t he ra n d o mizati o n date t o t he start of t he 
s u bse q ue nt ne w l y m p h o ma t hera p y or deat h fr o m a n y ca use. S u bjects w h o ha ve n ot recei ve d 
s u bse q ue nt ne w t hera p y a n d are still ali ve will be ce ns ore d at t he last c o ntact date. 
1 0. 2. 5.  A n al ysis S u bsets 
T he pri mar y a nal ysis of all efficac y e n d p oi nts, u nless n ote d ot her wise, will be c o n d ucte d o n t he 
f ull a nal ysis set ( F A S), defi ne d as all ra n d o mize d s u bjects.  S u bjects will be a nal yze d acc or di n g 
t o t he treat me nt first ra n d o mize d re gar dless of treat me nt recei ve d. 
T he safet y a nal ysis set is defi ne d as t he s u bset of all ra n d o mize d s u bjects w h o recei ve at least 
o ne d ose of a xica bta ge ne cil ole ucel as pr ot oc ol t hera p y or S O C c he m ot hera p y as pr ot oc ol 
t hera p y.  S u bjects will be a nal yze d b y t he pr ot oc ol t hera p y recei ve d. 
T he safet y a nal ysis set – A S C T is defi ne d as t he s u bset s u bjects ra n d o mize d t o t he S O C ar m w h o 
u n der g o tra ns pla nt as part of pr ot oc ol t hera p y. 
T he pri mar y a nal ysis of H R Q o L will be perf or me d o n t he s u bset of s u bjects i n t he F A S w h o 
ha ve a baseli ne a n d at Da y [ADDRESS_1175276]-ra n d o mizati o n assess me nt. 
1 0. 2. 6.  C o v ari ates 
T he f oll o wi n g baseli ne c o variates ma y be use d t o e xa mi ne efficac y a n d/ or safet y i n s u b gr o u ps or 
c o variate a nal yses: 
•Ge o gra p hic re gi o n ( N ort h A merica, E ur o pe) 
•E C O G perf or ma nce stat us at scree ni n g ( 0, 1) 
•A ge at ra n d o mizati o n ( ≥ 6 5, < 6 5) 
•Se x 
•Race/et h nicit y 
•Res p o nse t o first-li ne t hera p y ( pri mar y refract or y, rela pse ≤ [ADDRESS_1175277] li ne t hera p y vs 
rela pse > 6 a n d ≤ [ADDRESS_1175278]-li ne t hera p y) 
•A ge-a dj uste d I PI ( 0 t o 1 vs 2 t o 3) at ti me of scree ni n g 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 7 8 1 4 A pril 2 0 2 3  •Disease t y pe ( D L B C L, T F L) 
•M olec ular s u b gr o u p ( ger mi nal ce nter B-cell li ke [ G B C], acti vate d B-cell li ke [ A B C]) 
•D o u ble hit ( C- M Y C alterati o ns a n d eit her B C L- 2 or B C L- 6 alterati o ns) stat us b y FI S H 
•Tri ple hit ( B C L- 2, B C L- 6, a n d C- M Y C alterati o ns) stat us b y FI S H 
F or t he pri mar y a nal ysis of efficac y, t he I X R S val ues of res p o nse t o first-li ne t hera p y a n d a ge- 
a dj uste d I PI [INVESTIGATOR_845637] d.  Se nsiti vit y a nal yses ma y be c o n d ucte d wit h val ues c ollecte d i n E D C.  
C o variate le vels t hat are s parse (ie, less t ha n 3 0 e ve nts f or ti me t o e ve nt a nal yses or s u bjects f or 
O R R a nal yses) ma y be c olla pse d f or p ur p oses of statistical m o deli n g.  If t his occ urs, t he strata 
f or rela pse ≤ [ADDRESS_1175279]. 
1 0. 3. S a m ple Size C o nsi der ati o ns 
A n E F S hazar d rati o (test/c o ntr ol ar m) of 0. 6 7 is h y p ot hesize d i n t he F A S set.  Ass u mi n g a n 
e x p o ne ntial distri b uti o n f or E F S a n d a me dia n E F S of 4 m o nt hs i n t he S O C ar m, t his i m plies a 
5 0 % relati ve i m pr o ve me nt i n E F S a n d c orres p o n ds t o me dia n E F S of 4 vers us 6 m o nt hs (c o ntr ol 
vs test ar m).  T he pri mar y a nal ysis is pla n ne d w he n 2 5 0 E F S e ve nts ha ve bee n o bser ve d; t he 
st u d y has bee n size d t o ac hie ve a p pr o xi matel y 9 0 % p o wer at t he 1-si de d 2. 5 % si g nifica nce le vel 
t o detect a 5 0 % i m pr o ve me nt i n E F S.  T he mi ni m u m effect size t hat ca n be deter mi ne d t o be 
statisticall y si g nifica nt is a n E F S hazar d rati o of 0. 7 9, or a 2 7 % relati ve i m pr o ve me nt i n E F S.  
F urt her, ass u mi n g a c o nca ve accr ual distri b uti o n wit h 5 0 % of accr ual i n t he last 3 3 % of t he 
accr ual peri o d of 2 4 m o nt hs a n d a 1 0 % rate ( 5 % b y m o nt h 1 a n d c u m ulati ve 1 0 % b y m o nt h 8) of 
l oss t o f oll o w- u p i n t he a xica bta ge ne cil ole ucel ar m a n d 1 5 % rate ( 1 0 % b y m o nt h 1 a n d 
c u m ulati ve 1 5 % b y m o nt h 8) of l oss t o f oll o w- u p i n t he S O C ar m, it is a ntici pate d t hat t he e ve nt 
g oal will be ac hie ve d if 3 5 0 s u bjects are ra n d o mize d ( 1 7 5/ar m) a n d will occ ur a p pr o xi matel y 
[ADDRESS_1175280] u d y will ha ve a n o verall al p ha of 2. 5 % wit h 1-si de d testi n g.  T o preser ve t he o verall 
si g nifica nce le vel, statistical testi n g of t he pri mar y a n d ke y sec o n dar y efficac y e n d p oi nts will 
f oll o w a hierarc hical sc he me.  E F S will be teste d first at t he pri mar y E F S a nal ysis.  C o n diti o nal 
o n a statisticall y si g nifica nt i m pr o ve me nt i n E F S, O R R will be teste d at t he 2. 5 % le vel at t he 
ti me of t he pri mar y E F S a nal ysis.  C o n diti o nal o n a statisticall y si g nifica nt i m pr o ve me nt i n E F S 
a n d O R R, O S will be teste d u p t o 3 ti mes at a n o verall 1-si de d al p ha le vel of 2. 5 %. 
F or t he a nal ysis of O R R, res p o nse rates of 3 6 % a n d 7 8 % i n t he c o ntr ol a n d test ar ms are 
ass u me d.  O R R will be teste d wit h a stratifie d (ra n d o mizati o n fact ors) C oc hra n- Ma ntel- Hae nszel 
test at t he 2. 5 % le vel a m o n g s u bjects wit h meas ura ble disease at baseli ne. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 7 9 1 4 A pril 2 0 2 3  A n O S hazar d rati o of 0. 7 3 is h y p ot hesize d i n t he F A S set.  Ass u mi n g a n e x p o ne ntial distri b uti o n 
f or O S a n d a me dia n O S of 1 5. 8 m o nt hs i n t he c o ntr ol ar m, t his i m plies a 3 7 % relati ve 
i m pr o ve me nt i n O S a n d c orres p o n ds t o me dia n O S of [ADDRESS_1175281] is ra n d o mize d .
Stratifie d (ra n d o mizati o n fact ors) l o g-ra n k tests will be use d t o test t he n ull h y p ot hesis of n o 
differe nce i n E F S a n d O S usi n g a n o verall 1-si de d al p ha le vel of 2. 5 %.  A stratifie d 
(ra n d o mizati o n fact ors) C oc hra n- Ma ntel- Hae nszel test will be use d t o test O R R at a n o verall 
1-si de d al p ha le vel of 2. 5 %. 
T he E F S a nal yses are e ve nt- dri ve n a n d will occ ur w he n t he re q uire d n u m ber of e ve nts ha ve bee n 
o bser ve d. 
T he st u d y testi n g sc he me is pr o vi de d i n Fi g ure [ADDRESS_1175282] u d y Testi n g Sc he me 
E nr oll me nt o ver 2 4 m o nt hs 
E F S f utilit y 
a n al ysis 
( 1 3 5 
e v e nts) 
D S M B 1 9 m os 2 4 
E F S pri m ar y 
a n al ysis 2 5 0  
e v e nts) 
Al p h a = 2. 5 % 3 1 m os 
O R R pri m ar y 
a n al ysis 
Al p h a = 2. 5 % 
O S i nt eri m a n al ysis 
1
R h o  F a mil y 
Al p h a = 0. 1 % al p h a 
all oc ati o n O S pri m ar y a n al ysis 
~2 1 0 e v e nts) 
Al p h a = 2 % 6 0 m os D S M B s afet y re vie ws Q 6 m o nt hs u ntil t he pri m ar y E F S a n al ysis 
All testi n g will be perf or me d at t he 1-si de d 2. 5 % le vel. 
Hierarc hi cal testi n g of E F S, f oll o we d b y O R R, f oll o we d b y O S. 
T hree a nal yses of O S are pla n ne d; a first i nteri m a nal ysis at t he ti me of t he pri mar y E F S a nal ysis, a sec o n d i nteri m a nal ysis w he n 
a p pr o xi matel y [ADDRESS_1175283] is ra n d o mize d. 
E F S a nal yses are e ve nt- dri ve n a n d will occ ur w he n t he re q uire d n u m ber of e ve nts ha ve bee n o bser ve d re gar dless of a ntici pati n g ti mi n g. 4 8 m os 
O S i nt eri m 
a n al ysis  2 
R h o F a mil y 
Al p h a = 0. 4 % 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175284] a d diti o nal re vie ws 
b y t he D S M B if safet y c o ncer ns are i de ntifie d.  T he D S M B ma y meet m ore ofte n as nee de d. 
1 0. 5. 2. Effic ac y I nteri m A n al ysis 
O ne i nteri m a nal ysis of E F S a n d 2 i nteri m a nal yses of O S are pla n ne d. 
T he i nteri m E F S a nal ysis is f or f utilit y a n d will occ ur w he n 1 3 5 E F S e ve nts ha ve bee n o bser ve d.  
A n O’ Brie n- Fle mi n g s pe n di n g f u ncti o n of t he La n- De Mets fa mil y will be use d t o all ocate t he 
t y pe II err or bet wee n t he i nteri m a n d pri mar y a nal yses.  T he f utilit y st o p pi n g r ule is n o n- bi n di n g.  
U n der t he n ull h y p ot hesis, t he pr o ba bilit y of st o p pi n g f or f utilit y at t his i nteri m a nal ysis is 
a p pr o xi matel y 6 0 %.  O ne h u n dre d t hirt y-fi ve ( 1 3 5) E F S e ve nts are a ntici pate d t o occ ur 
a p pr o xi matel y [ADDRESS_1175285] is ra n d o mize d.  A s pe n di n g f u ncti o n of t he R h o fa mil y wit h para meter (r h o = 6) will be 
use d t o all ocate t he al p ha bet wee n t he 2 i nteri m a nal ysis of O S a n d t he pri mar y a nal ysis of O S 
wit h 0. 1 % a n d 0. 4 % at t he i nteri m O S a nal yses 1 a n d 2 res pecti vel y, a n d 2 % at t he pri mar y 
a nal ysis of O S.  A p pr o xi matel y [ADDRESS_1175286] a n ne d Met h o d of A n al ysis 
T he a nal ysis o bjecti ves a n d ti mi n g of a nal yses are descri be d i n Secti o n 1 0. 1 , Secti o n 1 0. 2 , a n d 
Secti o n 1 0. 3 .  Pri or t o t he pri mar y efficac y a nal ysis, m o deli n g a n d m o nit ori n g of c u m ulati ve 
E F S e ve nts will be perf or me d t o deter mi ne a data c ut off date t o ac hie ve t he pla n ne d a nal ysis 
tar get e ve nt g oal. 
T he pri mar y a nal ysis of E F S will be c o n d ucte d w he n all ra n d o mize d s u bjects ha ve ha d t he 
o p p ort u nit y t o be f oll o we d t o t he M o nt h 9  disease assess me nt a n d 2 5 0 E F S e ve nts as deter mi ne d 
b y bli n de d ce ntral re vie w ha ve bee n o bser ve d. If m ore t ha n 2 5 0 E F S e ve nts are o bser ve d at t he 
ti me of t he data c ut off f or t he pri mar y a nal ysis, all o bser ve d e ve nts will be use d i n t he a nal ysis. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175287] u d y Re p ort ( C S R) will be writte n at t he ti me of t he pri mar y E F S a nal ysis a n d will 
i ncl u de res ults of t he first i nteri m a nal ysis of O S. Res ults of t he sec o n d i nteri m a nal ysis a n d t he 
pri mar y a nal ysis of O S will be writte n s h ortl y after eac h a nal ysis is c o m plete d, or n o later t ha n 
[ADDRESS_1175288] is ra n d o mize d. 
1 0. 6. 1. E ve nt-free S ur vi v al 
T he a nal ysis of E F S will be c o n d ucte d o n t he F A S.  A stratifie d (ra n d o mizati o n stratificati o n 
fact ors) l o g-ra n k test will be use d f or t he pri mar y c o m paris o n of E F S.  A d diti o nall y, stratifie d 
(ra n d o mizati o n fact or) C o x re gressi o n m o dels will be use d t o pr o vi de t he esti mate d E F S hazar d 
rati o a n d 2-si de d 9 5 % c o nfi de nce i nter vals f or a xica bta ge ne cil ole ucel relati ve t o S O C.  T he 
me dia n E F S ti me a n d e ve nt-free rates at 3- m o nt h i nter vals will be pr o vi de d.  T he stratificati o n 
fact ors as c ollecte d i n t he ra n d o mizati o n s yste m at t he ti me of t he s u bjects’ ra n d o mizati o n will 
be use d f or stratifie d a nal yses (l o g-ra n k test a n d C o x re gressi o n m o dels). Se nsiti vit y a nal yses 
will be perf or me d usi n g t he act ual stratificati o n fact or val ues, i n w hic h t he strata f or rela pse 
≤ [ADDRESS_1175289]-li ne t hera p y. 
E F S hazar d rati os will be assesse d i n s u b gr o u ps defi ne d b y c o variates i n Secti o n 1 0. 2. 6 .
Se nsiti vit y a nal yses of E F S will be perf or me d t o assess ascertai n me nt ti me bias i n disease 
pr o gressi o n as f oll o ws: 
•Pr o gressi o n e ve nts t hat occ ur i n bet wee n sc he d ule d assess me nts will be m o ve d f or war d t o 
t he ne xt sc he d ule d assess me nt after t he o bser ve d pr o gressi o n 
•Pr o gressi o n e ve nts t hat occ ur i n bet wee n sc he d ule d assess me nts will be m o ve d bac k war d t o 
t he last sc he d ule d assess me nt pri or t o t he pr o gressi o n 
•E F S e ve nts t hat occ ur after m ore t ha n o ne misse d visit will be ce ns ore d at t he last e val ua ble 
disease assess me nt or visit pri or t o t he o bser ve d pr o gressi o n 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 8 2 1 4 A pril 2 0 2 3  •A d diti o nall y, a se nsiti vit y a nal ysis f or E F S will be perf or me d as f oll o ws: 
•A se nsiti vit y a nal ysis i n w hic h s u bjects i n t he a xica bta ge ne cil ole ucel ar m w h o u n der g o S C T 
w hile i n a n a xica bta ge ne cil ole ucel i n d uce d res p o nse are c o nsi dere d t o ha ve a n E F S e ve nt o n 
t he date of S C T, wit h E F S ti me defi ne d as ti me fr o m ra n d o mizati o n t o t he date of S C T. 
E F S base d o n i n vesti gat or disease assess me nts will be a nal yze d wit h t he sa me met h o ds as E F S.  
T he c o nc or da nce of pr o gressi o n e ve nts a n d E F S ti me per t he i n vesti gat or a n d per bli n de d ce ntral 
re vie w will be s u m marize d. 
[ADDRESS_1175290] bi n o mial 2-si de d 9 5 % c o nfi de nce i nter val will 
be ge nerate d f or t he o bjecti ve res p o nse rate a n d best res p o nse rates f or eac h treat me nt ar m.  
Wils o n’s sc ore met h o d wit h c o nti n uit y c orrecti o n will be use d t o calc ulate 9 5 % c o nfi de nce 
i nter vals f or t he differe nce i n o bjecti ve res p o nse rates bet wee n treat me nt ar ms { Ne wc o m be 
1 9 9 8 }. 
C o n diti o nal u p o n de m o nstrati n g a statisticall y si g nifica nt i m pr o ve me nt i n E F S, testi n g of O R R 
will be perf or me d wit h a stratifie d (ra n d o mizati o n fact or) C oc hra n- Ma ntel- Hae nszel test f or t he 
c o m m o n o d ds rati o of res p o nse. 
O d ds rati os f or O R R will be assesse d i n s u b gr o u ps defi ne d b y c o variates i n Secti o n 1 0. 2. 6 .
1 0. 6. 3.  O S 
T he a nal ysis of O S will be c o n d ucte d o n t he F A S.  A stratifie d (ra n d o mizati o n stratificati o n 
fact ors) l o g-ra n k test will be use d f or t he pri mar y c o m paris o n of O S.  A d diti o nall y, stratifie d 
(ra n d o mizati o n fact or) C o x re gressi o n m o dels will be use d t o pr o vi de t he esti mate d O S hazar d 
rati o a n d 2-si de d 9 5 % c o nfi de nce i nter vals f or a xica bta ge ne cil ole ucel relati ve t o S O C.  T he 
me dia n O S ti me a n d e ve nt-free rates at 6- m o nt hl y i nter vals will be pr o vi de d.   T he stratificati o n 
fact ors as c ollecte d i n t he ra n d o mizati o n s yste m at t he ti me of t he s u bjects’ ra n d o mizati o n will 
be use d f or stratifie d a nal yses (l o g-ra n k test a n d C o x re gressi o n m o dels). Se nsiti vit y a nal yses 
will be perf or me d usi n g t he act ual stratificati o n fact or val ues, i n w hic h t he strata f or rela pse 
≤ [ADDRESS_1175291] me nt met h o ds. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175292] u d y treat me nt 
(a xica bta ge ne cil ole ucel i nf usi o n or S O C), e xcl u di n g bri d gi n g t hera p y.  S u bject i nci de nce rates 
of T E A Es, i ncl u di n g all, seri o us, fatal, C T C A E Gra de 3 or hi g her, a n d treat me nt relate d A Es 
re p orte d will be ta b ulate d b y preferre d ter m a n d s yste m or ga n class c o de d wit h t he Me dical 
Dicti o nar y f or Re g ulat or y Acti vities ( Me d D R A).  C ha n ges i n la b orat or y val ues a n d vital si g ns 
will be s u m marize d wit h descri pti ve statistics.  T he i nci de nce of c o nc o mita nt me dicati o ns will be 
s u m marize d. 
Ta bles a n d/ or narrati ves of deat hs t hr o u g h t he l o n g-ter m f oll o w- u p a n d treat me nt relate d S A Es 
will be pr o vi de d. 
T he i nci de nce, pre vale nce, d urati o n, a n d re versi bilit y of c yt o pe nias will be s u m marize d. 
[ADDRESS_1175293]-ra n d o mizati o n visit will be s u m marize d wit h descri pti ve 
statistics. T he W P AI will be sc ore d per t he i nstr u me nt de vel o p me nt al g orit h m 
(htt p:// w w w.reill yass ociates. net/ W P AI _ Sc ori n g. ht ml).  C ha n ges i n t he W P AI sc ore fr o m 
scree ni n g t o M o nt h [ADDRESS_1175294]-ra n d o mizati o n visit will be s u m marize d wit h descri pti ve statistics.  
I n a d diti o n, t he mea n/ me dia n c ha n ges i n E O R T C Q L Q- C [ADDRESS_1175295] will be s u m marize d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175296] o ne d ose of a xica bta ge ne cil ole ucel as pr ot oc ol t hera p y will be 
f oll o we d f or s ur vi val f or u p t o a p pr o xi matel y 1 5 years after ra n d o mizati o n; L T F U assess me nt 
will be perf or me d o n s u bjects after tra nsiti o n t o t he L T F U st u d y (refer t o Secti o n 3. 5. 2  a n d 
Secti o n 3. 5. 3 ). N o f or mal h y p ot hesis testi n g will be perf or me d base d o n data o btai ne d after t he 
pri mar y a nal ysis of O S.  Descri pti ve esti mates of ke y efficac y a n d safet y a nal yses ma y be 
u p date d t o assess t he o verall treat me nt pr ofile. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175297] u d y will be c o n d ucte d i n acc or da nce wit h t he pr ot oc ol a n d wit h t he f oll o wi n g: 
•C o nse ns us et hical pri nci ples deri ve d fr o m i nter nati o nal g ui deli nes i ncl u di n g t he Declarati o n 
of Helsi n ki 
•A p plica ble I nter nati o nal C o nfere nce o n Har m o nisati o n (I C H) G o o d Cli nical Practice ( G C P) 
G ui deli nes 
•A p plica ble la ws a n d re g ulati o ns 
1 1. 1. I n de pe n de nt Re vie w B o ar d/I n de pe n de nt Et hics C o m mittee 
A c o p y of t he pr ot oc ol, I C F, a n d a n y a d diti o nal s u bject or trial i nf or mati o n s uc h as s u bject 
recr uit me nt materials m ust be s u b mitte d t o eac h site’s res pecti ve I R B/I E C f or a p pr o val.  After 
a p pr o val is o btai ne d fr o m t he I R B/I E C, all d oc u me nts m ust be pr o vi de d t o t he ke y s p o ns or 
c o ntact bef ore s u bject recr uit me nt ca n be gi n. 
T he i n vesti gat or m ust als o recei ve I R B/I E C a p pr o val f or all pr ot oc ol a n d I C F c ha n ges or 
a me n d me nts. I n vesti gat ors m ust e ns ure t hat o n g oi n g/c o nti n u o us I R B/I E C a p pr o val (ie, a n n ual 
a p pr o val) is pr o vi de d t hr o u g h o ut t he c o n d uct of t he st u d y  acc or di n g t o a p plica ble la w.  C o pi[INVESTIGATOR_1309] 
I R B/I E C a p pr o val are t o be f or war de d t o t he ke y s p o ns or c o ntact f or arc hi vi n g. 
D uri n g t he c o urse of t he st u d y, i n vesti gat ors are t o s u b mit site-s pecific a n d st u d y seri o us a d verse 
e ve nts ( pr o vi de d t o t he site b y t he ke y s p o ns or c o ntact) al o n g wit h a n y pr ot oc ol de viati o ns t o 
t heir I R B/I E C i n acc or da nce wit h t heir res pecti ve I R B/I E C p olicies. 
[ADDRESS_1175298].  
T he f oll o wi n g r ules are t o be a p plie d. 
•S u bjects will be i de ntifie d b y a u ni q ue i de ntificati o n n u m ber. 
•Year of birt h/a ge at ti me of e nr oll me nt will be re p orte d acc or di n g wit h l ocal la ws a n d 
re g ulati o ns. 
F or re p orti n g of seri o us a d verse e ve nts, s u bjects will be i de ntifie d b y t heir res pecti ve s u bject 
i de ntificati o n n u m ber, i nitials, a n d year of birt h (as per t heir l ocal re p orti n g re q uire me nts f or 
b ot h i nitials a n d year of birt h). 
Per c o u ntr y-s pecific re g ulati o ns a n d I C H/ G C P g ui deli nes, i n vesti gat ors a n d i nstit uti o ns are 
re q uire d t o per mit a ut h orizati o n t o t he s p o ns or, C o ntract Researc h Or ga nizati o n ( C R O), 
I R B/I E C, a n d re g ulat or y a ge ncies t o s u bject’s ori gi nal s o urce d oc u me nts f or verificati o n of st u d y 
data.  T he i n vesti gat or is res p o nsi ble f or i nf or mi n g p ote ntial s u bjects t hat s uc h i n di vi d uals will 
ha ve access t o t heir me dical rec or ds w hic h i ncl u des pers o nal i nf or mati o n. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175299] u d y re p ort will be si g ne d b y t he c o or di nati n g i n vesti gat or.  T he c o or di nati n g 
i n vesti gat or will be i de ntifie d b y Kite P har ma u n der t he f oll o wi n g criteria: 
•A rec o g nize d e x pert i n t he disease setti n g 
•Pr o vi de d si g nifica nt c o ntri b uti o ns t o t he desi g n or a nal ysis of st u d y data 
•Partici pate i n t he st u d y a n d e nr olle d a hi g h n u m ber of eli gi ble s u bjects 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 8 7 1 4 A pril 2 0 2 3  1 2. P R O T O C O L A M E N D M E N T S A N D T E R MI N A TI O N 
If t he pr ot oc ol is a me n de d, t he S p o ns or a n d I n vesti gat or Si g nat ure Pa ge wit h t he a me n d me nt a n d 
t he I R B/I E C a p pr o val of t he a me n d me nt m ust be o btai ne d.  D oc u me ntati o n ac k n o wle d gi n g 
a p pr o val fr o m b ot h parties are t o be s u b mitte d t o t he ke y s p o ns or c o ntact. 
B ot h Kite P har ma a n d t he i n vesti gat or reser ve t he ri g ht t o ter mi nate t he i n vesti gat or’s 
partici pati o n i n t he st u d y as per t he ter ms of t he a gree me nt i n t he st u d y c o ntract.  T he 
i n vesti gat or is t o pr o vi de writte n c o m m u nicati o n t o t he I R B/I E C of t he trial c o m pleti o n or earl y 
ter mi nati o n a n d pr o vi de t he C R O wit h a c o p y of t he c orres p o n de nce. 
Kite P har ma reser ves t he u nilateral ri g ht, at its s ole discreti o n, t o deter mi ne w het her t o 
ma n ufact ure a xica bta ge ne cil ole ucel a n d pr o vi de it t o sites a n d s u bjects after t he c o m pleti o n of 
t he st u d y a n d bef ore treat me nt bec o mes c o m merciall y a vaila ble. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175300] u d y data are 
c ollecte d a n d verifie d.  E xa m ples of s uc h s o urce d oc u me nts ma y i ncl u de, b ut are n ot li mite d t o, 
h os pi[INVESTIGATOR_21036] a n d patie nt c harts; la b orat or y, p har mac y, ra di ol o g y a n d rec or ds; s u bject diaries; 
micr ofic hes; c orres p o n de nce; a n d deat h re gistries.  C R F e ntries ma y be c o nsi dere d as s o urce data 
if t he site of t he ori gi nal data c ollecti o n is n ot a vaila ble.  H o we ver, use of t he C R Fs as s o urce 
d oc u me ntati o n as a r o uti ne practice is n ot rec o m me n de d. 
T he i n vesti gat or a n d st u d y staff are res p o nsi ble f or mai ntai ni n g a c o m pre he nsi ve a n d ce ntralize d 
fili n g s yste m of all s u bject rec or ds t hat are rea dil y retrie ve d t o be m o nit ore d a n d or a u dite d at 
a n y ti me b y t he ke y s p o ns or c o ntact, re g ulat or y a ut h orities a n d I R B/I E Cs.  T he fili n g s yste m will 
i ncl u de at mi ni m u m: 
•S u bject c o nte nt i ncl u di n g I C Fs a n d s u bject i de ntificati o n lists 
•Esse ntial d oc u me nts f or t he c o n d uct of t his cli nical st u d y ( pr ot oc ols a n d pr ot oc ol 
a me n d me nts, I B, c o pi[INVESTIGATOR_10468]-st u d y d oc u me ntati o n, a n d all I R B/I E C a n d s p o ns or 
c o m m u nicati o n) 
•Pr o of of recei pt, e x peri me ntal treat me nt fl o w rec or ds, a n d e x peri me ntal pr o d uct-relate d 
c orres p o n de nce 
Ori gi nal s o urce d oc u me nts s u p p orti n g e ntries i nt o C R Fs m ust be mai ntai ne d at t he site a n d 
rea dil y a vaila ble u p o n re q uest.  N o st u d y d oc u me nts s h o ul d be discar de d wit h o ut pri or writte n 
a gree me nt bet wee n Kite P har ma a n d t he i n vesti gat or.  If st ora ge is n o l o n ger a vaila ble t o arc hi ve 
s o urce d oc u me nts or m ust be m o ve d t o a n alter nati ve l ocati o n, t he researc h staff s h o ul d n otif y 
t he ke y s p o ns or c o ntact pri or t o s hi p pi n g t he d oc u me nts. 
Tracea bilit y rec or ds f or t he pr o d uct, fr o m pr oc ure me nt t hr o u g h ma n ufact ure t o a d mi nistrati o n of 
t he pr o d uct, s h o ul d be ke pt b y eac h rele va nt part y (e g, t he s p o ns or a n d i n vesti gat or/i nstit uti o n) 
f or a mi ni m u m of [ADDRESS_1175301]. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175302]’s st u d y rec or ds t o a n ot her part y or m o vi n g t he m t o a n ot her l ocati o n. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175303] rec or ds as i de ntifie d i n Secti o n 1 3 .
B y si g ni n g t he i n vesti gat or a gree me nt, t he i n vesti gat or a grees t o c o o perate wit h t he m o nit or t o 
a d dress a n d res ol ve iss ues i de ntifie d d uri n g m o nit ori n g visits. 
I n acc or da nce wit h I C H/ G C P, a n d t he a u dit pla n, a site ma y be c h ose n f or a site a u dit.  A site 
a u dit w o ul d i ncl u de, b ut is n ot li mite d t o, a n i ns pecti o n of t he facilit y(ies), re vie w of s u bject- a n d 
st u d y-relate d rec or ds, f or c o m plia nce wit h pr ot oc ol re q uire me nts as well as I C H/ G C P, a n d 
a p plica ble l ocal re g ulati o ns. 
All data will be c ollecte d i n a n e C R F s yste m.  All e ntries m ust be c o m plete d i n E n glis h, a n d 
c o nc o mita nt me dicati o ns s h o ul d be i de ntifie d b y tra de na mes.  F or a d diti o nal details a b o ut 
c o m pleti n g C R Fs, please refer t o t he C R F c o m pleti o n g ui deli nes. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 9 1 1 4 A pril 2 0 2 3  1 5. P U B LI C A TI O N 
A ut h ors hi p of p u blicati o ns fr o m data ge nerate d i n Z U M A- 7 will be deter mi ne d base d o n t he 
u nif or m re q uire me nts f or ma n uscri pts s u b mitte d t o bi o me dical j o ur nals (as o utli ne d i n t he 
I nter nati o nal C o m mittee of Me dical J o ur nal E dit ors Dece m ber 2 0 1 3), w hic h states a ut h ors hi p 
s h o ul d be base d o n: 
•S u bsta ntial c o ntri b uti o ns t o t he c o nce pti o n or desi g n of t he w or k, ac q uisiti o n of data, 
a nal ysis, or i nter pretati o n of data f or t he w or k; a n d 
•Drafti n g t he article or re visi n g it criticall y f or i m p orta nt i ntellect ual c o nte nt; a n d 
•Fi nal a p pr o val of t he versi o n t o be p u blis he d; a n d 
•A gree me nt t o be acc o u nta ble f or all as pects of t he w or k i n e ns uri n g t hat q uesti o ns relate d t o 
t he acc urac y or i nte grit y of a n y part of t he w or k are a p pr o priatel y i n vesti gate d or res ol ve d 
W he n a lar ge, m ultice nter gr o u p has c o n d ucte d t he w or k, t he gr o u p s h o ul d i de ntif y t he 
i n di vi d uals w h o acce pt direct res p o nsi bilit y f or t he ma n uscri pt.  T his i n di vi d ual s h o ul d f ull y 
meet t he criteria f or a ut h ors hi p defi ne d a b o ve. 
F u n di n g, c ollecti o n of data, or ge neral s u per visi o n of t he researc h al o ne or i n c o m bi nati o n d oes 
n ot q ualif y a n i n di vi d ual f or a ut h ors hi p. 
A n y p u blicati o n, i n a n y f or m, t hat is deri ve d fr o m t his st u d y m ust be s u b mitte d t o Kite P har ma 
f or re vie w a n d a p pr o val.  T he st u d y c o ntract bet wee n t he i nstit uti o n, pri nci pal i n vesti gati o n, a n d 
Kite P har ma or its dele gate will o utli ne t he re q uire me nts f or p u blicati o n re vie w. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175304] u d y-relate d ill ness or i nj ur y p urs ua nt t o t he 
i nf or mati o n o utli ne d i n t he i nj ur y secti o n of t he I C F. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 9 3 1 4 A pril 2 0 2 3  1 7.  R E F E R E N C E S 
Barri n gt o n S F, Mi k haeel N G, K osta k o gl u L, Mei g na n M, H utc hi n gs M, M ueller S P, et al. R ole 
of i ma gi n g i n t he sta gi n g a n d res p o nse assess me nt of l y m p h o ma: c o nse ns us of t he 
I nter nati o nal C o nfere nce o n Mali g na nt L y m p h o mas I ma gi n g W or ki n g Gr o u p. J 
Cli n O nc ol 2 0 1 4; 3 2 ( 2 7): 3 0 4 8- 5 8. 
Barri n gt o n S F, Qia n W, S o mer EJ, Fra ncesc hett o A, Ba g ni B, Br u n E, et al. C o nc or da nce 
bet wee n f o ur E ur o pea n ce ntres of P E T re p orti n g criteria desi g ne d f or use i n 
m ultice ntre trials i n H o d g ki n l y m p h o ma. E ur J N ucl Me d M ol I ma gi n g 2 0 1 0; 3 7 
( 1 0): 1 8 2 4- 3 3. 
Bla nc V, B o ussea u A, Car o n A, Carrez C, L utz RJ, La m bert J M. S A R 3 4 1 9: A n A nti- C D 1 9- 
Ma yta nsi n oi d I m m u n oc o nj u gate f or t he Treat me nt of B- Cell Mali g na ncies. Cli n 
Ca ncer Res 2 0 1 1; 1 7 ( 2 0): 6 4 4 8- 5 8. 
C ha ga nti S, Illi d ge T, Barri n gt o n S, Mc Ka y P, Li nt o n K, C w y nars ki K, et al. G ui deli nes f or t he 
ma na ge me nt of diff use lar ge B-cell l y m p h o ma. Br J Hae mat ol 2 0 1 6; 1 7 4 ( 1): 4 3- 
5 6. 
C hes o n B D, Fis her RI, Barri n gt o n S F, Ca valli F, Sc h wartz L H, Z ucca E, et al. 
Rec o m me n dati o ns f or i nitial e val uati o n, sta gi n g, a n d res p o nse assess me nt of 
H o d g ki n a n d n o n- H o d g ki n l y m p h o ma: t he L u ga n o classificati o n. J Cli n O nc ol 
2 0 1 4; 3 2 ( 2 7): 3 0 5 9- 6 8. 
Cli nical Trials Facilitati o n a n d C o or di nati o n Gr o u p ( C T F G). Rec o m me n dati o ns relate d t o 
c o ntrace pti o n a n d pre g na nc y testi n g i n cli nical trials. Versi o n 1. 1.  2 1/ 0 9/ [ADDRESS_1175305] u d y c o m pari n g 
rit u xi ma b- C H O P t o sta n dar d C H O P c he m ot hera p y i n D L B C L patie nts: a st u d y b y 
t he Gr o u pe d' Et u des des L y m p h o mes de l' A d ulte. Bl o o d 2 0 1 0; 1 1 6 ( 1 2): [ADDRESS_1175306] ol o g y B-cell n o n- H o d g ki n l y m p h o ma: a P hase II st u d y b y t he Nati o nal Ca ncer 
I nstit ute of Ca na da Cli nical Trials Gr o u p ( N CI C- C T G). Ca ncer 2 0 0 4; 1 0 1 
( 8): [ADDRESS_1175307] or y A g gressi ve L y m p h o mas: 
N CI C- C T G L Y. 1 2. J o ur nal of Cli nical O nc ol o g y 2 0 1 4; 3 2 ( 3 1): 3 4 9 0- 6. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175308] o me a n d ac ute m yel o ge n o us 
le u ke mia f oll o wi n g hi g h- d ose c he m ora di ot hera p y a n d a ut ol o g o us ste m-cell 
tra ns pla ntati o n f or l y m p h oi d mali g na ncies. J Cli n O nc ol 1 9 9 4; 1 2 ( 1 2): 2 5 2 7- 3 4. 
D u dle y M E, Ya n g J C, S herr y R, H u g hes M S, R o yal R, Ka m m ula U, et al. A d o pti ve cell t hera p y 
f or patie nts wit h metastatic mela n o ma: e val uati o n of i nte nsi ve m yel oa blati ve 
c he m ora diati o n pre parati ve re gi me ns. J Cli n O nc ol 2 0 0 8; 2 6 ( 3 2): 5 2 3 3- 9. 
Fall o wfiel d L. Q ualit y- of- Life: t he o bjecti ve meas ure me nt of s u bjecti ve res p o nses t o ca ncer a n d 
its treat me nt. Ca ncer T o pi[INVESTIGATOR_1102] 1 9 8 7; 6: [ADDRESS_1175309] u d y i n t he treat me nt of el derl y patie nts wit h diff use lar ge 
B-cell l y m p h o ma: a st u d y b y t he Gr o u pe d' Et u de des L y m p h o mes de l' A d ulte. J 
Cli n O nc ol 2 0 0 5; 2 3 ( 1 8): 4 1 1 7- 2 6. 
Fl o wers C R, Si n ha R, V ose J M. I m pr o vi n g o utc o mes f or patie nts wit h diff use lar ge B-cell 
l y m p h o ma. C A: A Ca ncer J o ur nal f or Cli nicia ns 2 0 1 0; 6 0 ( 6): [ADDRESS_1175310] or f u ncti o n i n vitr o para d o xicall y i m pairs t he i n vi v o a ntit u m or efficac y 
of a d o pti vel y tra nsferre d C D 8 + T cells. J Cli n I n vest 2 0 0 5; 1 1 5 ( 6): 1 6 1 6- 2 6. 
Gissel brec ht C, Glass B, M o u nier N, Si n g h Gill D, Li nc h D C, Tr ne n y M, et al. Sal va ge re gi me ns 
wit h a ut ol o g o us tra ns pla ntati o n f or rela pse d lar ge B-cell l y m p h o ma i n t he 
rit u xi ma b era. J Cli n O nc ol 2 0 1 0; 2 8 ( 2 7): [ADDRESS_1175311] o v A R, Peters d orf S H, G o ole y T A, Da niels J T, et al. Efficac y a n d 
safet y of ge mcita bi ne, car b o plati n, de xa met has o ne, a n d rit u xi ma b i n patie nts wit h 
rela pse d/refract or y l y m p h o ma: a pr os pecti ve m ulti-ce nter p hase II st u d y b y t he 
P u get S o u n d O nc ol o g y C o ns orti u m. Le u k L y m p h o ma 2 0 1 0; 5 1 ( 8): [ADDRESS_1175312] us c ycl o p h os p ha mi de, d o x or u bici n, 
vi ncristi ne, a n d pre d nis o ne. J Cli n O nc ol 2 0 1 2; 3 0 ( 2 8): 3 4 6 0- 7. 
G u gliel mi C, G o mez F, P hili p T, Ha ge n bee k A, Martelli M, Se b ba n C, et al. Ti me t o rela pse has 
pr o g n ostic val ue i n patie nts wit h a g gressi ve l y m p h o ma e nr olle d o nt o t he Par ma 
trial. J Cli n O nc ol 1 9 9 8; 1 6 ( 1 0): [ADDRESS_1175313] or y diff use lar ge B-cell 
l y m p h o ma. Bl o o d 2 0 0 3; 1 0 2 ( 6): 1 9 8 9- 9 6. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 9 5 1 4 A pril 2 0 2 3  H o wla der N, N o o ne A, Kra pc h o M, Miller D, Bis h o p K, Alte kr use S, et al. S E E R Ca ncer 
Statistics Re vie w, 1 9 7 5- 2 0 1 3. Nati o nal Ca ncer I nstit ute. Bet hes da, M D, 
htt p://seer.ca ncer. g o v/csr/ 1 9 7 5 _ 2 0 1 3/, base d o n N o ve m ber 2 0 1 5 S E E R data 
s u b missi o n, p oste d t o t he S E E R we b site, A pril 2 0 1 6. 2 0 1 5. 
Kle ba n off C A, Gatti n o ni L, T ora bi- Parizi P, Kersta n n K, Car d o nes A R, Fi n kelstei n S E, et al. 
Ce ntral me m or y self/t u m or-reacti ve C D 8 + T cells c o nfer s u peri or a ntit u m or 
i m m u nit y c o m pare d wit h effect or me m or y T cells. Pr oc Natl Aca d Sci U S A 
2 0 0 5; 1 0 2 ( 2 7): 9 5 7 1- 6. 
K oc he n derfer J N, D u dle y M E, Fel d ma n S A, Wils o n W H, S pa ner D E, Maric I, et al. B-cell 
de pleti o n a n d re missi o ns of mali g na nc y al o n g wit h c yt o ki ne-ass ociate d t o xicit y i n 
a cli nical trial of a nti- C D 1 9 c hi meric-a nti ge n-rece pt or-tra ns d uce d T cells. Bl o o d 
2 0 1 2; 1 1 9 ( 1 2): [ADDRESS_1175314] or y Diff use Lar ge B- Cell L y m p h o ma a n d I n d ole nt B- 
Cell Mali g na ncies Ca n Be Effecti vel y Treate d Wit h A ut ol o g o us T Cells 
E x pressi n g a n A nti- C D 1 9 C hi meric A nti ge n Rece pt or. J Cli n O nc ol 2 0 1 5; 3 3 
( 6): 5 4 0- 9. 
K oc he n derfer J N, Fel d ma n S A, Z ha o Y, X u H, Blac k M A, M or ga n R A, et al. C o nstr ucti o n a n d 
Precli nical E val uati o n of a n A nti- C D 1 9 C hi meric A nti ge n Rece pt or. J 
I m m u n ot her 2 0 0 9; 3 2 ( 7): 6 8 9- 7 0 2. 
K oc he n derfer J N, S o mer ville R P T, L u T, S hi V, B ot A, R ossi J, et al. L y m p h o ma re missi o ns 
ca use d b y a nti- C D 1 9 c hi meric a nti ge n rece pt or T cells are ass ociate d wit h hi g h 
ser u m i nterle u ki n- 1 5 le vels. J Cli n O nc ol 2 0 1 7; Mar 1 4: d oi: 
1 0. 1 2 0 0/J C O. 2 0 1 6. 7 1. 3 0 2 4. 
K oc he n derfer J N, Y u Z, Fras heri D, Restif o N P, R ose n ber g S A. A d o pti ve tra nsfer of s y n ge neic 
T cells tra ns d uce d wit h a c hi meric a nti ge n rece pt or t hat rec o g nizes m uri ne C D 1 9 
ca n era dicate l y m p h o ma a n d n or mal B cells. Bl o o d 2 0 1 0; 1 1 6 ( 1 9): 3 8 7 5- 8 6. 
K o w oli k C M, T o p p M S, G o nzalez S, Pfeiffer T, Oli vares S, G o nzalez N, et al. C D 2 8 
c osti m ulati o n pr o vi de d t hr o u g h a C D 1 9-s pecific c hi meric a nti ge n rece pt or 
e n ha nces i n vi v o persiste nce a n d a ntit u m or efficac y of a d o pti vel y tra nsferre d T 
cells. Ca ncer Res 2 0 0 6; 6 6 ( 2 2): 1 0 9 9 5- 1 0 0 4. 
Li g n o n J, Si b o n D, Ma delai ne I, Brice P, Fra nc hi P, Briere J, et al. Rit u xi ma b, De xa met has o ne, 
C ytara bi ne, a n d O xali plati n ( R- D H A X) Is a n Effecti ve a n d Safe Sal va ge Re gi me n 
i n Rela pse d/ Refract or y B- Cell N o n- H o d g ki n L y m p h o ma. Cli nical L y m p h o ma 
M yel o ma a n d Le u ke mia 2 0 1 0; 1 0 ( 4): 2 6 2- 9. 
L oc ke F L, Neela p u S S, Bartlett N L, Si d di qi T, C ha vez J C, H osi n g C M, et al. P hase 1 Res ults of 
Z U M A- 1: A M ultice nter St u d y of K T E- C [ADDRESS_1175315] or y A g gressi ve L y m p h o ma. M ol T her 2 0 1 7; 2 5 ( 1): 2 8 5- 9 5. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 9 6 1 4 A pril 2 0 2 3  Martelli M, Ferreri AJ M, A g osti nelli C, Di R occ o A, Pfre u n dsc h u h M, Pi[INVESTIGATOR_12348] S A. Diff use lar ge 
B-cell l y m p h o ma. Critical Re vie ws i n O nc ol o g y / He mat ol o g y 2 0 1 3; 8 7 ( 2): [ADDRESS_1175316] or y diff use lar ge B-cell l y m p h o ma: t he 
i nfl ue nce of pri or e x p os ure t o rit u xi ma b o n o utc o me. A G E L/ T A M O st u d y. 
Hae mat ol o gica 2 0 0 8; 9 3 ( 1 2): 1 8 2 9- 3 6. 
M ort o n L M, Wa n g S S, De vesa S S, Hart ge P, Weise n b ur ger D D, Li net M S. L y m p h o ma 
i nci de nce patter ns b y W H O s u bt y pe i n t he U nite d States, 1 9 9 2- 2 0 0 1. Bl o o d 
2 0 0 6; 1 0 7 ( 1): 2 6 5- 7 6. 
Ne wc o m be R G. I nter val esti mati o n f or t he differe nce bet wee n i n de pe n de nt pr o p orti o ns: 
c o m paris o n of ele ve n met h o ds. Stat Me d 1 9 9 8; 1 7 ( 8): 8 7 3- 9 0. 
Nic h ols o n I C, Le nt o n K A, Little DJ, Dec ors o T, Lee F T, Sc ott A M, et al. C o nstr ucti o n a n d 
c haracterisati o n of a f u ncti o nal C D 1 9 s pecific si n gle c hai n F v fra g me nt f or 
i m m u n ot hera p y of B li nea ge le u kae mia a n d l y m p h o ma. M ol I m m u n ol 1 9 9 7; 3 4 
( 1 6- 1 7): 1 1 5 7- 6 5. 
O' Brie n S M, Ka ntarjia n H M, C ortes J, Bera n M, K oller C A, Giles FJ, et al. Res ults of t he 
fl u dara bi ne a n d c ycl o p h os p ha mi de c o m bi nati o n re gi me n i n c hr o nic l y m p h oc ytic 
le u ke mia. J Cli n O nc ol 2 0 0 1; 1 9 ( 5): 1 4 1 4- 2 0. 
P hili p T, G u gliel mi C, Ha ge n bee k A, S o mers R, Va n der Lelie H, Br o n D, et al. A ut ol o g o us 
b o ne marr o w tra ns pla ntati o n as c o m pare d wit h sal va ge c he m ot hera p y i n rela pses 
of c he m ot hera p y-se nsiti ve n o n- H o d g ki n's l y m p h o ma. N E n gl J Me d 1 9 9 5; 3 3 3 
( 2 3): 1 5 4 0- 5. 
Se h n L H, Gasc o y ne R D. Diff use lar ge B-cell l y m p h o ma: o pti mizi n g o utc o me i n t he c o nte xt of 
cli nical a n d bi ol o gic heter o ge neit y. Bl o o d 2 0 1 5; 1 2 5 ( 1): [ADDRESS_1175317] o me as a late c o m plicati o n f oll o wi n g a ut ol o g o us b o ne marr o w 
tra ns pla ntati o n f or n o n- H o d g ki n's l y m p h o ma. J Cli n O nc ol 1 9 9 4; 1 2 ( 1 2): 2 5 3 5- 4 2. 
S wer dl o w S H, Ca m p o E, Pi[INVESTIGATOR_12348] S A, Harris N L, Stei n H, Sie bert R, et al. T he 2 0 1 6 re visi o n of t he 
W orl d Healt h Or ga nizati o n classificati o n of l y m p h oi d ne o plas ms. Bl o o d 
2 0 1 6; 1 2 7 ( 2 0): [ADDRESS_1175318] u d y. B o ne Marr o w Tra ns pla nt 2 0 1 6; 5 1 
( 1): 5 1- 7. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175319] or y Diff use Lar ge B- Cell L y m p h o ma: T he O R C H A R R D St u d y. J Cli n 
O nc ol 2 0 1 7; 3 5 ( 5): 5 4 4- 5 1. 
Velle n ga E, va n P utte n W L, va n 't Veer M B, Zijlstra J M, Fi b be W E, va n Oers M H, et al. 
Rit u xi ma b i m pr o ves t he treat me nt res ults of D H A P- VI M- D H A P a n d A S C T i n 
rela pse d/ pr o gressi ve a g gressi ve C D 2 0 + N H L: a pr os pecti ve ra n d o mize d H O V O N 
trial. Bl o o d 2 0 0 8; 1 1 1 ( 2): [ADDRESS_1175320] u d y 
of R- C H O P Vers us D A- E P O C H- R a n d M olec ular A nal ysis of U ntreate d Diff use 
Lar ge B- Cell L y m p h o ma: C A L G B/ Allia nce 5 0 3 0 3. Bl o o d ( A S H A n n ual Meeti n g 
A bstracts) 2 0 1 6: A bstract # 4 6 9 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 9 8 1 4 A pril 2 0 2 3  1 8.  A P P E N DI C E S 
A p pe n di x A. S p o ns or a n d I n vesti gat or Si g nat ure Pa ge 
A p pe n di x B. L u ga n o Classificati o n { C hes o n 2 0 1 4 } 
A p pe n di x C. Patie nt Re p orte d O utc o mes 
A p pe n di x D. C o u ntr y-s pecific Re g ulat or y A ge nc y Re q uire me nts 
A p pe n di x E. C hil d beari n g P ote ntial a n d Birt h C o ntr ol 
A p pe n di x F. Pa n de mic Ris k Assess me nt a n d Miti gati o n Pla n 
A p pe n di x G. Pr ot oc ol A me n d me nt Hist or y 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175321] u d y E val uati n g t he Efficac y of A xica bta ge ne Cil ole ucel 
vers us Sta n dar d of Care T hera p y i n S u bjects wit h Rela pse d/ Refract or y Diff use Lar ge B Cell 
L y m p h o ma ( Z U M A- 7) 
A me n d me nt 6, 1 4 A pril 2 0 2 3 
T his pr ot oc ol has bee n a p pr o ve d b y Kite P har ma, I nc. T he f oll o wi n g si g nat ure d oc u me nts t his 
a p pr o val. 
C hristi na T o [ Refer t o t he a p pe n de d electr o nic si g n at ure] 
Kite Me dical M o nit or Na me ( Pri nte d) Si g nat ure 
[ Refer t o t he a p pe n de d electr o nic si g n at ure] 
Date 
I N V E S TI G A T O R S T A T E M E N T 
I ha ve rea d t he pr ot oc ol, i ncl u di n g all a p pe n dices, a n d I a gree t hat it c o ntai ns all necessar y details 
f or me a n d m y staff t o c o n d uct t his st u d y as descri be d. I will c o n d uct t his st u d y as o utli ne d herei n 
a n d will ma ke a reas o na ble eff ort t o c o m plete t he st u d y wit hi n t he ti me desi g nate d. 
I a gree t o c o m pl y wit h t he I nter nati o nal C o u ncil f or Har m o nisati o n of Tec h nical Re q uire me nts 
f or P har mace uticals f or H u ma n Use (I C H) Har m o nise d Tri partite G ui deli ne o n G o o d Cli nical 
Practice a n d a p plica ble nati o nal or re gi o nal re g ulati o ns a n d g ui deli nes. I will pr o vi de all st u d y 
pers o n nel u n der m y s u per visi o n c o pi[INVESTIGATOR_1309] t he pr ot oc ol a n d access t o all i nf or mati o n pr o vi de d b y 
Kite P har ma, I nc. I will disc uss t his material wit h t he m t o e ns ure t hat t he y are f ull y i nf or me d 
a b o ut t he i n vesti gati o nal pr o d uct a n d st u d y. 
I a gree a n d will e ns ure t hat fi na ncial discl os ure state me nts will be c o m plete d b y: 
•Me (i ncl u di n g, if a p plica ble, m y s p o use, le gal part ner, a n d de pe n de nt c hil dre n) 
•S u bi n vesti gat ors (i ncl u di n g, if a p plica ble, t heir s p o use, le gal part ner, a n d de pe n de nt c hil dre n) 
at t he start of t he st u d y a n d f or u p t o [ADDRESS_1175322] of t he cli nical i n vesti gati o n wit h o ut pri or writte n c o nse nt 
fr o m Kite P har ma, I nc. 
Pri nci pal I n vesti gat or Na me ( Pri nte d) Si g nat ure 
Date St u d y Site N u m ber 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 0 1 4 A pril 2 0 2 3  A p pe n di x B. L u g a n o Cl assific ati o n { C hes o n 2 0 1 4 }
Please refer t o i ma gi n g ma n ual a n d { C hes o n 2 0 1 4 } f or details of assess me nt. 
5- P oi nt Sc ale ( 5 P S) { B arri n gt o n 2 0 1 4 }
Sc ore Descri pti o n 
1 N o u pta ke a b o ve bac k gr o u n d 
2 U pta ke ≤  me diasti n u m 
3 U pta ke > me diasti n u m b ut ≤ li ver 
4 U pta ke m o deratel y hi g her t ha n li ver 
5 U pta ke mar ke dl y hi g her t ha n li ver a n d/ or ne w lesi o ns 
X Ne w areas of u pta ke u nli kel y t o be relate d t o l y m p h o ma.  
C o m plete Re missi o n: 
C o m plete Met a b olic Res p o nse ( C M R) f or P E T- C T- B ase d Res p o nse 
T he desi g nati o n of C M R re q uires all of t he f oll o wi n g: 
•A 5 P S ( 5- p oi nt scale) sc ore of 1, 2, or 3, wit h or wit h o ut a resi d ual mass. 
I n Wal de yer’s ri n g or e xtra n o dal sites wit h hi g h p h ysi ol o gic u pta ke or wit h acti vati o n 
wit hi n s plee n or marr o w, u pta ke ma y be greater t ha n n or mal me diasti n u m a n d/ or li ver. I n 
t his circ u msta nce, C M R ma y be i nferre d if u pta ke at sites of i nitial i n v ol ve me nt is n o 
greater t ha n s urr o u n di n g n or mal tiss ue e ve n if t he tiss ue has hi g h p h ysi ol o gic u pta ke. 
•N o ne w sites of disease s h o ul d be o bser ve d. 
•N o e vi de nce of F D G-a vi d disease i n b o ne marr o w 
C o m plete R a di ol o gic Res p o nse ( C R R) f or C T- B ase d Res p o nse 
T he desi g nati o n of C R R re q uires all of t he f oll o wi n g: 
•Tar get n o des/ n o dal masses m ust re gress t o ≤ 1. [ADDRESS_1175323] tra ns verse dia meter of a lesi o n 
( L Di) 
•N o e xtral y m p hatic sites of disease 
•A bse nt n o n meas ure d lesi o n 
•Or ga n e nlar ge me nt re gress t o n or mal 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 1 1 4 A pril 2 0 2 3  •N o ne w sites of disease s h o ul d be o bser ve d. 
•B o ne marr o w n or mal b y m or p h ol o g y; if i n deter mi nate, I H C ne gati ve 
P arti al Re missi o n: 
P arti al Met a b olic Res p o nse ( P M R) f or P E T- C T B ase d Res p o nse 
T he desi g nati o n of P M R re q uires all of t he f oll o wi n g: 
•A 5 P S sc ore of 4 or 5, wit h re d uce d u pta ke c o m pare d t o baseli ne (scree ni n g), a n d resi d ual 
mass(es) of a n y size. 
N ote: 
At i nteri m, t hese fi n di n gs s u g gest res p o n di n g disease. 
At e n d of treat me nt ( E O T), t hese fi n di n gs s u g gest resi d ual disease. 
•N o ne w sites of disease s h o ul d be o bser ve d. 
•Resi d ual u pta ke hi g her t ha n u pta ke i n n or mal b o ne marr o w b ut re d uce d c o m pare d wit h 
baseli ne ( diff use u pta ke c o m pati ble wit h reacti ve c ha n ges fr o m c he m ot hera p y all o we d). 
If t here are persiste nt f ocal c ha n ges i n t he marr o w i n t he c o nte xt of a n o dal res p o nse, 
c o nsi derati o n s h o ul d be gi ve n t o f urt her e val uati o n wit h M RI or bi o ps y or a n i nter val sca n. 
Partial Ra di ol o gic Res p o nse ( P R R) f or C T- Base d Res p o nse 
T he desi g nati o n of P R R re q uires all of t he f oll o wi n g: 
•≥ 5 0 % decrease i n s u m of t he pr o d uct of t he per pe n dic ular dia meters ( S P D) of u p t o 6 tar get 
meas ura ble n o des a n d e xtra n o dal sites. 
W he n a lesi o n is t o o s mall t o meas ure o n C T, assi g n 5 m m x 5 m m as t he defa ult val ue 
W he n n o l o n ger visi ble, 0 x 0 m m 
F or a n o de  > [ADDRESS_1175324] ual meas ure me nt f or 
calc ulati o n 
•A bse nt/ n or mal, re gresse d, b ut n o i ncrease of n o n meas ure d lesi o ns. 
•S plee n m ust ha ve re gresse d b y > 5 0 % i n le n gt h be y o n d n or mal 
•N o ne w sites of disease s h o ul d be o bser ve d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 2 1 4 A pril 2 0 2 3  S D: 
N o Met a b olic Res p o nse ( N M R) f or P E T- C T B ase d Res p o nse 
T he desi g nati o n of N M R re q uires all of t he f oll o wi n g: 
•A 5 P S sc ore of 4 or 5, wit h n o si g nifica nt c ha n ge i n F D G u pta ke c o m pare d t o baseli ne 
(scree ni n g) at a n i nteri m ti me p oi nt or e n d of treat me nt. 
•N o ne w sites of disease s h o ul d be o bser ve d. 
•N o c ha n ge fr o m baseli ne i n b o ne marr o w 
St a ble R a di ol o gic Dise ase ( S R D) f or C T- B ase d Res p o nse 
T he desi g nati o n of S R D re q uires all of t he f oll o wi n g: 
•< 5 0 % decrease fr o m baseli ne i n t he s u m of t he pr o d uct of t he per pe n dic ular dia meters 
( S P D) of u p t o 6 d o mi na nt, meas ura ble n o des a n d e xtra n o dal sites; n o criteria f or pr o gressi ve 
disease are met 
•N o i ncrease c o nsiste nt wit h pr o gressi o n i n n o n meas ure d lesi o n a n d or ga n e nlar ge me nt 
•N o ne w sites of disease s h o ul d be o bser ve d. 
P D: 
Pr o gressive Met a b olic Dise ase ( P M D) f or P E T- C T B ase d Res p o nse 
T he desi g nati o n of P M D re q uires at least 1 of t he f oll o wi n g: 
•A 5 P S sc ore 4 or 5 wit h a n i ncrease i n i nte nsit y of u pta ke fr o m na dir a n d/ or 
•Ne w F D G-a vi d f oci c o nsiste nt wit h l y m p h o ma at i nteri m or e n d of treat me nt assess me nt 
•Ne w F D G-a vi d f oci c o nsiste nt wit h l y m p h o ma rat her t ha n a n ot her eti ol o g y (e g, i nfecti o n, 
i nfla m mati o n). If u ncertai n re gar di n g eti ol o g y of ne w lesi o ns, bi o ps y or i nter val sca n ma y be 
c o nsi dere d 
•Ne w or rec urre nt F D G-a vi d f oci i n b o ne marr o w. 
Pr o gressive R a di ol o gic Dise ase ( P R D) f or C T- B ase d Res p o nse 
T he desi g nati o n of P R D re q uires at least 1 of t he f oll o wi n g: 
•A n i n di vi d ual n o de/lesi o n m ust be a b n or mal wit h: 
L o n gest tra verse dia meter ( L Di) > 1. 5 c m a n d 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 3 1 4 A pril 2 0 2 3  I ncrease b y ≥ 5 0 % fr o m cr oss pr o d uct of L Di a n d per pe n dic ular dia meter ( P P D) na dir 
a n d 
A n i ncrease i n L Di or S Di, s h ortest a xis per pe n dic ular t o t he L Di, ( S Di) fr o m na dir 
■ 0. 5 c m f or lesi o ns ≤ 2 c m 
■1. 0 c m f or lesi o ns > 2 c m 
I n t he setti n g of s ple n o me gal y, t he s ple nic le n gt h m ust i ncrease b y > 5 0 % of t he e xte nt of 
its pri or i ncrease be y o n d baseli ne (e g, a [ADDRESS_1175325] i ncrease t o > 1 6 c m). If n o 
pri or s ple n o me gal y, m ust i ncrease b y at least 2 c m fr o m baseli ne; 
Ne w or rec urre nt s ple n o me gal y 
•Ne w or clear pr o gressi o n of pree xisti n g n o n meas ure d lesi o ns 
•Ne w lesi o n 
Re gr o wt h of pre vi o usl y res ol ve d lesi o ns 
A ne w n o de > 1. 5 c m i n a n y a xis 
A ne w e xtra n o dal site > 1. 0 c m i n a n y a xis; if < 1. [ADDRESS_1175326] be attri b uta ble t o l y m p h o ma 
Assessa ble disease of a n y size u ne q ui v ocall y attri b uta ble t o l y m p h o ma 
•Ne w or rec urre nt b o ne marr o w i n v ol ve me nt 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 4 1 4 A pril 2 0 2 3  A p pe n di x C. P atie nt Re p orte d O utc o mes 
E O R T C Q L Q C- 3 0 
    
                 
                   
     
     
  
    
  
         
      
         
          
    
     
    
   
  
 
 
  
  
        
           
        
     
         
       
          
     
     
    
     
         
 
  
 
 
 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 5 1 4 A pril 2 0 2 3          
  
     
    
         
 
  
   
 
 
  
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 6 1 4 A pril 2 0 2 3  E Q- 5 D- 5 L 
 
  
     
              
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 7 1 4 A pril 2 0 2 3                
 
         
       
       
       
        
 
        
        
        
         
        
         
  
          
          
        
         
           
   
       
      
      
      
       
   
      
      
      
      
      
 
             
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 8 1 4 A pril 2 0 2 3                 
        
         
        
                 
              
 
  
 
                 
   
  
  
   
  
 
 
  
 
   
  
 
   
 
  
   
  
 
   
   
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 0 9 1 4 A pril 2 0 2 3  W P AI Q uesti o n n aire ( V 2. 0) ( S A M P L E) 
      
    
                
             
               
          
         
            
                
              
                
      
 
                
              
 
             
       
     
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 1 0 1 4 A pril 2 0 2 3                 
       
                
               
              
             
    
        
     
     
   
                 
   
    
                 
             
               
            
               
              
              
    
           
            
    
     
                
    
  
    
     
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175327]-i nf usi o n m o nit ori n g of s u bjects i n t his pr ot oc ol will be e xte n de d b y 
m o nit ori n g o n da y 8, da y 9, a n d da y 1 0, acc or di n g t o pr oce d ures o utli ne d i n 
Ta ble 2 , c ol u m n “I P a d mi nistrati o n peri o d, 1- 7.” T he s u bject ma y sta y 
h os pi[INVESTIGATOR_18552] d or ret ur n t o t he cli nic dail y f or t his e xte n de d m o nit ori n g at t he 
discreti o n of t he i n vesti gat or. 
T he dail y m o nit ori n g will i ncl u de vital si g ns (see Secti o n 7. 6 ), bl o o d dra w 
f or c he mistr y pa nel wit h C R P, bl o o d dra w f or C B C w/ differe ntial (see 
Secti o n 7. 1 1. 1 ), a n d ne ur ol o gical assess me nt ( w hic h ma y i ncl u de M M S E 
[see Secti o n 7. 7 ]). A n y o bser ve d t o xicit y will be e val uate d acc or di n g t o 
Secti o n 7. 9  of t his pr ot oc ol a n d ma na ge d acc or di n g t o t he I B. 
A b bre viati o ns: C B C, c o m plete bl o o d c o u nt; C R P, C-reacti ve pr otei n; I P, i n vesti gati o nal pr o d uct; M M S E, Mi ni- Me ntal Stat us 
E xa mi nati o n. 
Fr a nce 
A b bre viati o ns: A N S M, Nati o nal A ge nc y f or t he Safet y of Me dici nes a n d Healt h Pr o d ucts; C A R, c hi meric a nti ge n rece pt or; 
C B C, c o m plete bl o o d c o u nt; C R P, C-reacti ve pr otei n; I P, i n vesti gati o nal pr o d uct; M M S E, Mi ni- Me ntal Stat us E xa mi nati o n. 
S witzerl a n d 
Pr ot oc ol Secti o n C o u ntr y-s pecific Re q uire me nt 
Secti o n 5. [ADDRESS_1175328] or use d i n t he cr y o preser vati o n of C A R T cells 
a n d fre q ue ntl y f or C D 3 4 + ste m cells, a n d is as f oll o ws: 
Hist or y of se vere i m me diate h y perse nsiti vit y reacti o n t o t ociliz u ma b or a n y 
of t he a ge nts use d i n t his st u d y, i ncl u di n g t he e xci pie nts D M S O a n d De xtra n 
[ADDRESS_1175329] or. 
A b bre viati o ns: C A R, c hi meric a nti ge n rece pt or; D M S O, di met h yl s ulf o xi de. Pr ot oc ol Secti o n C o u ntr y-s pecific Re q uire me nt 
Secti o n 7. [ADDRESS_1175330]-i nf usi o n m o nit ori n g of s u bjects i n t his pr ot oc ol will be e xte n de d b y 
m o nit ori n g o n da y 8, da y 9, a n d da y 1 0, acc or di n g t o pr oce d ures o utli ne d i n 
Ta ble 2 , c ol u m n “I P a d mi nistrati o n peri o d, 1- 7.” T he A N S M rec o m me n ds a 
[ADDRESS_1175331]. 
T he dail y m o nit ori n g will i ncl u de vital si g ns (see Secti o n 7. 6 ), bl o o d dra w 
f or c he mistr y pa nel wit h C R P, bl o o d dra w f or C B C w/ differe ntial (see 
Secti o n 7. 1 1. 1 ), a n d ne ur ol o gical assess me nt ( w hic h ma y i ncl u de M M S E 
[see Secti o n 7. 7 ]). A n y o bser ve d t o xicit y will be e val uate d acc or di n g t o 
Secti o n 7. 9  of t his pr ot oc ol a n d ma na ge d acc or di n g t o t he I B. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 1 2 1 4 A pril 2 0 2 3  S we de n 
Pr ot oc ol Secti o n C o u ntr y-s pecific Re q uire me nt 
N/ A 1. RI S K A N D B E N E FI T A S S E S S M E N T 
Kite P har ma is c o n d ucti n g a gl o bal P hase 3, ra n d o mize d, o pe n-la bel st u d y t o 
e val uate t he efficac y of a xica bta ge ne cil ole ucel vers us sta n dar d of care 
t hera p y i n s u bjects wit h rela pse d/refract or y diff use lar ge B cell l y m p h o ma 
( Pr ot oc ol n u m ber K T E- C 1 9- 1 0 7 [ Z U M A- 7]). 
1. 1. I m p ort a nt I de ntifie d a n d P ote nti al Ris ks rel ate d t o I M P 
T he ris ks of a xica bta ge ne cil ole ucel/ K T E- C 1 9 t hera p y are well descri be d. 
T w o i m p orta nt i de ntifie d ris ks , w hic h are n ot c o m m o nl y e nc o u ntere d i n 
ge neral o nc ol o g y practice, i ncl u de C R S a n d ne ur ol o gic e ve nts. T hese e ve nts 
ha ve a n earl y o nset, ge nerall y wit hi n 1 wee k after t he t hera p y, a n d are m ostl y 
re versi ble ( > 9 5 %). A d diti o nal i m p orta nt i de ntifie d ris ks i ncl u de c yt o pe nias, 
i nfecti o n a n d h y p o ga m ma gl o b uli ne mia. Strate gies ha ve bee n de vel o pe d t o 
m o nit or f or a n d ma na ge t hese A d verse E ve nts ( A Es) a n d are i ncl u de d i n t he 
m ost rece nt versi o n of t he I n vesti gat or Br oc h ure (I B). T he i m p orta nt p ote ntial 
ris ks ass ociate d wit h a xica bta ge ne cil ole ucel/ K T E- C 1 9 are re plicati o n 
c o m pete nt retr o vir us ( R C R), sec o n dar y mali g na nc y, a ut oi m m u ne dis or ders 
reacti vati o n/ ne w o nset, i m m u n o ge nicit y a n d t u m or l ysis s y n dr o me ( T L S). 
1. 2. Miti g ati o n of I M P-rel ate d ris ks 
1. 2. 1. S u bject selecti o n (i ncl usi o n/e xcl usi o n criteri a) 
T he i ncl usi o n a n d e xcl usi o n criteria descri be d i n secti o n [ADDRESS_1175332] u d y. 
I ncl usi o n criteria: 
•[ADDRESS_1175333] or y or s us pi[INVESTIGATOR_37180] o n of ce ntral ner v o us s yste m ( C N S) 
i n v ol ve me nt b y l y m p h o ma 
•1 1 0. A de q uate b o ne marr o w, re nal, he patic, p ul m o nar y a n d car diac 
f u ncti o n defi ne d as: 
oA bs ol ute ne utr o p hil c o u nt ( A N C) ≥ 1 0 0 0/ μ L 
oPlatelet c o u nt ≥ 7 5, 0 0 0/ μ L 
oA bs ol ute l y m p h oc yte c o u nt ≥ 1 0 0/ μ L 
oCar diac ejecti o n fracti o n ≥ 5 0 %, n o e vi de nce of pericar dial eff usi o n 
as deter mi ne d b y a n ec h ocar di o gra m ( E C H O), a n d n o cli nicall y 
si g nifica nt electr ocar di o gra m ( E C G) fi n di n gs 
oBaseli ne o x y ge n sat urati o n > 9 2 % o n r o o m air 
E xcl usi o n criteria: 
•[ADDRESS_1175334] or y of se vere, i m me diate h y perse nsiti vit y reacti o n attri b ute d t o 
a mi n o gl yc osi des 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 1 3 1 4 A pril 2 0 2 3  Pr ot oc ol Secti o n C o u ntr y-s pecific Re q uire me nt 
•2 0 9. Prese nce of f u n gal, bacterial, viral, or ot her i nfecti o n t hat is 
u nc o ntr olle d or re q uiri n g i ntra ve n o us (I V) a nti micr o bials f or 
ma na ge me nt. Si m ple uri nar y tract i nfecti o n ( U TI) a n d u nc o m plicate d 
bacterial p har y n gitis are per mitte d if res p o n di n g t o acti ve treat me nt. 
•[ADDRESS_1175335] or y of cere br os pi [INVESTIGATOR_55498] d 
mali g na nt cells or brai n metastases 
•[ADDRESS_1175336] or y or prese nce of n o n- mali g na nt C N S dis or der s uc h as seiz ure 
dis or der, cere br o vasc ular isc he mia/ he m orr ha ge, de me ntia, cere bellar 
disease, or a n y a ut oi m m u ne disease wit h C N S i n v ol ve me nt 
•[ADDRESS_1175337] or y of a ut oi m m u ne disease, re q uiri n g s yste mic 
i m m u n os u p pressi o n a n d/ or s yste mic disease m o dif yi n g a ge nts wit hi n t he 
last [ADDRESS_1175338] 
7 da ys t o m o nit or f or si g ns a n d s y m pt o ms of C R S a n d ne ur ol o gic e ve nts. 
Alter nati vel y, s u bjects ma y be h os pi[INVESTIGATOR_18552] d t o recei ve t heir a xica bta ge ne 
cil ole ucel i nf usi o n a n d be o bser ve d f or C R S a n d ne ur ol o gic e ve nts i n t he 
h os pi[INVESTIGATOR_845632] n g, if dee me d a p pr o priate b y t he i n vesti gat or. 
If s u bjects are h os pi[INVESTIGATOR_18552] d, s u bjects s h o ul d n ot be disc har ge d fr o m t he 
h os pi[INVESTIGATOR_307] u ntil all a xica bta ge ne cil ole ucel relate d n o n- he mat ol o gical t o xicities 
res ol ve t o ≤ Gra de 1 or ret ur n t o baseli ne. S u bjects ma y be disc har ge d wit h 
n o n-critical a n d cli nicall y sta ble or i m pr o vi n g t o xicities (e g re nal 
i ns ufficie nc y) e ve n if > Gra de 1, if dee me d a p pr o priate b y t he i n vesti gat or. 
S u bjects s h o ul d re mai n i n a h os pi[INVESTIGATOR_307] f or o n g oi n g a xica bta ge ne cil ole ucel 
relate d fe ver, h y p ote nsi o n, h y p o xia, or o n g oi n g ne ur ol o gic e ve nts > Gra de 1, 
or if dee me d necessar y b y t he i n vesti gat or. S u bjects s h o ul d be i nstr ucte d t o 
re mai n wit hi n pr o xi mit y of t he cli nical st u d y site f or at least 4 wee ks 
f oll o wi n g a xica bta ge ne cil ole ucel i nf usi o n. S u bjects a n d t heir fa mil y 
me m bers/care gi vers s h o ul d be e d ucate d o n p ote ntial C R S a n d ne ur ol o gic 
s y m pt o ms s uc h as fe ver, d ys p nea, c o nf usi o n, a p hasia, d ys p hasia, s o m n ole nce, 
e nce p hal o pat h y, ata xia, or tre m or. S u bjects or t heir fa mil y 
me m bers/care gi vers s h o ul d be i nstr ucte d t o i m me diatel y c o ntact t he treati n g 
i n vesti gat or or see k i m me diate me dical atte nti o n if a n y of t hese s y m pt o ms 
de vel o p. 
T oxicity m a n a ge me nt 
T he g oal of C R S ma na ge me nt i n a nti- C D 1 9 c hi meric a nti ge n rece pt or ( C A R) 
T-cell t hera p y is t o pre ve nt life-t hreate ni n g c o n diti o ns w hile preser vi n g t he 
be nefits of a ntit u m or effects. Caref ull y m o nit or s u bjects f or si g ns a n d 
s y m pt o ms of C R S. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 1 4 1 4 A pril 2 0 2 3  Pr ot oc ol Secti o n C o u ntr y-s pecific Re q uire me nt 
T he C R S gra di n g scale a n d a C R S ma na ge me nt al g orit h m are pr o vi de d i n 
secti o n 6. 5 of t he I n vesti gat or’s Br oc h ure t o direct t he i n vesti gat ors. T his 
C R S ma na ge me nt strate g y is base d o n t he e x perie nce t o date wit h 
a xica bta ge ne cil ole ucel/ K T E- C 1 9 i n a d diti o n t o ot her a nti- C D 1 9 C A R T-cell 
pr o d ucts ( Lee et al, 2 0 1 4). 
Caref ull y m o nit or s u bjects f or si g ns a n d s y m pt o ms of ne ur ol o gic e ve nts. R ule 
o ut ot her ca uses of ne ur ol o gic s y m pt o ms. T he ne ur ol o gic e ve nts ma na ge me nt 
al g orit h m is pr o vi de d i n secti o n 6. 5 of t he i n vesti gat or’s br oc h ure. T his 
ne ur ol o gic e ve nt ma na ge me nt strate g y is base d o n t he e x perie nce t o date wit h 
a xica bta ge ne cil ole ucel/ K T E- C 1 9 i n a d diti o n t o ot her a nti- C D 1 9 C A R T-cell 
pr o d ucts ( Br u d n o a n d K oc he n derfer 2 0 1 6). 
1. 3. Be nefit- Ris k A n al ysis 
Patie nts wit h r/r D L B C L es peciall y pri mar y refract or y a n d earl y rela pse 
wit hi n 1 year of firstli ne rit u xi ma b- base d c he m oi m m u n ot hera p y ha ve p o or 
pr o g n osis e ve n wit h hi g h- d ose t hera p y-a ut ol o g o us ste m cell tra ns pla nt 
( H D T- A S C T). Beca use t hese patie nts li kel y are resista nt t o c he m ot hera p y, 
t he y ma y be nefit fr o m t hera pi[INVESTIGATOR_33082] h differe nt mec ha nis ms of acti o n. 
I m m u n ot hera p y, w hic h is base d o n t he e n ha nce me nt of a n i m m u ne res p o nse 
a gai nst t he t u m or, is a pr o misi n g a p pr oac h t o treati n g ma n y ca ncer t y pes. 
T-cells pla y a n i m p orta nt r ole i n destr o yi n g disease d cells t hr o u g h o ut t he 
b o d y. St u dies wit h i m m u ne c hec k p oi nt i n hi bit ors a n d bi-s pecific T-cell 
e n ga gers ha ve de m o nstrate d t he p ote ntial of T-cells t o treat ca ncer. T-cells 
nee d t o p ossess t he a p pr o priate s pecificit y f or a t u m or, be prese nt i n s ufficie nt 
n u m bers, a n d o verc o me a n y l ocal i m m u n os u p pressi ve fact ors t o be effecti ve. 
C hi meric a nti ge n rece pt or ( C A R) e n gi neere d T-cells ma y a d dress t hese iss ues 
a n d are a pr o misi n g a p pr oac h f or ca ncer t hera p y. 
A xica bta ge ne cil ole ucel is a n e n gi neere d a ut ol o g o us T-cell i m m u n ot hera p y 
b y w hic h a patie nt ’s o w n T cells are c ollecte d a n d s u bse q ue ntl y ge neticall y 
altere d t o rec o g nize C D [ADDRESS_1175339] or y a g gressi ve N H L, 
a xica bta ge ne cil ole ucel si g nifica ntl y i m pr o ve d O R R ( P < 0. 0 0 0 1) c o m pare d 
t o hist orical c o ntr ol. T he O R R was 8 3 % wit h a c o m plete res p o nse ( C R) rate 
of 5 8 %. Wit h a me dia n f oll o w u p of 2 7. 1 m o nt hs, 3 9 % of s u bjects ha d 
o n g oi n g res p o nses ( 3 7 % i n C R). 7 6 % of patie nts i n Z U M A- [ADDRESS_1175340] or y 
t o 2n d  or later li ne of t hera p y a n d 2 3 % ha d a n earl y rela pse after A S C T. A Es, 
w hic h ca n be se vere or occasi o nall y life-t hreate ni n g, were well defi ne d, 
ge nerall y re versi ble, a n d ma na gea ble, wit h n o a p pare nt l o n g-ter m 
c o nse q ue nces ot her t ha n B-cell a plasia. T he m ost c o m m o n e ve nts were 
c yt o pe nias, w hic h are e x pecte d fr o m t he c o n diti o ni n g c he m ot hera p y, as well 
as C R S a n d ne ur ol o gic e ve nts. T he rates of se vere C R S a n d ne ur ol o gic e ve nts 
decrease d o ver t he c o urse of t he Z U M A- [ADDRESS_1175341] li ne c he m oi m m u n ot hera p y was o nl y 4 0 % a n d 4 6 % 
res pecti vel y ( G u gliel mi et al, 1 9 9 8) ( Gissel brec ht et al, 2 0 1 0). A xica bta ge ne 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175342] or y disease a n d l o wer disease 
b ur de n. T heref ore a xica bta ge ne cil ole ucel will be c o m pare d t o sta n dar d of 
care ( S O C) as [ADDRESS_1175343] u d y. 
1. 4. C o ncl usi o n 
Treat me nt of patie nts wit h r/r D L B C L re mai ns c halle n gi n g a n d t here is a 
si g nifica nt u n met nee d f or better t hera pi[INVESTIGATOR_014] i n t hese patie nts. T his patie nt 
p o p ulati o n has a s pecificall y p o or pr o g n osis e ve n wit h H D T- A S C T .
Z U M A- [ADDRESS_1175344] sta n dar d of care as 
deter mi ne d b y t he i n vesti gat or base d o n g ui da nce fr o m t he pr ot oc ol. T his 
desi g n is e x pecte d t o all o w f or a p pr o priate assess me nt of t he be nefit of 
a xica bta ge ne cil ole ucel i n patie nts wit h r/r D L B C L c o m pare d t o c urre nt 
sta n dar d of care treat me nt, w hile mai ntai ni n g a n acce pta ble safet y pr ofile f or 
t he i m p orta nt i de ntifie d ris ks of C R S, ne ur ol o gic e ve nts, c yt o pe nias, 
i nfecti o ns a n d h y p o ga m ma gl o b uli ne mia. 
2. S P O N S O R R E P O R TI N G R E Q UI R E M E N T S 
De pe n di n g o n rele va nt l ocal le gislati o n or re g ulati o ns, i ncl u di n g t he 
a p plica ble U S F D A C o de of Fe deral Re g ulati o ns, t he E U Cli nical Trials 
Directi ve ( 2 0 0 1/ 2 0/ E C) a n d rele va nt u p dates, a n d ot her c o u ntr y-s pecific 
le gislati o n or re g ulati o ns, Kite ma y be re q uire d t o e x pe dite t o w orl d wi de 
re g ulat or y a ge ncies re p orts of S A Es, seri o us a d verse dr u g reacti o ns ( S A D Rs), 
or s us pecte d u ne x pecte d seri o us a d verse reacti o ns ( S U S A Rs). I n acc or da nce 
wit h t he E U Cli nical Trials Directi ve ( 2 0 0 1/ 2 0/ E C), t he s p o ns or or a s pecifie d 
desi g nee will n otif y w orl d wi de re g ulat or y a ge ncies a n d t he rele va nt I E C i n 
c o ncer ne d Me m ber States of a p plica ble S U S A Rs as o utli ne d i n c urre nt 
re g ulati o ns. 
Assess me nt of e x pecte d ness f or S A Es will be deter mi ne d b y Kite usi n g 
refere nce safet y i nf or mati o n s pecifie d i n t he i n vesti gat or’s br oc h ure or 
rele va nt l ocal la bel as a p plica ble. 
All i n vesti gat ors will recei ve a safet y letter n otif yi n g t he m of rele va nt 
S U S A R re p orts ass ociate d wit h a n y st u d y I M P. T he i n vesti gat or s h o ul d 
n otif y t he I R B or I E C of S U S A R re p orts as s o o n as is practical, w here t his is 
re q uire d b y l ocal re g ulat or y a ge ncies, a n d i n acc or da nce wit h t he l ocal 
i nstit uti o nal p olic y. 
3. C O N T A C T P E R S O N F O R M E DI C A L A N D S A F E T Y Q U E RI E S 
I n vesti gat ors ca n c o ntact t he E ur o pea n me dical m o nit or f or me dical a n d 
safet y q ueries: 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175345] or, Cli nical De vel o p me nt 
M o bile P h o ne: + 4 1 7 9 8 9 4 1 5 8 1 
E mail: msc h u p p @ kite p har ma.c o m 
Ur ge nt Safet y Iss ues C o ntact 
A n na va n Tr o oste n b ur g 
Vice Presi de nt P har mac o vi gila nce a n d E pi [INVESTIGATOR_32450] o g y 
E U Q P P V 
P h o ne: + 4 9 8 9 8 9 9 8 9 0 1 8 1 
E mail: A n na. va n Tr o oste n b ur g @ gilea d.c o m 
A d verse e ve nt a n d S U S A R re p orti n g 
Safet y _ F C @ gilea d.c o m 
Rele va nt S A Es will be re p orte d t o M P A b y t he s p o ns or i n acc or da nce wit h 
l ocal re q uire me nts. T his i ncl u des S U S A Rs fr o m all a p plica ble trial sites. 
4. S T U D Y DI S C O N TI N U A TI O N 
B ot h t he s p o ns or a n d t he i n vesti gat or reser ve t he ri g ht t o ter mi nate t he st u d y 
at a n y ti me. S h o ul d t his be necessar y, b ot h parties will arra n ge 
disc o nti n uati o n pr oce d ures a n d n otif y t he a p pr o priate re g ulat or y 
a ut h orit y(ies), I R Bs, a n d I E Cs. I n ter mi nati n g t he st u d y, Kite a n d t he 
i n vesti gat or will ass ure t hat a de q uate c o nsi derati o n is gi ve n t o t he pr otecti o n 
of t he s u bjects’ i nterests. 
5. R E F E R E N C E S 
Br u d n o J N, K oc he n derfer J N. T o xicities of C hi meric A nti ge n Rece pt or T 
Cells: Rec o g niti o n a n d Ma na ge me nt. Bl o o d. 2 0 1 6; 1 2 7( 2 6): 3 3 2 1- 3 0. 
Gissel brec ht C, Glass B, M o u nier N, Si n g h Gill D, Li nc h D C, Tr ne n y M, et 
al. Sal va ge re gi me ns wit h a ut ol o g o us tra ns pla ntati o n f or rela pse d lar ge 
B-cell l y m p h o ma i n t he rit u xi ma b era. J Cli n O nc ol. 2 0 1 0; 2 8( 2 7): 4 1 8 4- 
9 0. 
G u gliel mi C, G o mez F, P hili p T, Ha ge n bee k A, Martelli M, Se b ba n C, et al. 
Ti me t o rela pse has pr o g n ostic val ue i n patie nts wit h a g gressi ve 
l y m p h o ma e nr olle d o nt o t he Par ma trial. J Cli n O nc ol. 
1 9 9 8; 1 6( 1 0): [ADDRESS_1175346] o me. Bl o o d. 2 0 1 4; 1 2 4( 2): 1 8 8- 9 5. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175347] u d y will f oll o w t he rec o m me n dati o ns fr o m t he Cli nical Trials Facilitati o n Gr o u p ( C T F G) 
{Cli nical Trials Facilitati o n a n d C o or di nati o n Gr o u p ( C T F G) 2 0 2 0 }, as descri be d bel o w. 
1. Defi niti o n of C hil d beari n g P ote ntial 
A w o ma n is c o nsi dere d of c hil d beari n g p ote ntial (ie, fertile) f oll o wi n g me narc he a n d u ntil 
bec o mi n g p ost me n o pa usal u nless per ma ne ntl y sterile. Per ma ne nt sterilizati o n met h o ds i ncl u de 
h ysterect o m y, bilateral sal pi n gect o m y, a n d bilateral o o p h orect o m y. 
A p ost me n o pa usal state is defi ne d as n o me nses f or 1 2 m o nt hs wit h o ut a n alter nati ve me dical 
ca use. A hi g h f ollicle sti m ulati n g h or m o ne ( F S H) le vel i n t he p ost me n o pa usal ra n ge ma y be use d 
t o c o nfir m a p ost me n o pa usal state i n w o me n n ot usi n g h or m o nal c o ntrace pti o n or h or m o nal 
re place me nt t hera p y. H o we ver i n t he a bse nce of [ADDRESS_1175348] o m y. 
2. Birt h C o ntr ol Met h o ds T hat Ma y Be C o nsi dere d as Hi g hl y Effecti ve 
Met h o ds t hat ca n ac hie ve a fail ure rate of less t ha n 1 % per year w he n use d c o nsiste ntl y a n d 
c orrectl y are c o nsi dere d as hi g hl y effecti ve birt h c o ntr ol met h o ds. S uc h met h o ds i ncl u de: 
•C o m bi ne d (estr o ge n- a n d pr o gester o ne-c o ntai ni n g) h or m o nal c o ntrace pti o n ass ociate d wit h 
i n hi biti o n of o v ulati o n a:
Oral 
I ntra va gi nal 
Tra ns der mal 
•Pr o gest o ge n- o nl y h or m o nal c o ntrace pti o n ass ociate d wit h i n hi biti o n of o v ulati o n a:
Oral 
I njecta ble 
I m pla nta ble a
•I ntra uteri ne de vice (I U D) a
a  C o ntrace pti o n met h o ds t hat i n t he c o nte xt of t his g ui da nce are c o nsi dere d t o ha ve l o w user de pe n de nc y. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 1 8 1 4 A pril 2 0 2 3  •I ntra uteri ne h or m o ne-releasi n g s yste m (I U S) a
•Bilateral t u bal occl usi o n a
•Vasect o mize d part ner a,b
•Se x ual a bsti ne nce c
3. U nacce pta ble Birt h C o ntr ol Met h o ds 
Birt h c o ntr ol met h o ds t hat are u nacce pta ble i ncl u de peri o dic a bsti ne nce (cale n dar, 
s y m pt ot her mal, p ost o v ulati o n met h o ds), wit h dra wal (c oit us i nterr u pt us), s per mici des o nl y, a n d 
lactati o nal a me n orr h oea met h o d ( L A M). A fe male c o n d o m a n d a male c o n d o m s h o ul d n ot be 
use d t o get her. 
b  Vasect o mize d part ner is a hi g hl y effecti ve birt h c o ntr ol met h o d pr o vi de d t hat part ner is t he s ole se x ual part ner of 
t he w o ma n of c hil d beari n g p ote ntial trial partici pa nt a n d t hat t he vasect o mize d part ner has recei ve d me dical 
assess me nt of t he s ur gical s uccess. 
c  I n t he c o nte xt of t his g ui da nce se x ual a bsti ne nce is c o nsi dere d a hi g hl y effecti ve met h o d o nl y if defi ne d as 
refrai ni n g fr o m heter ose x ual i nterc o urse d uri n g t he e ntire peri o d of ris k ass ociate d wit h t he st u d y treat me nts. T he 
relia bilit y of se x ual a bsti ne nce nee ds t o be e val uate d i n relati o n t o t he d urati o n of t he cli nical trial a n d t he 
preferre d a n d us ual lifest yle of t he s u bject. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175349] u d y. 
T hese ris ks ca n be s u m marize d as f oll o ws: 
1) S u bject safet y m o nit ori n g a n d f oll o w- u p: 
a) S u bjects ma y be u na ble or u n willi n g t o c o me t o t he i n vesti gati o nal site f or t heir 
sc he d ule d st u d y visits as re q uire d per pr ot oc ol. 
Miti gati o n pla n: F or s u bjects w h o ma y be u na ble or u n willi n g t o visit t he i n vesti gati o nal 
site f or t heir sc he d ule d st u d y visits as re q uire d per pr ot oc ol, t he pri nci pal i n vesti gat or or 
q ualifie d dele gate will c o n d uct a re m ote st u d y visit, via p h o ne or vi de o c o nfere nci n g, t o 
assess t he s u bjects wit hi n t he tar get visit wi n d o w date w he ne ver p ossi ble. D uri n g t he 
re m ote st u d y visit, t he f oll o wi n g i nf or mati o n at mi ni m u m will be re vie we d: 
i) C o nfir m if s u bject has e x perie nce d a n y a d verse e ve nts ( A Es)/seri o us a d verse e ve nts 
( S A Es)/s pecial sit uati o ns (i ncl u di n g pre g na nc y) a n d f oll o w- u p o n a n y u nres ol ve d 
A Es/ S A Es. 
ii) Re vie w t he c urre nt list of c o nc o mita nt me dicati o ns a n d d oc u me nt a n y ne w 
c o nc o mita nt me dicati o ns. 
iii) If a p plica ble, c o nfir m electr o nic/ pa per diar y q uesti o n naires a n d patie nt-re p orte d 
o utc o mes ha ve bee n c o m plete d a n d tra ns mitte d. 
b) S u bjects ma y be u na ble or u n willi n g t o tra vel t o t he site f or pla n ne d assess me nts (e g, 
bl o o d dra ws, i ma gi n g, p h ysical e xa ms). 
Miti gati o n pla n: L ocal la b orat ories or ot her ve n d ors ma y be utilize d as a p pr o priate t o 
m o nit or s u bject safet y u ntil t he s u bject ca n ret ur n t o t he site f or t heir re g ular f oll o w- u p 
per pr ot oc ol. A n y c ha n ges i n t he part y c o n d ucti n g la b orat or y assess me nts f or t he st u d y 
beca use of t he pa n de mic will be d oc u me nte d acc or di n gl y. Pre g na nc y testi n g ma y be 
perf or me d usi n g a h o me uri ne pre g na nc y test if l ocal la b orat or y pre g na nc y testi n g is n ot 
feasi ble. Ce ntral la b kits ma y be se nt t o s u bject’s l ocal h os pi[INVESTIGATOR_845638] b f or sa m ple c ollecti o n. 
Rele va nt i ma gi n g (e g, P E T- C T, C T) ca n be d o ne at t he s u bject’s l ocal h os pi[INVESTIGATOR_307] a n d 
i ma ges tra nsferre d or se nt t o t he i n vesti gati ve site. P h ysical e xa ms ca n be c o m plete d b y a 
l ocal p h ysicia n wit h res ults se nt t o i n vesti gati ve site. 
c) S u bjects ma y be u na ble or u n willi n g t o atte n d t he st u d y visit t o si g n a n u p date d i nf or me d 
c o nse nt f or m versi o n. 
Miti gati o n pla n: T he site staff will f oll o w t heir a p pr o ve d i nf or me d c o nse nt pr ocess a n d 
re mai n i n c o m plia nce wit h t he l ocal et hics c o m mittee/i nstit uti o nal re vie w b oar d a n d 
nati o nal la ws a n d re g ulati o ns. Re m ote c o nse nt will be all o we d if has bee n a p pr o ve d b y 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt 6 
C O N FI D E N TI A L Pa ge 1 2 0 1 4 A pril 2 0 2 3  t he l ocal et hics c o m mittee/i nstit uti o nal re vie w b oar d. T he c o nse nt pr ocess will be 
d oc u me nte d a n d c o nfir me d b y n or mal c o nse nt pr oce d ure at t he i n vesti gati ve site at t he 
earliest o p p ort u nit y. 
2) Pr ot oc ol a n d m o nit ori n g c o m plia nce: 
a) Pr ot oc ol de viati o ns ma y occ ur i n sit uati o ns w here sc he d ule d visits or pr oce d ures ca n n ot 
be c o n d ucte d as pla n ne d per pr ot oc ol. 
Miti gati o n pla n: If it is n ot p ossi ble t o c o m plete a re q uire d pr oce d ure at a 
pr ot oc ol-s pecifie d ti me p oi nt, a n u nsc he d ule d visit s h o ul d be c o n d ucte d as s o o n as 
p ossi ble w he n c o n diti o ns all o w s o t hat t he re q uire d pr oce d ure ca n be perf or me d. T he 
sit uati o n s h o ul d be rec or de d a n d e x plai ne d as a pr ot oc ol de viati o n. A n y misse d s u bject 
visits m ust be re p orte d i n t he e C R F, if p ossi ble, a n d rec or de d as de viati o ns t o t he 
pr ot oc ol beca use of t he pa n de mic, s o t hat t he y ca n be a p pr o priatel y d oc u me nte d a n d 
descri be d i n t he cli nical st u d y re p ort. A n y re m ote st u d y visits t hat are c o n d ucte d i n lie u 
of cli nic visits beca use of t he pa n de mic will be d oc u me nte d as a pr ot oc ol de viati o n 
relate d t o t he pa n de mic. 
b) St u d y m o nit ors ma y be u na ble t o carr y o ut s o urce data re vie w or s o urce data verificati o n, 
or st u d y dr u g acc o u nta bilit y or assess pr ot oc ol a n d G o o d Cli nical Practice c o m plia nce. 
T his ma y lea d t o dela ys i n s o urce data verificati o n, a n i ncrease i n pr ot oc ol de viati o ns, or 
u n derre p orti n g of A Es. 
Miti gati o n pla n: T he st u d y m o nit or is t o re mai n i n cl ose c o m m u nicati o n wit h t he site t o 
e ns ure o n g oi n g data e ntr y a n d q uer y res ol uti o n. Re m ote s o urce data verificati o n ma y be 
arra n ge d if all o we d b y l ocal re g ulati o n a n d t he St u d y M o nit ori n g Pla n. T he st u d y m o nit or 
is t o refere nce t he St u d y M o nit ori n g Pla n f or g ui da nce o n h o w t o c o n d uct a n off-site 
m o nit ori n g visit. T he st u d y staff is t o sa ve a n d d oc u me nt all rele va nt c o m m u nicati o n i n 
t he st u d y files. T he stat us of sites t hat ca n n ot acce pt m o nit ori n g visits a n d/ or s u bjects 
o n-site, m ust be trac ke d ce ntrall y a n d u p date d o n a re g ular basis. 
3) Missi n g data a n d data i nte grit y: 
T here ma y be a n i ncrease d a m o u nt of missi n g data beca use of s u bject’s missi n g 
visits/assess me nts. T his c o ul d ha ve a n i m pact o n t he a nal ysis a n d t he i nter pretati o n of 
cli nical st u d y data. 
Miti gati o n pla n: I m plicati o ns of a pa n de mic o n met h o d ol o gical as pects f or t he st u d y will be 
t h or o u g hl y assesse d a n d d oc u me nte d, a n d rele va nt acti o ns will be ta ke n as a p pr o priate (e g, 
m o dificati o n of t he statistical a nal ysis pla n) a n d i n c o m plia nce wit h re g ulat or y a ut h orities’ 
g ui da nce. O verall, t he cli nical st u d y re p ort will descri be t he i m pact of t he pa n de mic o n t he 
i nter preta bilit y of st u d y data. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175350] u d y s u bjects re mai ns 
u nc ha n ge d. 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175351]. 
A se parate trac ke d c ha n ge (re d-li ne d) d oc u me nt c o m pari n g t he pre vi o us pr ot oc ol versi o n 
( A me n d me nt 5, date d 2 5 J u ne 2 0 2 0) a n d U S A c o u ntr y-s pecific versi o n ( A me n d me nt 5. 1, date d 
1 6 Se pte m ber 2 0 2 0) t o t his a me n d me nt will be ma de a vaila ble u p o n t he p u blicati o n of t his 
pr ot oc ol. 
•A me n d me nt 6 ( D ate d 1 4 A pril 2 0 2 3) 
•C ha n ges fr o m A me n d me nt 5 ( date d 2 5 J u ne 2 0 2 0) t o A me n d me nt 6 ( date d 1 4 A pril 2 0 2 3) 
are detaile d bel o w: 
Secti o n N u m ber a n d N a me Hi g h-le vel Descri pti o n of C h a n ge Brief R ati o n ale 
Title Pa ge 
Secti o n 7. 1 5 L o n g-ter m F oll o w- 
u p ( A xica bta ge ne Cil ole ucel 
a n d Sta n dar d of Care Ar ms) 
Secti o n [ADDRESS_1175352] u d y 
D oc u me ntati o n a n d Arc hi ve 
Secti o n 1 8, A p pe n di x A: 
S p o ns or a n d I n vesti gat or 
Si g nat ure Pa ge 
Secti o n 1 8, A p pe n di x E: 
C hil d beari n g P ote ntial a n d 
Birt h C o ntr ol Mi n or a d mi nistrati ve c ha n ges ha ve bee n 
ma de t hr o u g h o ut t he pr ot oc ol t o ali g n wit h 
Kite’s latest pr ot oc ol te m plate. T o ali g n wit h Kite’s latest 
rec o m me n dati o ns a n d 
pr ocesses 
Pr ot oc ol S y n o psis 
St u d y Sc he ma 
Secti o n 3. [ADDRESS_1175353] Partici pati o n 
Secti o n 7. 1 1. 2. 2 R C R Testi n g 
Secti o n 7. 1 5 L o n g-ter m F oll o w- 
u p ( A xica bta ge ne Cil ole ucel 
a n d Sta n dar d of Care Ar ms) 
Ta ble [ADDRESS_1175354] of t he re g ulat or y a ge nc y. 
A d diti o nal mi n or c ha n ges ma de f or 
ali g n me nt of la n g ua ge i n pr ot oc ol Re q ueste d b y a re g ulat or y 
a ge nc y 
A xica bta ge ne cil ole ucel; K T E- C 1 9 Kite P har ma, I nc. 
Cli nical Pr ot oc ol: K T E- C 1 9- 1 0 7 ( Z U M A- 7) A me n d me nt [ADDRESS_1175355] ca n 
be retreate d. F or clarificati o n 
Secti o n 9. 4 Re p orti n g of 
Seri o us A d verse E ve nts Safet y re p orti n g e mail u p date d t o: 
Safet y _ F C @ gilea d.c o m. Clarificati o n a d de d 
re gar di n g a n y rele va nt i nf or mati o n o n 
o n g oi n g S A Es p ost t he data base cl os ure, 
w hic h m ust be s u b mitte d t o Kite wit hi n 
2 4 h o urs after t he i n vesti gat or’s k n o wle d ge 
of t he e ve nt. F or clarificati o n 
Secti o n 1 0. 6. 6 P har mac o ki netic 
A nal yses A nti- C D 1 9 C A R T le vels meas ure d i n 
peri p heral bl o o d will be s u m marize d wit h 
descri pti ve statistics. F or clarificati o n 
Secti o n 1 8 A p pe n di x D 
C o u ntr y-s pecific Re g ulat or y 
A ge nc y Re q uire me nts 
Secti o n 5. 2 E xcl usi o n Criteri o n 
# [ADDRESS_1175356] or y A d diti o n of a n a p pe n di x ( Pr ot oc ol 
A me n d me nt Hist or y a d de d) prese nti n g a 
hi g h-le vel s u m mar y of c ha n ges f or t he 
a me n d me nt. A d diti o n t o reflect Pr ot oc ol 
A me n d me nt [ADDRESS_1175357] aft 
E L E C T R O NI C SI G N A T U R E S 
Si g n e d b y M e a ni n g of Si g n at ur e S er v er D at e 
( d d- M M M- 
y y y y h h: m m: s s) 
C hri sti n a T o 1 Cli ni c al D e v el o p m e nt 
e Si g n e d 2 0- A pr- 2 0 2 3 
0 9: 3 1: 2 3 